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University of Pittsburgh, 2011 
 
 
Altered oligodendrocyte structure and function is implicated in major mental illnesses, 
including low density and reduced expression of oligodendrocyte-specific gene 
transcripts in major depressive disorder (MDD). These features are also observed in the 
unpredictable chronic mild stress (UCMS) and chronic corticosterone (CORT) rodent 
models of the illness; however, whether oligodendrocyte changes are a causal 
component of MDD is not known. The oligodendrocyte-specific gene 2’-3’-cyclic 
nucleotide-3’-phosphodiesterase (CNP1) is a key component of axoglial communication 
and has previously been implicated in psychiatric disorders. A recent study in our lab 
found decreased levels of CNP1 in the amygdala (a central region of mood regulation) 
of human post-mortem MDD subjects and mice exposed to UCMS.     
In an attempt to determine whether altered CNP1 (or disrupted oligodendrocyte 
integrity) represents a causal factor in MDD, we investigated MDD-related features in 
mice lacking CNP1 (CNP1KO mice). In terms of technical development, we: 1) initiated 
use of a novel Z-score normalization procedure to counteract variability and extract a 
more comprehensive and translational view of our behavioral analyses, and 2) propose 
that the fear conditioning paradigm can be used to assess corticolimbic dysfunctions 
relating to mechanisms of MDD. Together, our studies in CNP1KO mice reveal a 
surprising profile of behavioral resilience that is accompanied by patterns of amygdala-
 v 
related dysfunction. In addition, we show robust upregulation of oligodendrocyte and 
immune related transcripts in the basolateral amygdala of CNP1KO mice. This pattern is 
suggestive of compensatory changes for oligodendrocyte structure/function and 
indicative of an association between oligodendrocytes and immune function. Together, 
these studies demonstrate that disruption of oligodendrocyte function (via CNP1 
ablation) can impact circuits mediating emotionality in mice resulting in abnormal 
affective behaviors. However, downstream molecular changes combined with the 
observation of longterm detrimental consequences in these mice (e.g. 
neurodegeneration), is suggestive of a maladaptive role for CNP1 in MDD. 
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1.0  INTRODUCTION 
 
Major depressive disorder (MDD) is a genetically diverse and etiologically undefined 
disorder, likely involving complex molecular interactions in multiple brain regions.  While 
there are ample clinical and postmortem human studies on MDD, conclusions regarding 
the mechanisms underlying MDD are difficult to draw because 1) external factors are 
difficult to control in human populations and 2) only minimally invasive techniques can 
be utilized.  Thus, mechanistic studies on MDD rely heavily on studies in animal models 
where external factors can be more controlled and a single characteristic can be more 
thoroughly examined.  However, interpreting results from animal studies and translating 
back to the human disorder can also prove challenging.  
Both human and animal studies have implicated disturbances of 
oligodendrocytes in MDD and/or stress, but the functional consequences of 
oligodendrocyte disturbance on mood have not been investigated.  The studies reported 
here use a knockout mouse to model a deficiency in oligodendrocyte function and also 
present a novel method for analyzing emotionality in mice.  Below, I introduce current 
knowledge of clinical and neurobiological aspects of MDD focusing on two clinical 
factors relevant to these studies: age and sex.  I then discuss corresponding 
neurobiological studies in animal models followed by a brief review of glial cell types 
and an overview of glial changes in MDD, focusing on oligodendrocytes.  Finally, I 
discuss the structure and function of the oligodendrocyte-specific gene 2’-3’-cyclic 
nucleotide 3’-phosphodiesterase (CNP1) and evidence for its involvement in MDD and 
other psychiatric disorders. 
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1.1 MAJOR DEPRESSIVE DISORDER 
 
Major depressive disorder (MDD), a devastating chronic illness of altered mood, is a 
syndrome defined by the core symptoms of excessive sadness (depressed mood) and 
anhedonia (inability to experience pleasure) for a minimum period of two weeks.  A 
diagnosis of depression requires at least one of the core symptoms accompanied by 
five additional symptoms such as guilt, despair, weight gain or loss, impaired cognitive 
functions, and changes in sleep and eating patterns (DSM-IV-TR 2000).  MDD has an 
unknown and potentially heterogeneous etiology but factors that are known to increase 
susceptibility to MDD include female sex, increasing age, genetic makeup, prior episode 
of MDD, and environmental factors (i.e. chronic stress).  MDD is a significant contributor 
to the development and progression of systemic and organ diseases (Musselman et al. 
1998; Ciechanowski et al. 2000; Schulz et al. 2000), and in MDD patients, lifetime 
mortality due to suicide reaches 15% (Mann 2003).  The global impact of MDD is severe 
and major depression is considered the leading cause of disability worldwide (WHO 
2008) in terms of years of life lived with the disability (YLD).  In the United States, the 
annual cost of MDD was estimated to be well over $25 billion in direct medical costs 
alone in the year 2000 (Greenberg et al. 2003).  However, equally significant 
contributors to the financial burden of depression are indirect medical costs such as 
absenteeism or lost productivity at work.  While it is likely that effective treatment of 
MDD will offset medical costs by increasing worker productivity (Donohue and Pincus 
2007), remission rates of individuals using a single pharmacological treatment are about 
30% (Kennedy et al. 2001; Nemeroff et al. 2008).  Even with combined treatment 
approaches a remission rate of only 50% is typically achieved (Blier et al. 2010).  This 
clearly points toward a need to develop more effective antidepressant treatments, 
however, there is a paucity of novel molecular targets due to the lack of understanding 
regarding the basic molecular mechanisms of mood (Blier 2010). 
While the exact mechanism of low mood is unclear, there are five leading 
hypotheses of the neurobiological causes underlying depression [Reviewed in 
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(Belmaker and Agam 2008; Krishnan and Nestler 2008)].  1) The monoamine 
hypothesis: The advent and success of antidepressants such as selective serotonin 
reuptake inhibitors (SSRIs), which act to block the serotonin transporter (SERT), and 
monoamine oxidase inhibitors (MAOIs) initially generated focused research effort on the 
role of serotonin and other monoamines in MDD.  However monoamine depletion 
studies and in depth molecular studies show that there are likely additional mechanisms 
underlying depression (Belmaker and Agam 2008).  2) The glucocorticoid hypothesis: 
MDD patients frequently have altered levels of circulating cortisol and alterations in 
corticotrophin releasing factor (CRH) levels, suggestive of dysfunction of the 
glucocorticoid system.  While the exact mechanistic relationship between stress and 
depression has remained vague, stress is a predominant risk factor for MDD (Holsboer 
2000).  3) The neurotrophic hypothesis:  Indirect evidence in rodents indicates that 
antidepressants increase levels of brain-derived neurotrophic factor (BDNF) and 
infusion of BDNF into the hippocampus induces antidepressant effects (Shirayama et al. 
2002; Deltheil et al. 2009).  Direct evidence in humans is more limited and includes 
decreased circulating BDNF levels in MDD patients (Molendijk et al. 2010) and 
decreased BDNF levels in postmortem tissue from the hippocampus of MDD patients 
(Thompson Ray et al. 2011).  However, it is likely that these effects are not causal, but 
rather have a specific modulatory role (Duman and Monteggia 2006; Castren et al. 
2007).  4) The inflammatory hypothesis: People with infections, autoimmune diseases, 
or interferon treatments develop depression and some antidepressants have anti-
inflammatory effects.  Increases in certain cytokines, humoral mediators of immunity, 
have been implicated in depression, however, more research is necessary to elucidate 
the precise roles of the immune system in depression (Miller et al. 2009).  5) The 
GABAergic hypothesis: Reduced levels of gamma-aminobutyric acid (GABA) and 
altered GABA receptor subunit composition have been observed in MDD.  Disruptions 
of GABA have also been tied to HPA axis regulation and monoaminergic transmission 
suggesting GABA may have downstream effects on other systems involved in mood 
(Luscher et al. 2011).  While there is evidence for disruptions in all of these 
neurobiologic processes in MDD, each hypothesis on its own is likely too simplistic and 
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it is very probable that MDD involves a complex integration of these theories.  Further 
research is also necessary to decipher whether these hypotheses represent causes, 
consequences, or confounds (neutral side effects) of the underlying pathophysiology of 
the disease.   
 
 
1.1.1 Relevant Clinical Risk Factors for MDD 
 
Similar to many psychiatric disorders, MDD is thought to arise from a combination of 
environmental, psychosocial, and neurobiological risk factors (Caspi and Moffitt 2006).  
The predominant environmental risk factors for MDD include adverse childhood 
experiences and stressful life events, such as hardships in job, health and relationship 
status.  Predominant neurobiological risk factors include female sex, personality traits 
such as neuroticism, and genetic risk (Fava and Kendler 2000).  However, MDD is 
known to have individual heterogeneity in clinical presentation, neurobiological factors, 
and treatment response (Rush 2007), which have led to the description of various 
subtypes (e.g. postpartum, atypical).  Thus, environmental and underlying 
neurobiological predispositions combine to determine the relative risk of an individual.  
Below, I review two clinical factors that are relevant to the study: age and sex.  
 
1.1.1.1 Sex Differences in MDD     
 
One of the most replicated epidemiological findings in all of psychiatry is that women 
have higher rates of depression compared with men; a finding consistent across 
community-based epidemiological studies throughout the world (Weissman and 
Klerman 1985; Kessler et al. 1993).  Approximately one in four women and one in ten 
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men will experience at least one debilitating episode of mood disorder in the course of a 
lifetime (Kendler 1998).  Females are twice as likely to develop a single depressive 
episode compared to males (Kornstein et al. 2000), and are four times as likely to have 
recurrent episodes (Perugi et al. 1990).  Females also tend to have more symptoms, 
different combinations of symptoms, and greater severity of the disorder (Angst and 
Dobler-Mikola 1984; Hirschfeld et al. 1984; Frank et al. 1988; Young et al. 1990; 
Grigoriadis and Robinson 2007).  Even when controlling for factors such as willingness 
to seek help and gender bias of diagnosis, the risk for MDD is approximately two times 
higher in women than men (Kessler et al. 1994; Regier et al. 1998; Kornstein et al. 
2000; Grigoriadis and Robinson 2007) and this sex difference persists into the elderly 
population (Krause 1986), suggesting an underlying biological predisposition for 
females to develop MDD. 
While the underlying pathology of this sexual dimorphism in MDD is unknown, 
depressive episodes in women usually arise after the onset of puberty and often 
correspond with seasonal and biological rhythms (Kendler 1998; Becker et al. 2007).  
Women also experience higher rates of depression during times of low estrogen, such 
as premenstrual and postpartum periods (Fink et al. 1996), together suggesting 
potential hormonal origins of this sexual dimorphism rather than underlying genetic 
factors, a critical distinction [reviewed in (Grigoriadis and Robinson 2007)].  While few 
studies have examined sex differences in rodent models of depression, our lab has 
found that female mice lacking SERT, an MDD-associated gene, are more susceptible 
to developing a depressive-like syndrome following exposure to the unpredictable 
chronic mild stress paradigm (Joeyen-Waldorf et al. 2009).  Ovarian hormones have 
also been shown to influence emotionality in female mice (Zimmerberg and Farley 
1993; Mora et al. 1996), however, few studies have examined the effect of hormonal 
fluctuations on female vulnerability to a depressive-like syndrome.  In an ongoing study, 
our lab recently found that vulnerability to depressive-like symptoms in female mice is 
likely due to organizational effects of hormones (i.e. permanent effects of developmental 
hormones on brain development) rather than activational effects (i.e. transient effects of 
gonadal hormones) [M. Seney, personal communication; reviewed in (Cooke et al. 
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1998)].  Thus, effects of sex hormones seem to be a critical factor involved in the 
precipitation of depressive symptoms and the underlying neurological and hormonal 
factors need to be more thoroughly examined.   
 
1.1.1.2 MDD and Age 
 
Greater than 50% of elderly MDD patients experience their first depressive episode 
after age 60 (Brodaty et al. 2001), a striking pattern representing a subtype of MDD 
termed late-onset depression.  The predominant risk factors for late-onset depression 
include sleep disturbances, disability, and bereavement, which are mainly stress-related 
(Cole and Dendukuri 2003; Djernes 2006).  However, characteristics of the natural 
aging process have also been implicated in the onset of late-onset MDD.  For example, 
alterations in the serotonin system (decreased 5HT2A receptor binding), impaired 
endocrine function, cognitive deficits and dementia, and poor vascular health 
(hypertension and stroke) have all been implicated as potential biological factors 
involved in late-onset depression (Alexopoulos 2002; Schweitzer et al. 2002; Sheline et 
al. 2002; Blazer and Hybels 2005).  While late-onset depression is a subclass of MDD 
and older adults appear to be at greater biological risk for developing MDD, the 
frequency of developing depression is actually lower in older adults compared with 
younger adults (Byers et al. 2010); [reviewed in (Blazer and Hybels 2005)].  
Surprisingly, the co-morbidity of MDD with physical disorders also decreases with age, 
suggesting that the low MDD rates in elderly are not due to psychological confounds 
associated with physical disorders (Kessler et al. 2010). This lower rate of incidence 
could be due to factors such as age-related increases in psychological resilience (i.e. 
wisdom), religious involvement, and participation in valued activities (Hendrie et al. 
2006).  In accord, Fiske and colleagues recently proposed that a common pathway to 
depression onset in older adults may be a decrease of daily activities (Fiske et al. 
2009).    
22 
 
Age-related illnesses have also been suggested to be causative for development 
of late-onset depression.  There is substantial comorbidity between MDD and dementia 
and MDD is found in approximately 20% of all Alzheimers patients (Patterson et al. 
1990). MDD, in combination with pre-morbid cognitive deficits, increases the risk for 
Alzheimer’s (Alexopoulos et al. 1993), suggesting that late-onset MDD may be a pre-
morbid marker for other neurological disorders.  Thus, late-onset MDD is a significant 
medical concern in the elderly and there is potential that late-onset MDD shares a 
common pathophysiology with certain age-related cognitive and neurodegenerative 
disorders (Olin et al. 2002).  
 
1.1.2 Neurobiology of MDD 
1.1.2.1  Neurocircuitry of MDD 
 
Studies of anatomical regions underlying depression have revealed dysfunction of 
corticolimbic circuitry in MDD (Figure 1.1).  Neuroimaging studies have shown failure of 
coordinated activity between cortical and limbic regions in MDD subjects (Mayberg 
1997), reduced correlation between amygdala and prefrontal cortex (PFC) activity 
(Siegle et al. 2007), and reduced functional connectivity between the amygdala and 
perigenual cingulate cortex in individuals genetically susceptible to MDD (serotonin 
transporter s-allele carriers) (Pezawas et al. 2005).  In addition, decreased functional 
coupling of the supragenual cingulate and amygdala was positively correlated with 
depressive symptom severity (Matthews et al. 2008). Using microarray data, robust 
coordinated shifts in gene transcript level (ie. gene synchrony) were reported between 
amygdala and cingulate cortex in MDD subjects (Gaiteri et al. 2010).  A meta-analysis 
using both imaging data and mathematical modeling confirmed abnormal connectivity 
between corticolimbic regions and differentiated treatment responders from non-
responders (Seminowicz et al. 2004). 
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Studies of anatomical regions suggest the amygdala plays a central role in 
mood-related disorders (Mayberg 1997; Krishnan and Nestler 2008).  Functional 
magnetic resonance imaging (fMRI) studies revealed MDD patients had increased 
amygdala reactivity associated with exposure to increasingly sad faces (Surguladze et 
al. 2005), sustained amygdala activity in response to negative emotional stimulation 
(Siegle et al. 2002), and increased amygdala responsiveness to sad or fearful faces 
even when presented below the level of conscious awareness (Sheline et al. 2001; 
Suslow et al. 2010; Victor et al. 2010).  In contrast, other studies in MDD subjects have 
revealed no alterations in amygdala reactivity perhaps highlighting the heterogeneity of 
the disorder or the diversity of the paradigms (Monk et al. 2008; Townsend et al. 2010).  
Neuroimaging studies have also revealed alterations in amygdala volume in MDD 
subjects (Sheline et al. 1998; van Eijndhoven et al. 2009; Lorenzetti et al. 2010), 
however, results are inconsistent and could be due to changes in the density of specific 
cell types (Campbell and MacQueen 2006; Rajkowska and Miguel-Hidalgo 2007).  
Other brain regions implicated in MDD include the anterior cingulate cortex (ACC), 
hippocampus, and nucleus accumbens, all regions that are functionally connected to 
the amygdala (Krishnan and Nestler 2008), supporting a central role for the amygdala in 
MDD.  Rodent studies have further dissected the pathways involved in emotion and fear 
regulation and have revealed the basolateral nuclei in the amygdala (BLA) as a critically 
important structure in these processes (see 1.2.3).  
  The role of corticolimbic circuitry has also been well established in fear and 
anxiety in humans, primarily through fear conditioning and extinction paradigms.  
Individuals with post traumatic stress disorder (PTSD) show deficits in fear extinction 
and/or extinction retention, which are corticolimbic-specific tasks (Bremner et al. 2005; 
Wessa and Flor 2007; Milad et al. 2008); [reviewed in (Jovanovic and Ressler 2010)], 
and PTSD shares a strong comorbidity with depression (Kessler et al. 1995; Blanchard 
et al. 1998).  A review of literature found that over 25 studies associated amygdala 
activation to fearful stimuli (Phan et al. 2002), and the ventromedial PFC (vmPFC) - 
amygdala circuit is thought to be disrupted in PTSD, similar to MDD (Rauch et al. 2006; 
Delgado et al. 2008).  Also akin to MDD, PTSD patients frequently display disruptions of 
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cortisol levels (Yehuda et al. 2004) and cortisol administration reduces symptoms of 
PTSD (Aerni et al. 2004; Soravia et al. 2006).  Together, this evidence suggests 
common mechanisms at play between MDD and PTSD.  While investigations of these 
pathways in humans is limited to non-invasive techniques, fear conditioning and 
extinction circuits have been thoroughly dissected in rodents (see 1.2.3) and these 
pathways show robust phylogenetic conservation across species (Figure 1.1).    
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Figure 1.1. Phylogenetic conservation of corticolimbic brain regions involved in 
mood regulation. Human ventromedial prefrontal cortex (vmPFC) is reciprocally 
connected to amygdala (red arrows).  Similarly, mouse prelimbic and infralimbic cortices 
are reciprocally connected to amygdala (red arrows). Human figure modified from (Tost 
and Meyer-Lindenberg 2010); mouse figure modified from (Heintz and Mamounas 
2011). HYP=hypothalamus; ACG=anterior cingulated gyrus; PFC=prefrontal cortex; 
vmPFC=ventromedial PFC; AMY=amygdala; HPC=hippocampus. 
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1.1.2.2  Stress and Neuroendocrine Changes in MDD 
 
The link between stress and the onset of MDD is well established (Hammen 2005). 
While stressful life events are a causal component in MDD (Kendler et al. 1999), 
depression, in turn, increases susceptibility to stressful life events which may account 
for chronicity and/or recurrence in the disorder (Hammen 1991); [reviewed in (Liu and 
Alloy 2010)]. In addition, numerous studies indicate that individuals exposed to early 
adverse experiences are more susceptible to developing mental disorders (Heim and 
Nemeroff 2001).  In particular, childhood maltreatment and abuse are significant risk 
factors for developing MDD in women (McCauley et al. 1997; Kendler et al. 2004). 
Furthermore, stressful life events have been shown to precipitate MDD in genetically 
susceptible individuals (Caspi et al. 2003), and early life stress is suspected to lead to 
epigenetic susceptibility to MDD (McGowan et al. 2009), suggesting a need to consider 
both genetic and environmental factors when studying MDD. 
Neurobiological stress mechanisms, such as the hypothalamic-pituitary-adrenal 
(HPA) axis, have also been implicated in MDD.  Severe depressive episodes are 
frequently associated with high cortisol levels (hypercortisolaemia) (Brouwer et al. 2005) 
and patients with Cushing’s Syndrome (a disorder resulting in high circulating cortisol) 
are prone to depression (McEwen 2007).  In contrast, atypical depression 
(characterized by hypersomnia and hyperphagia) is associated with lower cortisol levels 
(hypocortisolaemia) (Gold and Chrousos 2002; Brouwer et al. 2005).  However, the 
level of cortisol in MDD also varies with sex, age, and genetic risk (Kaufman et al. 2004; 
Alexopoulos 2005; Kudielka and Kirschbaum 2005), indicating that a variety of external 
factors could contribute to the HPA disruptions.  Patients with MDD consistently show 
blunted stress reactivity and impaired stress-recovery (Burke et al. 2005), and have 
alterations in both corticotropin releasing hormone (CRH) receptor and glucocorticoid 
receptor levels in limbic brain regions (Webster et al. 2002; Merali et al. 2004).  Overall, 
it has been suggested that dysfunction of these critical stress mediators can disrupt the 
stability of the system leading to “allostatic load”, a concept whereby maladaptive stress 
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responses lead to wear and tear and eventually can evolve into disorders such as MDD 
(McEwen 2003). 
 
1.1.2.3  Genetics of MDD 
 
MDD is a polygeneic, epistatic disorder with a heterogenous etiology (Fava and Kendler 
2000).  Twin studies have revealed there is a strong genetic component to MDD 
(Kendler et al. 1995; Kendler and Prescott 1999) and a meta-analysis revealed that the 
heritability estimates of MDD range between 31-42% (Sullivan et al. 2000).  Genetic risk 
factors that influence stressful life events are also correlated with genetic risk factors for 
MDD (Kendler and Karkowski-Shuman 1997), however, the complexity of MDD has 
made it difficult to find potential susceptibility genes and only a handful of genetic risk 
factors have been uncovered (Lopez-Leon et al. 2008).  For instance, a polymorphism 
in the promoter region of the SERT gene combined with stressful life events was 
associated with risk for depression (Caspi et al. 2003) and specific epigenetic changes 
in the glucocorticoid receptor gene were associated with suicide victims who suffered 
childhood abuse (McGowan et al. 2009).          
Genome wide association studies (GWAS) have been performed on MDD 
subjects with minimal success.  Two recent GWAS studies failed to find any single 
nucleotide polymorphisms (SNPs) that contribute to the risk for MDD (Muglia et al. 
2010; Shi et al. 2011).  While a recent GWAS study found four MDD risk genes, the 
authors admit there is a likely possibility these are false discoveries (Bosker et al. 2011).  
Together, these results suggest that using GWAS to identify SNPs associated with 
MDD may be difficult due to heterogeneity of the disorder, uncontrolled environmental 
factors, and potentially small effect sizes of MDD-associated gene variants.  
Interestingly, a recent study assessing genetic variants in relation to cortisol secretion 
and depression found several SNPs in a single gene that were associated with both 
conditions (Velders et al. 2011).  Thus, using GWAS for a more focused approach may 
help to identify variants related to subtypes of MDD or could play a role in 
individualization of treatment using pharmacogenetic approaches (Malhotra 2010). 
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1.2 USING RODENTS TO INVESTIGATE MDD 
 
1.2.1 Difficulties in Using Rodents to Investigate MDD 
 
Rodent models have been invaluable for studying emotion and fear-related behaviors 
as more invasive techniques can be used to explore the mechanism(s) underlying 
mood.  However, modeling a complex human disorder such as MDD in a rodent poses 
many challenges. First, MDD is defined by symptomatology rather than neurobiology 
and the symptom heterogeneity between individuals can be vast (Hyman 2010), making 
it difficult for a single animal model or behavioral test to mimic all elements of the 
disorder.  Second, MDD likely involves uniquely human neural circuitry, such as the 
much expanded prefrontal cortex, that has higher functioning than in a rodent (Crawley 
2000).  Another problem is that rodent models and behavioral tests are at risk for 
anthropormorphism (Crawley 2000).  Emotions are highly species-specific and 
measuring abstract symptoms in rodents, such as depressed mood, presents a 
challenge as it is difficult to know the emotional capabilities of a rodent or what exactly a 
rodent is “feeling” (Cryan and Holmes 2005).  Thus, when using or developing animal 
models for a psychiatric disorder such as MDD, it is critical to assess the level of validity 
it achieves.  Animal models are typically assessed on construct, face, and predictive 
validity, which evaluate etiological, symptomatological, and pharmacological relevance 
respectively (Nestler and Hyman 2010).  While it is unlikely we can ever fully reproduce 
MDD in a rodent, we can aspire to animal models (whether genetic, environmental, or 
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pharmacological) that recapitulate many aspects of the disorder in an attempt to model 
a depressive-like “syndrome”. 
Overinterpretation of simple behavioral phenotypes is another concern in animal 
studies of MDD (Crawley 2000).  A single phenotype or a single test are often wrongly 
interpreted as modeling the disease, rather than a single aspect or component of the 
disease.  The focus on human endophenotypes, or a single heritable trait associated 
with the disorder, has provided more tangible measures to model in rodents (Cryan et 
al. 2005; Gould and Gottesman 2006).  Currently, most labs use the approach that 
multiple tests are needed to assess convergent “rodent endophenotypes” of depressive-
like behavior (Cryan and Mombereau 2004).  For example, the forced swim test and tail 
suspension tests are not models of depression but they do isolate “simple, quantifiable 
endophenotypes or response elements that are sensitive to stress and antidepressant 
action and amenable to biological analysis” (Crowley and Lucki 2005).  Thus, perhaps 
combining behavioral and physiological endpoints may provide a more tangible and 
comprehensive way to assess an MDD-like syndrome in rodents.  
Another inherent problem in evaluating rodent behavior is variability in behavior 
due to environmental factors such as time of day, experimenter, animal colony-related 
events, etc.  In a now classic study, several strains of inbred mice were simultaneously 
tested in three different laboratories.  The authors went to great efforts to normalize 
protocols, equipment, and animal husbandry between the labs and, while large 
differences between inbred strains were replicated across labs, they found systematic 
differences between behavioral tests across labs, which they attributed to subtle 
environmental differences between labs (Crabbe et al. 1999; Wahlsten et al. 2003).  
The unpredictable chronic mild stress paradigm (see below), in particular, has suffered 
from inter-lab reliability issues (Cryan and Mombereau 2004) leading to a high degree of 
variability between successful protocols.  In addition, there are multiple tests for 
assessing anxiety- and depressive-like behaviors in rodents and, adding to this issue, 
individual labs can even interpret results from a single test differently.  For instance, the 
forced swim test, a classic test originally used to test antidepressant efficacy of 
compounds, is now frequently used to test for “depressive-like” behavior, and 
30 
 
interpretations of the behavior vary widely (Cryan and Mombereau 2004; Crowley and 
Lucki 2005; Cryan et al. 2005).  Thus, multiple testing, along with a high degree of in-
house validation, is necessary for assessment of complex phenotypes such as 
emotionality in rodents (Wahlsten et al. 2003).   
 
1.2.2 UCMS and CORT Rodents Models of Depression 
 
1.2.2.1 Behavioral Correlates of MDD 
 
Two rodent models have been shown to recapitulate multiple symptoms of MDD and 
are thus highly utilized to study the neurobiological mechanisms underlying the disorder.  
The unpredictable chronic mild stress (UCMS) rodent model for depression mimics the 
role of “psycho-social” stress in precipitating depressive pathology in humans, while the 
chronic corticosterone model (CORT) recapitulates the physiological role of stress in 
MDD onset.  The UCMS model consists of exposing mice to various randomized 
environmental and social stressors for at least four weeks (Ducottet et al. 2004; Willner 
2005), while the CORT model consists of exposing mice to a low dose of exogenous 
corticosterone for at least four weeks (Ardayfio and Kim 2006; David et al. 2009), both 
attempts at construct validity.  These models have been shown to induce a “depressive-
like” syndrome (face validity), with symptoms reminiscent of the human disease 
[Reviewed in (Willner 2005; Sterner and Kalynchuk 2010)].  Following either paradigm, 
mice exhibit increased anxiety and depressive-like symptoms, increased anhedonia-like 
symptoms measured by decreased consumption of sucrose, and decreased fur coat 
state [CORT: (Ardayfio and Kim 2006; David et al. 2009; Gourley and Taylor 2009)], 
[UCMS: (Mineur et al. 2006; Ibarguen-Vargas et al. 2008; Surget et al. 2008)].  The 
UCMS paradigm has also been shown to mimic sex differences in human MDD patients 
(Dalla et al. 2005; Joeyen-Waldorf et al. 2009; Guilloux et al. 2011) and both paradigms 
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are sensitive to chronic antidepressant treatment (predictive validity), similar to human 
MDD patients (Surget et al. 2008; David et al. 2009).  A reliable marker of the 
progression of both the UCMS and CORT syndromes is the degradation of fur coat 
quality, thought to be an impaired grooming response, which is a visual marker of the 
syndrome also reversed with chronic antidepressant treatment (Mineur et al. 2006; 
Surget et al. 2008; David et al. 2009).  While both paradigms mimic multiple behavioral 
symptoms of MDD, a caveat is that they are exclusively dependent on environmental or 
physiological stressors, a precipitating factor for several other psychiatric disorders (e.g. 
anxiety disorders) as well as MDD.  However, the cellular and physiological 
characteristics recapitulated by these models are more specific to those seen in MDD.  
 
1.2.2.2 Cellular and Physiological Effects 
 
Chronic stress has been shown to elicit enhanced dendritic arborization (hypertrophy) 
(Vyas et al. 2002) and enhanced synaptic connectivity (Vyas et al. 2006) in the BLA.  
Amygdala hypertrophy was found to persist for weeks after stress, unlike the reversible 
hypotrophy found in the hippocampus (Vyas et al. 2004).  In addition, acute and 
uncontrollable stress, along with corticosterone administration, enhance BLA firing 
(Kavushansky and Richter-Levin 2006; Kavushansky et al. 2006), pointing toward an 
overall stress-induced increase in amygdala reactivity.  In contrast to the amygdala, 
decreased glial cell proliferation and hypotrophy were observed in cortical regions 
following UCMS and chronic corticosterone administration (Wellman 2001; Banasr et al. 
2007).  Even a brief uncontrollable stress paradigm (3 days of forced swimming) elicited 
a significant retraction of dendrites in the infralimbic cortex (IL) (Izquierdo et al. 2006).  
Significant stress-related cellular changes have also been found in the hippocampus of 
rodents, including loss of neuronal plasticity in the CA3 region (Gould and Tanapat 
1999; Sapolsky 2003) and decreased hippocampal neurogenesis (Gould et al. 1997; 
Gould et al. 1998).  However, direct evidence supporting involvement of the 
hippocampus in MDD is limited to reports indicating that smaller hippocampal volumes 
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in MDD subjects are associated with loss of neuropil (Stockmeier et al. 2004).  
Interestingly, antidepressant-induced increases in hippocampal neurogenesis have 
recently been attributed to mediating effects of the BLA (Castro et al. 2010), thereby 
underscoring the pivotal role of this structure in mood regulation.  Thus, chronic stress 
paradigms, such as UCMS and CORT, paradigms elicit cellular changes in regions 
impacted by MDD (Figure 1.2).   
In addition to cellular alterations, UCMS exposure has been shown to induce 
alterations in the HPA-axis. UCMS exposure elicits increased glucocorticoid levels 
(Ayensu et al. 1995; Banasr et al. 2007) and mice exposed to the CORT paradigm have 
a blunted stress response exemplified by attenuated stress-induced corticosterone 
levels (David et al. 2009).  UCMS also causes significant changes in both mRNA and 
protein levels of CRH receptors in the orbitofrontal cortex of mice (Anisman et al. 2007). 
Furthermore, chronic administration of CRF1 antagonists had antidepressant effects 
and reversed transcriptome changes in both cingulate cortex and amygdala following 
UCMS (Surget et al. 2008). Thus, similar to findings in MDD (see 1.1.2.2), UCMS and 
CORT elicit disruptions in the HPA-axis.  In summary, the UCMS and CORT rodent 
models of depression achieve a crucial combination of construct, face, and predictive 
validity making them quite comprehensive models for MDD. 
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Figure 1.2. Stress-induced changes in dendritic structure in rodents.  Chronic 
stress causes dendritic hypertrophy in the amygdala of rodents, but dendritic 
hypotrophy in the infralimbic prefrontal cortex of rodents, both regions implicated in 
MDD.  These changes represent potential substrates for corticolimbic dysfunction in 
MDD, behaviors that are potentially detectable in fear conditioning paradigms.  
[Modified from (Rodrigues et al. 2009); originally from (Vyas et al. 2002; Izquierdo et al. 
2006)]. 
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1.2.3 Circuitry Underlying Fear and Emotion in Rodents 
 
The amygdala has been implicated as a central region involved in MDD (section 
1.1.2.1) and as previously discussed, there is significant conservation of corticolimbic 
circuitry between the mouse and human (Figure 1.1). This circuitry has been thoroughly 
examined in rodents using conditioned fear and the general pathway of fear 
assessment is widely acknowledged (Phelps and LeDoux 2005).  Briefly, the BLA 
serves as a site of convergence for sensory information from the thalamus.  This 
sensory input can then be modulated by regions such as hippocampus or prefrontal 
cortex and the information is then relayed to the central nucleus of the amygdala (CeA), 
the major output center of the amygdala. CeA outputs project to regions, such as the 
hypothalamus and periaquaductal gray, which control fear-associated responses 
[reviewed in (Phelps and LeDoux 2005)].  Below, I describe in depth how utilization of 
the fear conditioning paradigm in rodents has helped to shed light on the roles of these 
regions in mood regulation.   
 
1.2.3.1 Fear Conditioning 
 
A typical fear conditioning paradigm consists of learning of a fear association (fear 
learning), usually a conditioned stimulus (CS) (e.g. an audible tone) paired with an 
unconditioned fearful stimulus (US) (e.g. footshock), whereby the animal quickly learns 
to “fear” the CS, a response measured by freezing in rodents.  This is often followed by 
fear extinction in which the animal is repeatedly exposed to the CS without the US, 
whereby the fear response to the CS is diminished (section 1.2.3.2).  The BLA has been 
shown to play a central role in fear learning and is the site where sensory information 
about the CS and US converge during the learned fear association (Fanselow and 
LeDoux 1999).  Lesioning the BLA prior to fear learning eliminates the learned 
association, but also eliminates freezing (Maren et al. 1996) and even natural variation 
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in BLA volume correlates with changes in fear response. For instance, a small BLA 
volume is associated with enhanced fear learning and an exaggerated glucocorticoid 
response (Yang et al. 2008).  Fear learning also enhances firing in the BLA (Quirk et al. 
1995) and disruption of BLA activity during learning prevents the learned association 
(Muller et al. 1997).  On the other hand, the CeA is mainly involved in the output of the 
fear response, projecting to downstream targets in the brainstem and hypothalamus to 
coordinate motor and autonomic responses.  However, recent evidence also implicates 
the CeA in the acquisition and storage of conditioned fear responses and supports 
differential roles for the lateral and medial portions of CeA (Wilensky et al. 2006; 
Zimmerman et al. 2007; Ciocchi et al. 2010).  
 
1.2.3.2 Fear Extinction 
 
There is evidence that extinction of the conditioned fear association is a separate 
learning process that actually forms a new memory which inhibits the conditioned 
response (Quirk 2002).  The BLA is a critical component of fear extinction as well as 
fear conditioning, and it is necessary for acquisition of extinction (Herry et al. 2006; 
Sotres-Bayon et al. 2007). The basal (BA) and lateral (LA) nuclei have dissociable roles 
in these processes, and the BA is thought to be essential for accessing previously 
acquired fear memories (essential for extinction) (Anglada-Figueroa and Quirk 2005), 
while the LA may be involved in long-term storage of fear memories (Hobin et al. 2003; 
Rodrigues et al. 2004). While inhibiting the BLA with the GABAA receptor agonist 
muscimol will reduce fear expression (i.e. freezing) during extinction, it does not impair 
extinction learning (i.e. the rate) (Muller et al. 1997; Akirav et al. 2006), suggesting the 
BLA is not the only component involved in extinction learning.  Indeed, prefrontal 
regions including the prelimbic (PL) and infralimbic (IL) cortices (rodent analogues to 
the dorsal anterior cingulate cortex and vmPFC, respectively), have been implicated in 
extinction and fear expression (Peters et al. 2009).  Reports indicate the PL modulates 
fear expression during extinction via projections to BLA, the “common final path” for fear 
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expression, while the IL is necessary for extinction learning and retrieval (Sierra-
Mercado et al. 2011).  The resulting model is one where PL activation drives fear and IL 
activation inhibits fear through opposing connections with BLA (Figure 1.3).  
Intercalated neurons, an additional component of the circuit, mediate input from the IL to 
the CeA and are required for extinction learning (Likhtik et al. 2008). 
 
 
 
 
 
 
 
Figure 1.3. Circuits implicated in fear conditioning and extinction. Cortical regions 
such as PL and IL modulate BLA and ITC which project directly to CE where fear 
outputs are determined. PL=prelimbic cortex, IL=infralimbic cortex, LA=lateral 
amygdala, BA=basal amygdala, ITC=intercalated cells, CE=central amygdala. Modified 
from (Peters et al. 2009). 
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1.2.3.3 Corticolimbic Coordination in Fear Conditioning 
 
Similar to MDD, there is evidence for corticolimbic coordination in fear conditioning in 
rodents.  The BLA and orbitofrontal cortex cooperate to encode learning associations 
(Schoenbaum et al. 1998), with the BLA encoding motivational significance and the 
orbitofrontal cortex controlling the appropriate behavioral outcome (Schoenbaum et al. 
1999; Saddoris et al. 2005).  The mPFC-BLA connection is critical during consolidation 
of the extinction memory, and the IL likely controls feed-forward inhibition to the BLA 
when the extinguished CS is re-experienced (Milad and Quirk 2002).  Thus, the 
connection between BLA and PFC is considered crucial for encoding the 
motivational/emotional significance of a cue and determining the appropriate behavioral 
response (Davis and Whalen 2001; Rempel-Clower 2007).   
 
1.2.3.4 Effects of Stress on Fear Conditioning 
 
There is also well documented evidence that stress hormones influence the functioning 
of fear circuitry [reviewed in (Rodrigues et al. 2009)].  Exposure to stress and elevation 
of BLA glucocorticoid levels prior to conditioning enhances fear memory (Izquierdo et al. 
2002; Rau et al. 2005), while blockade of glucocorticoid signaling in BLA after fear 
conditioning disrupts fear memory consolidation (Jin et al. 2007; Rodrigues and 
Sapolsky 2009).  Glucocorticoid activation prior to extinction facilitates extinction 
learning and administration of glucocorticoid receptor antagonists or corticosterone 
inhibitors attenuates fear extinction (Cai et al. 2006; Yang et al. 2006).   Therefore, all 
evidence suggests that activation of the HPA-axis is crucial for the formation and 
extinction of fear memories.   
Rats selectively bred for increased susceptibility to the learned helplessness task 
(a paradigm which induces depression-like symptoms in rodents) showed enhanced 
fear learning and were resistant to fear extinction. Concomitant with these alterations, 
rats showed decreased sucrose preference, a rodent correlate to anhedonia (Shumake 
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et al. 2005), suggesting a connection between abnormal extinction mechanisms and a 
depressive phenotype.  Several other studies have noted that chronic stress impairs 
recall of extinction (Miracle et al. 2006; Garcia et al. 2008; Farrell et al. 2010), but not 
fear expression or extinction learning.  However, in two of these studies “extinction” was 
performed only 1 hour after initial fear conditioning, rather than the typical 24 hours, 
allowing no time for consolidation of the fear memory.  Instead, “extinction recall”, 
performed on day 2, is more akin to typical extinction training.  Taking this into 
consideration, the results obtained in these studies indicate chronic stress alters fear 
extinction and expression, an effect also shown to be sexually dimorphic (Baran et al. 
2009).  Notably, lesions of IL occlude this stress-induced impairment of extinction, an 
effect potentially mediated by stress-induced dendritic retraction in IL (Farrell et al. 
2010).  Furthermore, atrophy in IL neurons induced by brief stress is associated with 
resistance to fear extinction (Izquierdo et al. 2006).  Animals exposed to prior stress 
also have facilitation of fear conditioning associated with decreased GABA control and 
neuronal hyperexcitability (Rodriguez Manzanares et al. 2005). Thus, responses to fear 
conditioning, particularly extinction learning, are altered by glucocorticoids and chronic 
stress paradigms indicating this task can be used to assess corticolimbic function 
associated with stress-related disorders such as MDD. 
1.2.4 Using Knockout Mice 
Note on the following section:  Below is segment from a review article on the role of 
genetically modified animals in neuropharmacology that we wrote for the Encyclopedia 
of Neuropsychopharmacology (Authored by N. Edgar and E. Sibille).  I have included an 
abbreviated version of the section entitled “Gene knockout technology” below to 
highlight the importance of using knockout animals to shed light on gene function, as I 
have used the CNP1KO mouse to elucidate the function of the gene in this dissertation.  
The entire article, along with definitions for words highlighted in blue can be found in 
Appendix A.   
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The creation of a traditional knockout (i.e. removal of a gene) mouse consists of 
disrupting all or part of the coding sequence of a gene of interest (GOI) for the purpose 
of exploring the phenotype in the absence of the gene. The GOI is removed by 
transfecting an embryonic stem cell with a construct designed for homologous 
recombination, which typically contains a selectable marker in place of the GOI. 
Mutated stem cells are then selected in vitro and are microinjected into a blastocyst and 
implanted into a pseudopregnant female mouse (Figure A.1b).  Most of the offspring 
produced using this technique are chimeras (or mosaics) due to the presence of both 
mutated and non-mutated stem cells within the blastocyst. The next step consists of 
breeding chimeric mice to identify individuals with germ cells that have undergone 
homologous recombination. These founder mice will then be bred to produce 
homozygous mutant animals (Dale 2002). 
While knockout organisms have been paramount in the goal to elucidate the 
function of specific genes, problems associated with knockout technology include that 
removal of a gene is often lethal or that the absence of the gene product during 
development leads to compensatory events that can obscure the analysis of the 
function of the missing gene. Specifically, these compensatory developments likely 
differ from the disease mechanisms that the knockout animal is intended to model, as 
disease processes rarely include full loss of gene function. 
1.3 THE ROLE OF GLIA IN MDD 
1.3.1 Glial Structure and Function 
There are two major classes of cells in the brain:  neuons and glia.  While neurons are 
often the primary focus of brain research, glial cells actually comprise 90% of brain 
cells.  The two cell types differ in their electrical excitability.  While neurons can 
generate an action potential, which then propagates through neural networks, glia are 
unable to generate an action potential, although they do express voltage-gated 
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channels.  Glial cells are further delineated into macroglia (cells of neural [ectodermal] 
origin) and microglia (cells of non-neural [mesodermal] origin).  Macroglia include 
astrocytes, oligodendrocytes, and ependymal cells, while microglia are in a class of their 
own and actually originate from macrophages that invade the brain early in life.  
Historically, glial cells were thought to be a “connective substance” which literally acted 
as the glue that held neurons together and which was devoid of cellular function 
(Verkhratsky and Butt 2007).  While the functional significance of glial cells is often 
overlooked, increasing evidence is emphasizing the unique importance of glial cells and 
their role in mediating neuronal cell function. 
1.3.1.1 Microglia 
 
Microglia make up about 10% of all glial cells and are found throughout all regions of 
the brain.  Microglia form the immune system of the brain, which can be activated during 
injury and/or disease and they contain both classical immunological receptors along 
with neuroreceptors.  Each individual microglial cell covers an area of about 50,000μm3, 
never coming into contact with another microglial cell.  Within gray matter, microglial 
cells extend their processes in all directions; while in white matter, their processes are 
typically aligned perpendicular to white matter tracts.  Microglial cells appear in one of 
three states: 1) Resting microglia are found under normal physiological conditions and 
their processes are constantly moving to scan their territory for noxious agents, 2) 
Resting microglia become activated when an insult is detected. The cells retract many 
of their processes and the remaining processes become thicker.  The cell body 
enlarges, starts to produce immune response molecules, and becomes motile to 
remove any damaging agents (Rajkowska and Miguel-Hidalgo 2007).  3) If activated 
microglia are unable to clear the threat and cells begin to die, active cells become 
phagocytic, an irreversible state where the cells devour remnants of dead and dying 
neurons (Verkhratsky and Butt 2007).    
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1.3.1.2  Astrocytes 
 
Astrocytes comprise about 80% of glial cells in the CNS and consist of about ten 
different subtypes (Verkhratsky and Butt 2007).  The largest subgroup is the “true 
astrocytes”, including protoplasmic astrocytes, which are present in grey matter, and 
fibrous astrocytes, which are present in white matter.  The other major subgroup is 
radial glia, which primarily assist in neuronal migration during development.  The 
remaining groups are smaller, more specialized populations of astrocytes that are often 
region specific. With so many subtypes, astrocytes have diversified functional roles of 
which I will only touch on briefly here. One of the most critical functions of astrocytes is 
that of stem cells for both neurons and glia in the adult brain. Astrocytes are the stem 
elements found in the hippocampus and the subventricular zone that produce new 
neurons, and they are also the stem elements that produce all other types of glia 
throughout the brain.  Astrocytes also play a crucial role in maintaining the blood brain 
barrier and regulating microcirculation within the brain.  Astrocytes contain a variety of 
ion transporters for maintaining homeostasis of potassium and calcium in the 
extracellular space, along with glutamate transporters and aquaporins for regulating 
extracellular glutamate and water homeostasis, respectively (Rajkowska and Miguel-
Hidalgo 2007).  Astrocytes are also closely involved with regulating neuronal activity via 
tripartite synapses (an astrocyte synaptically associated with both pre- and post-
synaptic neurons) (Araque et al. 1999) and glucocorticoid receptors that act to alter 
production of neurotrophic factors (Gubba et al. 2004).  Finally, astrocytes modulate 
synaptic transmission by 1) reuptake and/or release of neurotransmitters at the synaptic 
cleft via specialized transporters or binding proteins; 2) morphological plasticity at the 
synapse [e.g. during lactation high levels of oxytocin trigger withdrawl of astrocyte 
processes thereby allowing more glutamate into the synaptic cleft; (Theodosis et al. 
2006)]; and 3) complex connectivity between themselves, neurons, other glial cells, 
allowing signal propagation throughout the “network” (Verkhratsky and Butt 2007).   
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1.3.1.3 Oligodendrocytes 
 
Oligodendrocytes, the main myelin forming cells of the central nervous system, 
comprise only about 5% of all glial cells, have fewer process than astrocytes, and are 
found in both grey and white matter. While they are morphologically distinguished into 
four phenotypes (Verkhratsky and Butt 2007), within the cortex and most subcortical 
regions, they are divided into perineuronal oligodendrocytes (found in grey matter; also 
termed Type I) and interfascicular oligodendrocytes (found in white matter; also termed 
Type II) (Rajkowska and Miguel-Hidalgo 2007).  Both types of oligodendrocytes have a 
small round cell body and about four to six branching processes which can myelinate 
ten to thirty axons.  Myelin consists of lipids (70%) and a variety of proteins (30%), 
including myelin basic protein (MBP), proteolipid protein (PLP) and 2’,3’-cyclic 
nucleotide-3’-phosphodiesterase (CNP), which together comprise about 85% of all 
myelin proteins.  When ensheathing axons, the cytoplasm is extruded from the cell 
processes and the opposing lipid bilayers are fused.  The myelin then forms compacted 
concentric layers (lamellae) around the bare axon (typically 10-100 lamellae), with the 
cytoplasmic edges termed the inner and outer mesaxon.  Oligodendrocytes play a role 
in regulating the development and periodicity of nodes of Ranvier, spaces of bare axon 
which contain ion channels critical for action potential propagation along the axon.  At 
the ends of the internodal regions of myelin sheath, the myelin lamellae form a junction 
with the axon termed the paranode region (Figure 1.4).  This region consists of septate-
like junctions between the axon and paranodal myelin, with the axonal proteins Caspr 
(contactin-associated protein) and contactin interacting with the glial protein NF155 to 
form the junction. This region appears to have three primary roles in maintaining a 
stable saltatory conduction: 1) spatial separation of Na+ and K+ channels, 2) sealing the 
myelin sheath in a way that allows only selected nutrients to diffuse into the internodal 
periaxonal space (space between the myelin and axon), and 3) stabilization of the entire 
structure in the face of mechanical stressors (Lazzarini 2004; Rosenbluth 2009). 
Functionally, mature oligodendrocytes provide critical insulation to facilitate 
axonal conduction.  The myelin sheath increases the resistance and lowers the 
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capacitance of the axonal membrane which allows faster conductance speeds in 
myelinated axons compared to unmyelinated axons of the same diameter.  While this 
function of myelin is well established, recent studies have indicated that myelin plays a 
more functional role than previously thought.  Electrophysiological changes in 
oligodendrcytes can rapidly modulate axonal conduction velocity (Yamazaki et al. 
2007).  Activity in axons has been shown to promote astrocyte activity which in turn 
promotes myelination, suggesting an activity dependent myelination process (Ishibashi 
et al. 2006).  Oligodendrocytes also monitor neural activity through a variety of 
receptors including glutamatergic (AMPA, NMDA, and kainate) (Patneau et al. 1994; 
Ziak et al. 1998) and GABAergic (GABAA) (Berger et al. 1992) receptors, which both 
depolarize the cell, the latter due to high intracellular levels of Cl-.  In addition, Nave 
suggests that trophic support from oligodendrocytes is required for mitochondrial energy 
metabolism in axons since the myelin sheath itself restricts axonal access to 
extracellular metabolic substrates (Nave 2010).  Additional evidence for myelin trophic 
support comes from studies of mice lacking oligodendrocyte-specific proteins. While 
lack of MBP leads to loss of compact myelin (Brady et al. 1999), mice lacking PLP, 
myelin associated glycoprotein (MAG), and CNP all have relatively normal myelin 
assembly, but develop progressive neurodegeneration (Klugmann et al. 1997; Griffiths 
et al. 1998; Yin et al. 1998).  In addition, PLP deficient mice also show disruption of fast 
axonal transport prior to axonal degeneration (Edgar et al. 2004).  These studies 
indicate that a disruption in oligodendrocyte proteins can have a major impact on axon 
survival, pointing toward a pivotal role for myelin in axon trophic support.  Together, 
these studies indicate that mature oligodendrocytes have a dynamic role in regulating 
neuronal signal transmission and support of axons. 
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Figure 1.4. Structure of a myelinating oligodendrocyte.  Oligodendrocyte cells 
extend processes of their cell membrane to form the myelin sheath.  Opposing sides of 
the cell membrane fuse together and this myelin sheath is wrapped in concentric circles 
around the axon. The segment of myelin sheath between the nodes of Ranvier 
(internode region) terminates at the paranode region, a site critical for axoglial 
interaction. From (Nave 2010). 
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1.3.1.4  NG2 Cells 
 
Mature oligodendrocytes are derived from oligodendrocyte precursor cells (OPC) which 
develop in specific ventricular zones in the brain, migrate to their final site in the brain, 
and finally differentiate.  During this time, various proteins are expressed that can mark 
the developmental stage.  A specific subtype of OPCs, which expresses a novel 
chondroitin sulphate proteoglycan (NG2) (Belachew et al. 2001; Mallon et al. 2002), is 
worth mentioning. NG2 cells are a relatively newly discovered class of cells that share a 
common lineage with oligodendrocytes and express several markers specific to OPCs 
(e.g. platelet-derived growth factor) but do not express markers for mature 
oligodendrocytes.  NG2 cells are thought to function as multipotent adult neural stem 
cells, as they can also differentiate into neurons and astrocytes.  In addition, NG2 cells 
give rise to both mature oligodendrocytes and a separate population of NG2-glia called 
synantocytes (Belachew et al. 2003; Aguirre and Gallo 2004).   While NG2 cells do not 
form contacts with each other, they do form contacts with neurons, oligodendrocytes, 
and astrocytes and express voltage-gated ion channels along with various receptors 
(Verkhratsky and Butt 2007).  In addition, GABAergic and glutamatergic neurons 
establish contact with NG2 cells (Trotter et al. 2010), and they are able to fire action 
potentials (Karadottir et al. 2008), suggesting an active role in signal conduction. NG2 
cells are also postulated to rapidly respond to changes in neuronal integrity to either 
stimulate formation of a glial scar, or to generate new neurons or glial cells if necessary 
(Butt et al. 2005).  Thus, while the functional role of NG2 cells is still being investigated, 
they are clearly a critical element for maintaining interactions between neurons and glia. 
However, care must be taken in future studies to properly distinguish between NG2 
cells and oligodendrocytes. 
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1.3.2 Glial Alterations in MDD 
Glial disruptions are postulated to contribute to the pathophysiology of MDD and 
alterations have been seen in all the major glial subtypes in MDD. [Reviewed in 
(Rajkowska and Miguel-Hidalgo 2007; Hercher et al. 2009)].  Studies of brain regions 
implicated in MDD (particularly corticolimibic regions) have described reductions in glial 
density or glia/neuron ratio in the subgenual PFC (Ongur et al. 1998), dorsolateral 
prefrontal cortex (Rajkowska et al. 1999; Cotter et al. 2002), orbitofrontal cortex 
(Rajkowska et al. 1999) anterior cingulate cortex (Cotter et al. 2001), and amygdala 
(Bowley et al. 2002; Hamidi et al. 2004).   In addition to glial cell density, increases in 
glial cell size have been reported in the dorsolateral PFC (Rajkowska et al. 1999) and 
anterior cingulate cortex (Chana et al. 2003) of MDD subjects.    
The above studies used generalized nissl staining which does not allow 
distinction between different types of glial cells.  However, studies with more specific 
immunostaining have revealed differences in subtypes of glia in MDD.  While the 
neuroinflammatory hypothesis for MDD points toward potential alterations of microglia, 
the main cell type for active immune defense in the CNS (Muller and Schwarz 2007; 
Miller et al. 2009), only a single study has examined microglia pathology in MDD 
subjects.  Steiner and colleagues showed increases in microglial density in a variety of 
brain regions in MDD subjects who committed suicide, but normal microglial densities in 
non-suicide MDD subjects (Steiner et al. 2008). They used a known microglial marker 
for neurodegeneration and neuroinflammation (HLA-DR), suggesting a role for these 
processes in suicidal behavior.  In rats, proliferation of microglial cells in the 
hippocampus (a region implicated in stress and mechanism for antidepressant action) 
was reduced by chronic corticosterone administration and electroconvulsive seizure 
treatment reversed this effect (Wennstrom et al. 2006) 
Alterations in astrocytes in MDD have primarily been found using immunostaining 
for GFAP (glial fibrillary acid protein) which stains for an intermediate filament protein 
found in astrocytes and ependymal cells.  Decreases in GFAP have been found in the 
dorsolateral PFC and orbitofrontal cortex of MDD subjects, however, they have primarily 
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been found only in young (age 30-45) subjects with MDD (Johnston-Wilson et al. 2000; 
Miguel-Hidalgo et al. 2000; Si et al. 2004). Furthermore, there are reports of altered 
astrocytic excitatory amino acid transporter gene expression (EAAT1 and EAAT2) in 
cortical regions of MDD subjects (Miguel-Hidalgo et al. 2010). Rodent studies have 
revealed that rats with astrocytes specifically ablated in the frontal cortex showed 
depressive-like behaviors reversible with antidepressant treatment (Banasr and Duman 
2008).  Chronic stress in rodents decreased the number and somal volume of 
astrocytes in the hippocampus (Czeh et al. 2006) and impaired glutamatergic cycling in 
the PFC, a pattern reversible via pharmacological increase of glutamate uptake (Banasr 
et al. 2010). Together, this evidence suggests an astrocyte-mediated 
dysfunction/depletion of prefrontal cortex glutamateric cycling and homeostatsis in MDD 
[Reviewed in (Valentine and Sanacora 2009)].    
While there is evidence for disruption in other glial subtypes, the role of 
oligodendrocyte alterations in MDD and other psychiatric disorders has become a 
primary focus of research (Fields 2008). In the amygdala and prefrontal cortex of MDD 
subjects, previously-reported decreases in glial cell number were attributed to reduced 
oligodendrocyte number, (Hamidi et al. 2004; Uranova et al. 2004) (Figure 1.5).  In 
addition, patterns of downregulation of oligodendrocyte-related transcripts in amygdala 
(Sibille et al. 2009) and nearby temporal cortex (Aston et al. 2005) were seen in MDD 
subjects. Studies using diffusion tensor imaging have also revealed white matter 
abnormalities in cortical and temporal regions in MDD subjects (Alexopoulos et al. 2002; 
Taylor et al. 2004; Bae et al. 2006; Ma et al. 2007), and loss of white matter correlates 
with depressive symptom severity (Nobuhara et al. 2006). 
Rodents exposed to chronic stress have a reduction in the proliferation of 
oligodendrocytes and NG2 cells in the PFC, a pattern that is reversible with 
antidepressant treatment (Banasr et al. 2007; Czeh et al. 2007).  Similar to chronic 
stress, chronic corticosterone exposure in rodents resulted in decreased cortical and 
amygdala oligodendrocyte (Banasr et al. 2007) and NG2 proliferation (Alonso 2000; 
Wennstrom et al. 2006), suggesting oligodendrocytes may be particularly susceptible to 
corticosterone induced toxicity. Following electroconvulsive seizure therapy, an 
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antidepressant treatment in humans, non-stressed rats showed increased proliferation 
of NG2 cells in amygdala and hippocampus (Wennstrom et al. 2003; Wennstrom et al. 
2004; Wennstrom et al. 2006) and increased proliferation of mature oligodendrocyte 
cells in the PFC (Madsen et al. 2005).  However, in non-stressed rats treated chronically 
with the antidepressant fluoextine, there were no changes observed in oligodendrocyte 
proliferation in prelimbic cortex (Kodama et al. 2004), suggesting oligodendrocyte 
changes are specific to chronic stress induced pathology and are not involved in the 
mechanism of pharmacological antidepressant treatment.  Thus, it appears that 
oligodendrocytes are altered in corticolimbic regions affected in MDD and may be 
vulnerable to stress-related insults.  However, it is unknown whether these changes 
represent a causal link to MDD or simply represent compensatory changes or neutral, 
confounding side effects.   
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Figure 1.5. Decreased oligodendrocyte density in the amygdala of MDD patients.  
Oligodendrocyte cells were determined by morphology following Nissl staining and the 
density of oligodendrocytes was determined by dividing the total oligodendrocyte cell 
count by the volume of the amygdala.  Densities were compared between control, MDD, 
and bipolar patients with only MDD exhibiting significantly decreased oligodendrocyte 
density compared with controls.   Figure modified from (Hamidi et al. 2004). 
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1.4 CNP 
1.4.1 Structure and Localization of CNP 
The genetic loci for CNP are on mouse chromosome 11 and human chromosome 17 
(Bernier et al. 1988; Douglas et al. 1992). The sequence homology of genomic DNA is 
highly conserved among species ranging from bullfrog to human, and the degree of 
homology between mouse and human is approximately 85% (Braun et al. 2004), 
suggesting a conserved function.  The CNP gene contains four exons and gives rise to 
two RNA transcripts (CNP1 and CNP2) via alternative promoters, which are translated 
into protein isoforms [Reviewed in (Braun et al. 2004).  However, the transcript for 
CNP2 contains alternative translation initiation sites for both CNP1 and CNP2, and is 
therefore able to produce both isoforms (O'Neill et al. 1997) (Figure 1.6A). CNP2 is the 
longer of the two isoforms as it contains a mitochrondrial localization sequence on the 
N-terminus, which is cleaved upon entering the mitochondria leaving a truncated form 
similar to CNP1 (Lee et al. 2006).  However, PKC-mediated phosphorylation can inhibit 
this translocation leaving an active CNP2 in the cytoplasm as well. CNP2 is also 
expressed at low levels in non-myelinating tissue, but is present only in mitochondria 
and is presumed to be involved in RNA and nucleotide processing (Lee et al. 2006).   
While CNP1 is also expressed at much lower levels outside the nervous system, 
in the central nervous system it is found in both mature and immature oligodendrocytes 
where it comprises approximately 4% of myelin-associated protein (Braun et al. 2004), 
making it ideal as a marker for oligodendrocytes.  Specifically, CNP1 is localized to the 
oligodendrocyte cell body, but is primarily found in the non-compact myelin of the inner 
mesaxon and paranodal loops (Trapp et al. 1988) (Figure 1.6B), the principle sites of 
communication between the axon and myelin sheath (see above).  In this region, the 
myelin sheath of the internode is separated from the axon by 12-14nm (the periaxonal 
space) and CNP1 is localized to the cytoplasmic side of the periaxonal membrane. 
During development, OPCs first express CNP2 around embryonic day 15 in the rat, 
followed by expression of CNP1 beginning at postnatal day 1 (Scherer et al. 1994).  
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Expression of both CNP1 and CNP2 peaks just prior to the final differentiation stages 
preceeding myelination (postnatal day 10 in the rat) (Amur-Umarjee et al. 1990), 
suggesting both forms are involved in myelin ensheathment, axon recognition, and 
process outgrowth (Verkhratsky and Butt 2007). 
 
 
 
 
 
 
Figure 1.6. Structure and localization of CNP1.  A). Diagram of the promoter regions 
of CNP DNA (top) and corresponding mRNA transcripts for CNP1 and CNP2 (bottom).  
The gene contains two promoter regions that alternately transcribe CNP1 or CNP2 
[From  (Braun et al. 2004)].  B)  Electron micrograph of a cross-section of an axon 
showing immunoreactivity for CNP in the inner and outer mesaxon loops (arrows).  
Figures modified from (Braun et al. 1988).   
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1.4.2 Function of CNP 
The high expression and paranodal localization of CNP would suggest an important 
functional role.  As a phosphodiesterase, CNP is able to catalyze cleavage of 2’,3’-cyclic 
nucleotides in vitro (Drummond et al. 1962; Sprinkle et al. 1978), however the 
physiological substrate in vivo remains unknown (or potentially non-existent), 
suggesting that the protein may serve a function other than enzymatic activity.  Efforts 
to identify the function of CNP in vitro have found a role for the protein in cytoskeletal 
organization and cell signaling.  OPCs express CNP in filopodia extensions that 
eventually form lamellae indicating a potential role in cytoskeleton organization and 
myelin construction (Braun et al. 1988).  Furthermore, CNP associates with F-actin, 
serves as an anchor for tubulin (Dyer and Benjamins 1989; Bifulco et al. 2002), and also 
possesses microtubule polymerization activity (Bifulco et al. 2002).  CNP 
overexpression in glial cells induces reorganization of the cytoskeletal network resulting 
in process outgrowth (Lee et al. 2005).  Recent evidence has also shown that CNP is an 
RNA-binding protein which inhibits protein translation and mediates RNA binding to 
tubulin (Gravel et al. 2009).  CNP has a binding site for ATP/GTP indicating it may be 
involved in signal transduction pathways (Stingo et al. 2007) and CNP has also been 
shown to associate with “lipid raft” membrane microdomains, which are presumed sites 
of organization for signaling complexes (Kim and Pfeiffer 1999).  In healthy primates, 
CNP was found to accumulate with age due to failure of the proteosomal degradation 
system, potentially resulting in dysfunction of lipid rafts and eventual age-related 
disorders (Hinman et al. 2008).  Thus, together this evidence suggests a role for CNP in 
cell signaling, perhaps mediating cytoskeletal assembly (Braun et al. 2004).  
Similar to in vitro results, adult mice overexpressing CNP1 show redundant and 
aberrant myelination resulting in extension of myelin from internodal regions (Gravel et 
al. 1996).  In addition, this myelin malformation was seen early in development prior to 
OPC differentiation, and resulted in relocation of CNP1 to compact myelin where it 
prevents fusion of the lamellae, likely by interfering with MBP binding (Yin et al. 1997).  
The CNP1 knockout mouse (CNP1KO) has normal myelin assembly, but has 
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progressive axonal degeneration and motor deficits with age (Lappe-Siefke et al. 2003).  
Furthermore, in the CNP1KO mouse, both nodal sodium channels and paranodal 
adhesion proteins (e.g. Caspr) become progressively disorganized with age (Rasband 
et al. 2005) and examination of myelin ultrastructure found degeneration of small 
diameter axons as early as postnatal day 15 (Edgar et al. 2009).  Together, the above 
suggests that removal of CNP compromises paranodal integrity leading to disrupted 
axoglial signaling and eventual axonal degradation.     
Recent experiments from our lab indicated that CNP1 was downregulated in the 
amygdala of postmortem human MDD subjects and mice exposed to the UCMS model 
of depression (Sibille et al. 2009) and this downregulation was reversed by 
antidepressant treatment in rodents (Surget et al. 2008).  The downregulation of this 
transcript was restricted to the amygdala, a critical brain region for mood regulation 
(Phelps and LeDoux 2005) and site of putative primary pathology in MDD (Drevets et al. 
2002; Hamidi et al. 2004), and was not altered in anterior cingulate cortex or dentate 
gyrus, suggesting it is selectively mediated in a central brain region implicated in MDD.  
Downregulation of CNP1 transcripts were previously reported in whole brain 
homogenates and in the temporal cortex of MDD subjects (Aston et al. 2005; Sequeira 
et al. 2009).  Furthermore, there is evidence of reduced levels of CNP in schizophrenia 
(Hakak et al. 2001; Davis et al. 2003; Flynn et al. 2003; Tkachev et al. 2003) and a 
single nucleotide polymorphism (SNP) linked to low CNP expression was significantly 
associated with schizophrenia (Peirce et al. 2006).  Thus, there is evidence supporting 
the general hypothesis that altered CNP levels (and associated oligodendrocyte 
dysfunction) could be a factor in the development of psychiatric disorders.  However, it 
remains to be determined whether oligodendrocyte-specific changes represent 
causative effects in MDD, or whether these changes are simply compensatory or 
neutral bystander effects.   
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1.5 SUMMARY OF INTRODUCTION AND SIGNIFICANCE OF RESEARCH 
MDD is a devastating chronic disorder of altered mood and is the leading cause of 
disability worldwide in terms of years lived with the disability.  While the specific 
mechanism(s) underlying MDD are not well understood, there is evidence for disrupted 
corticolimbic function, and the amygdala is thought to be a central brain region involved 
in mood regulation.  There is also growing evidence for disrupted oligodendrocyte 
structure and function in the same corticolimbic regions in MDD subjects and in animal 
models of MDD.  It is known that healthy oligodendrocytes are necessary to maintain 
optimal axon function (Nave 2010), however it remains to be determined whether 
oligodendrocyte-specific alterations are causal to MDD, or whether alterations are 
compensatory or simply neutral side effects in psychiatric disorders. CNP1 is a critical 
component of the paranode of oligodendrocytes, a region that is necessary to maintain 
the integrity of oligodendrocytes and proper axoglial interactions.  Altered levels of 
CNP1 have also been found in postmortem tissue of MDD subjects, suggesting it may 
play a role in the pathophysiology of MDD.   
Here, we investigated the effect of a lack of CNP1 on MDD-related features using 
the CNP1KO mouse.  We developed and applied a novel Z-score normalization 
procedure to obtain a more long-term and comprehensive measure for emotionality 
(anxiety- and depressive-like behaviors) and also, to counteract inherent variability in 
behavioral measures (Chapter 2).  We then examined whether the CNP1KO mouse 1) 
has altered baseline (trait) emotionality; 2) has altered vulnerability toward developing a 
depressive-like syndrome (state); and 3) has altered amygdala function and molecular 
characteristics (Chapter 3).  These studies explored whether alterations in the integrity 
of oligodendrocytes contribute to the onset of depressive-like symptoms in mice and 
have implications for the pathophysiological mechanisms underlying MDD in humans.   
 
55 
 
2.0  PAPER 1: INTEGRATED BEHAVIORAL Z-SCORING INCREASES THE 
SENSITIVITY AND RELIABILITY OF BEHAVIORAL PHENOTYPING IN MICE: 
RELEVANCE TO EMOTIONALITY AND SEX 
 
Jean-Philippe Guilloux1,2,*, Marianne Seney1,*, Nicole Edgar1,3, Etienne Sibille1,3,§ 
*contributed equally to this work 
 
1Department of Psychiatry, 3Center for Neuroscience, 3811 O’Hara street, BST 
W1643, University of Pittsburgh, Pittsburgh, PA 15213; 2Univ Paris-Sud EA 3544, Fac. 
Pharmacie, Châtenay-Malabry cedex F-92296, France. 
§To whom correspondence should be addressed. E-mail:sibilleel@upmc.edu 
 
 
 
 
 
 
 
 
 
 
 
Note on my contributions to this paper: I contributed a data set, participated in 
sections of the analysis, and helped with writing the manuscript.    
56 
 
 
2.1 ABSTRACT 
Defining anxiety- and depressive-like states in mice (“emotionality”) is best 
characterized by the use of complementary tests, leading sometimes to puzzling 
discrepancies and lack of correlation between similar paradigms. To address this issue, 
we hypothesized that integrating measures along the same behavioral dimensions in 
different tests would reduce the intrinsic variability of single tests and provide a robust 
characterization of the underlying “emotionality” of individual mouse, similarly as mood 
and related syndromes are defined in humans through various related symptoms over 
time. We describe the use of simple mathematical and integrative tools to help 
phenotype animals across related behavioral tests (syndrome diagnosis) and 
experiments (meta-analysis). We applied z-normalization across complementary 
measures of emotionality in different behavioral tests after unpredictable chronic mild 
stress (UCMS) or prolonged corticosterone exposure - two approaches to induce 
anxious-/depressive-like states in mice. Combining z-normalized test values, lowered 
the variance of emotionality measurement, enhanced the reliability of behavioral 
phenotyping, and increased analytical opportunities. Comparing integrated emotionality 
scores across studies revealed a robust sexual dimorphism in the vulnerability to 
develop high emotionality, manifested as higher UCMS-induced emotionality z-scores, 
but lower corticosterone-induced scores in females compared to males. Interestingly, 
the distribution of individual z-scores revealed a pattern of increased baseline 
emotionality in female mice, reminiscent of what is observed in humans. Together, we 
show that the z-scoring method yields robust measures of emotionality across 
complementary tests for individual mice and experimental groups, hence facilitating the 
comparison across studies and refining the translational applicability of these models. 
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2.2 INTRODUCTION 
Evaluation of behavioral and physiological parameters relating to emotion-like 
processes in animals is typically performed with several tests and without 
comprehensive analysis across paradigms. Mouse behavior is multimodal and full 
quantifiable assessment of emotionality (which covers anxiety-like and/or depressive-
like behavior) is only possible when the same animal is exposed to multiple behavioral 
tests covering a wide range of behaviors over several days (Crawley et al. 1997; 
Crawley and Paylor 1997). However, closely-related behavioral parameters that are 
specific to each test and that relate to aspects of emotionality (for instance, entries into 
open field center or into open arms of the elevated plus maze) do not necessarily agree 
within animals and/or across time, leading to behavioral noise that is difficult to interpret. 
This behavioral variability can be caused by the time of day, the experimenter and 
recent activity in the colony, or may represent false positive/negative results in 
experiments with small numbers of test subjects (less than 10). More often, the cause of 
the variability is unknown, but it is thought to reflect natural fluctuations over the 
underlying mean value. Thus, as mice can be in different emotional states within short 
periods of time (Ramos 2008), correlation analyses of behavioral parameters obtained 
from different tests may result in lack of statistical power and affect principal component 
types of integrative analyses (Carola et al. 2002). Hence, to assess emotionality, we 
need simple and comprehensive tools that allow integration of behavioral parameters 
obtained in multiple (but complementary) behavioral tests.  
It is important to note that convergent - rather than consistent - sets of symptoms 
are at the core of the clinical characterization of the human illness. Indeed, contrary to a 
putative “consistent” organ deficiency phenotype (i.e. muscle or liver function for 
instance), the manifestation of changes in emotionality can vary over time. This is one 
of the reasons why depression is diagnosed in humans by a set of variable symptoms 
(4-5 out of a list of 10) over time (2 weeks or more). It is not based on a single 
consistent behavior, but rather by a set of converging behavioral observations that 
together define a depressive syndrome. Here we are trying to provide a method to 
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operationalize this approach to rodent studies to increase the translational value of the 
models.  
Here, we z-normalized results from rodent behavioral tests, experiments and 
cohorts, with the goal of assessing the emotionality dimension of mice. Z-normalization 
is a methodology that standardizes observations obtained at different times and from 
different cohorts, thus allowing their comparison and/or compilation. Its value is 
obtained by subtracting the average of observations in a population from an individual 
raw value and then dividing this difference by the population standard deviation. This 
type of normalization, compared to percentiles, allows data on different scales to be 
compared. Indeed, based on a translational application of the illness definition (i.e. a 
syndrome as a collection of variable symptoms), we actually may not expect 
systematically the same or “consistent” behavioral outputs, but we do expect converging 
results from emotionality measures over time. This may also be the reason why 
principal component analyses (PCA) have not been successful at summarizing 
emotionality behavioral data, as one of the assumptions under PCA is that “consistent” 
values should be systematically obtained (Carola et al. 2002; Milner and Crabbe 2008). 
Instead, the proposed z-score approach relies on testing whether a particular 
experimental group deviates from mean behaviors in converging directions across tests 
and time.  
Furthermore, taking example from clinical study meta-analyses, where z-
normalization is used to compile related measures performed in different studies but 
that assess the same illness dimension, we evaluated the possibility of comparing 
integrated measures of emotionality across different rodent experiments. We first 
validated the approach using two common methods to induce anxious-/depressive-like 
states in mice - UCMS and chronic corticosterone exposure - (Mineur et al. 2006; David 
et al. 2009) and then report its use in providing additional analytical opportunities, such 
as differentiating more subtle sex differences under baseline and induced high 
emotionality across studies. 
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2.3 METHODS 
Animals 
Male and female C57BL/6NTac mice (Taconic, Hudson, NY) were used. Mice 
were maintained under standard conditions (12/12 h light/dark cycle, 22 ± 1 °C, food 
and water ad libitum, 4-5 animals/cage), and the protocol was approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee (protocol 
#0801794, Animal Assurance # A3187-01). Two different cohorts were used for each 
model (UCMS and corticosterone exposure) for a total of 4 cohorts. Baseline sex 
differences were established in 3 cohorts (Figs 2.1, 2.2, 2.4, 2.5).  
 
Estrous cycle  
Estrous state was monitored in female mice by vaginal smears in selected tests 
(Goldman et al. 2007). Briefly, 10 µl of saline was flushed into the vagina and then 
placed on a glass slide and coverslipped. Observation of stages of the estrous cycles 
was performed under light microscope with a 10X objective without staining. Vaginal 
smears were performed on the day of behavioral testing and on the day after to more 
accurately assess estrous stage. 
 
Unpredictable Chronic mild stress (UCMS) 
UCMS mimics the role of socio-environmental stressors in precipitating a 
depressive-like syndrome that shares characteristics with human depression, such as 
increased fearfulness/anxiety-like behavior, decreased consumption of palatable food 
and physiological changes (Santarelli et al. 2003; Pothion et al. 2004; Mineur et al. 
2006). Importantly, the UCMS-induced syndrome is blocked and reversed by chronic 
antidepressant treatment (Surget et al. 2009). UCMS consisted of a 4-week regimen (or 
6 weeks when fluoxetine was administered, see below) of pseudo-random 
unpredictable mild stressors: forced bath (~2 cm water in cage for 15 minutes), wet 
bedding, predator odor (1 hour exposure to fox urine), light cycle changes, social stress 
(rotate mice into previously occupied cage), tilted cage (45°), mild restraint (50mL 
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Falcon tube with air hold for 15 minutes) and bedding changes (Joeyen-Waldorf et al. 
2009; Surget et al. 2009).  
 
Fluoxetine treatment 
Fluoxetine (Sigma, St. Louis, MO) was dissolved and administered in the drinking 
water (18 mg/kg/d) for 4 weeks, 15 days after the onset of UCMS, in order to reverse 
and block the development of the depressive-like phenotype (Santarelli et al. 2003; 
Surget et al. 2009). 
 
Corticosterone Treatment 
Corticosterone (Sigma, St. Louis, MO) was dissolved in vehicle (0.45% β-
cyclodextrin) and delivered (35 µg/ml) in drinking water for 4 weeks, based on (David et 
al. 2009). Liquid consumption was monitored and bottles were changed every 3 days. 
This test models the elevated corticosteroid levels seen in some subjects with major 
depression (Brouwer et al. 2005; Antonijevic 2006). Chronic antidepressant treatment 
reverses the corticosterone-induced elevated emotionality (David et al. 2009; Gourley 
and Taylor 2009). 
 
Behavior 
Behavioral testing was performed using elevated plus-maze, open field and 
novelty suppressed feeding, three commonly used tests in the literature to measure 
components of emotionality. Tests were performed 3-5 days apart to minimize the 
impact of a previous test on the response for the same animals. Tests were performed 
in the order described below: 
 
Behavior in the EPM was measured using a cross maze with two open and two 
closed arms (30 × 5 cm arms). Time spent in the open arms and ratio of entries into the 
open arms (entries into open arms divided by total entries into any arm x 100) during a 
Elevated Plus Maze Test (EPM) 
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10 min test measured anxiety-related behaviors (Sibille et al. 2000). The total number of 
arm entries was used as an index of locomotor activity. 
 
The time and distance ratio spent in the center of a 43x43 cm open chamber 
were recorded for 10 min to evaluate anxiety-related behaviors (center was defined as a 
32x32 cm central arena). Here, we report time in the center of the open field and ratio of 
distance traveled in the center (distance traveled in the center divided by the total 
distance traveled x 100).The total distance traveled was used as an index of locomotor 
activity (David et al. 2009).  
Open Field Paradigm (OF) 
 
As an index of emotionality, the latency to start eating a food pellet was 
monitored in food-deprived animals in a brightly illuminated chamber. Briefly, animals 
were food-deprived for 16 hours prior to the test. Testing was performed in a 50x50 cm 
box covered with bedding and illuminated by a 70-watt lamp. Mice were tested 
individually by placing them in the box for a period of 10 minutes. The latency to eat was 
timed. Immediately afterwards, the animal was transferred to its home cage and the 
amount of food consumed in the subsequent 5 minutes was measured, serving as a 
control for change in appetite as a possible confounding factor. 
The Novelty Suppressed Feeding test (NSF) 
 
Emotionality and Locomotion Z-score calculation 
Z-scores are dimensionless mathematical tools that allow for mean-normalization 
of results within studies and for subsequent comparison of related data across studies. 
Z-scores are standardized scores (by the group mean and group standard deviation) 
and no normal assumption is made. They indicate how many standard deviations (σ) an 
observation (X) is above or below the mean of a control group (µ). 
 
X represents the individual data for the observed parameter. µ and σ represents 
σ
µ−
=
Xz
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the mean and the standard deviation for the control group, respectively. Here as we 
investigated stress and sex effects, the male control group was defined as the control 
group (except for Figure 2.2 where effects of antidepressant in females were monitored 
and thus, the control group was the unstressed female group). Z-score values were 
calculated for test parameters measuring emotionality and locomotor activity. The 
directionality of scores was adjusted so that increased score values reflected increased 
dimensionality (emotionality or locomotion). Standard measures of anxiety-/depressive-
like behaviors (Crupi et al. 2010; Post et al. 2010) were used here, but the approach 
can be customized to other tests, based on each lab's expertise.  
For instance, decreased normalized OF center activity and increased NSF 
latency were converted into positive standard deviation changes compared to group 
means indicating increased emotionality. To avoid any weighted effect of locomotion on 
anxious behavior in the OF and EPM, distance ratios (center/total distance in the OF; or 
open arm entry ratio in the EPM) are typically used (Crupi et al. 2010; Post et al. 2010), 
thus integrated parameters were normalized for the locomotor component. In the NSF, 
the time necessary to initially approach the food pellet is orders of magnitude smaller 
than the time to overcome the conflict of the aversive environment, thus locomotor 
activity is typically not controlled for; rather appetite and food consumption are 
measured across groups. The selection of these specific dimensions was made based 
on the fact that these parameters are the most frequently used in the 
neuropsychopharmacology field so that readers could easily identify these components 
in their own studies. Furthermore, we selected for EPM and OF parameters that are 
associated in some principal component analyses studies (PCA) with "anxious 
behaviour" or "anxious locomotor activity" such as time in the open arms or time in the 
center (Carola et al. 2002); however other studies could not fully dissociate 
"unambiguously parameters fully reflecting ‘activity’ or ‘anxiety'" (Milner and Crabbe 
2008). Finally, PCA analyses found that both these components had similar loads on 
anxious behaviour (Milner and Crabbe 2008).  
As an example, z-score in the open-field (ZOF) was calculated for each animal 
using normalization of “time in the center” (TC) and “distance in periphery/total distance 
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ratio” (DR) values. 
 
 
 
Similarly, in the elevated plus maze for each animal, Zepm calculation was 
performed using normalization of “time in the open arms” (TOA) and “Open/Closed 
arms entries ratio” (ER) values. 
Finally, in the novelty suppressed feeding, Znsf was calculated for each animal 
using normalization of the latency time to eat the pellet. 
Individual emotionality scores were then calculated by averaging z-score values 
across tests, thus leveraging potential biases induced by a single test. An emotionality 
z-score was calculated for each animal based on 3 different tests:  
 
testsofNumber
ZZZScoretyEmotionali NSFEPMOF ++=
 
 
Finally group emotionality score means (and standard deviations) were obtained 
by averaging individual values within each group for each experiment (Figures 1-3) and 
by integrating similar groups across experiments (Figures 4-5). 
 
Statistical analysis 
Based on the experiment, the number of groups and treatments applied, Student 
t-tests, one-way or two-way ANOVA (sex, treatment, estrous state as co-factor), 
followed by post-hoc PLSD (when main effects were observed significant) and χ2 
analysis, were performed.  
parametersofNumber
DRXTCX
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2.4 RESULTS 
Z-score normalization confirmed elevated emotionality and identified robust sex 
differences in the UCMS model of depression 
We employed emotionality z-scores to investigate the potential of combining 
results across different behavioral tests for anxiety- and depressive-like behaviors using 
the UCMS model, a validated paradigm to elicit anxious-/depressive-like behaviors. For 
this first analysis (Fig. 2.1), results from independent tests were as follows: in the OF, 
stress exposure did not affect time and relative distance traveled in the center of the OF 
(Fig 2.1A); in the EPM, UCMS-exposed animals spent significantly less time (p < 0.05) 
and entered proportionately less often (p < 0.05) into the open arms compared to 
controls (Fig 2.1A); in the NSF, there was a trend for UCMS-exposed animals to have 
increased latencies to eat the pellet (p = 0.09; Fig 2.1A). 
Z-score normalization was then performed, first, within the respective behavioral 
parameters, hence transforming absolute values to numbers of standard deviations 
from the control means (see methods). As described in the methods, the control group 
used was the male non-stressed group. Male and female results are pooled in figures 
2.1A-D, which underlie the slightly positive value for the "no stress" group that combine 
mean of z-normalized values of both sex (See further characterization in §3.4). This first 
step yielded, as expected, the same statistical p-values as before normalization (Fig 
2.1B). We then averaged these normalized behavioral parameter z-scores to obtain a 
single value per mouse and per behavioral test (Fig 2.1C). Analyses of test-specific z-
scores indicated a significant effect of stress exposure on EPM (p < 0.05), with UCMS-
exposed animals displaying higher z-scores than controls. There was no effect of stress 
on OF z-score (p > 0.4), but a trend for an effect of stress on NSF z-score (p = 0.09). 
Finally, these values were averaged to obtain a single “Emotionality Score” for each 
mouse, describing the integrated output of that experiment (Fig. 2.1D). Note that all 
three tests are weighted similarly, as within-test parameters were averaged at the prior 
step (Fig. 2.1C). Here, the analysis of the combined normalized measures of 
emotionality resulted in augmented statistical significance of the stress main effect (p < 
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0.015 versus 0.03 < p < 0.09, depending on the test). We further compared males and 
females and show that the UCMS effect on emotionality was driven by a significant 
effect of stress exposure on emotionality score in females (p < 0.05), but not males (p > 
0.1; Fig 2.1E). In summary, we showed that, in this particular experiment, z-scoring 
across complementary behavioral dimensions provided a more robust overall 
assessment of the effect of stress on emotionality (i.e. less sensitive to outlier values).  
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Figure 2.1. Integrated emotionality z-scores in mice exposed to unpredictable 
chronic mild stress.  (A) Raw data obtained from three independent behavioral tests 
performed in the same animal in both males and females mice (OF, EPM and NSF; 
n=14-15/group/sex) (B) Normalization of data using z-score method was performed for 
each parameter as described in the methods using the control male group as the 
baseline. (C) Test z-values were then calculated by averaging individual z-scores, and 
(D) averaged to obtain Emotionality z-score. (E) Controls and stress groups were split 
by sex to investigate sex differences to stress exposure. Data represent mean ± SEM 
(n=14-15/group). A-E: * p<0.05, ** p<0.01, *** p<0.001 for effects of UCMS exposure 
compared to the no-stress group. # describe statistical trends (p<0.1). 
 
 
Antidepressant reversal of elevated emotionality z-scores  
As the observed effect of stress was greater in females (Fig 2.1E), we studied the 
reversal effects of chronic fluoxetine administration on female mice with altered 
behavior induced by stress (Fig 2.2). In this second cohort of UCMS-exposed animals, 
female mice were exposed to similar stressors and behavioral testing, and an 
independent group was exposed to chronic fluoxetine at the onset of the UCMS 
syndrome (Surget et al. 2009). Emotionality z-scores were calculated as described 
above. Results from individual tests were as follows: in the OF, no significant effects of 
UCMS or fluoxetine were observed on parameters measured (Fig 2.2A); in the EPM, 
UCMS-exposed females spent significantly less time (p < 0.001) and entered 
proportionately less often (p < 0.01) into the open arms compared to controls, while 
chronic fluoxetine treatment blocked the development of those effects for both 
parameters (p < 0.05); in the NSF, fluoxetine-treated animals displayed lower latency to 
start eating the food pellet compared to saline treated UCMS-exposed mice (p<0.05). 
These variable results are somewhat typical to behavioral studies, so to assess whether 
results reflected behavioral noise or fluctuations over a more stable underlying trend, we 
performed z-score normalization, first, within behavioral parameters (yielding the same 
statistical p-values as before normalization; Fig 2.2B), and, then, averaged results to 
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obtain a single value per mouse and per behavioral test (Fig 2.2C). Fluoxetine-treated 
and UCMS-exposed mice did not differ from controls on measures of emotionality in the 
OF and in the NSF. No significant effect was observed in the OF (Fig. 2.2C). The final z-
score integration revealed a significant effect of UCMS, suggesting a stable underlying 
effect, although modest in this case. Control unstressed mice were compared to 
fluoxetine-treated stressed mice and no difference were observed for all experiments 
(Fig 2A-D). As expected, chronic SSRI treatment reversed the elevated stress-induced 
z-score measures of emotionality (p < 0.01, Fig 2D) (or blocked the development; see 
methods), bringing values back to baseline control levels. Together, this provides an 
additional example of using z-score normalization to extract a robust underlying trend 
out of more variable individual measures, and critically providing a pharmacological 
validation and a face validity of its application. 
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Figure 2.2. Chronic antidepressant treatment blocks stress-induced increase in 
emotionality z-scores (n=14-15/group). (A) Raw data obtained from three 
independent behavioral tests (OF, EPM and NSF; n=14-15/group) performed in the 
same animals. (B) Normalization of data using z-score method was performed for each 
parameter. (C) Test z-values were then calculated by averaging individual z-scores, and 
(D) averaged to obtain the Emotionality Score. Data represent mean ± SEM (n=14-
15/group). **, p<0.01 ***, p<0.001 for effects of UCMS exposure compared to the no-
stress group. $, p<0.05 $$, p<0.01 for effects of 4-weeks fluoxetine treatment compared 
to the stressed group. 
 
 
Elevated emotionality z-scores and increased statistical significance in the 
corticosterone-induced syndrome 
To test the reliability of the z-normalization method across models, we then 
derived emotionality z-scores using behavioral results obtained in the chronic 
corticosterone model as an additional test case, since chronic exposure reliably 
increases emotionality in mice (David et al. 2009; Gourley and Taylor 2009). In light of 
sex differences in the UCMS model, we present data analyzed by sex (Fig 2.3). In the 
OF, corticosterone-exposed animals spent less time in the center than controls (main 
effect of corticosterone exposure, p < 0.05; Fig 2.3A). This result was driven by the fact 
that corticosterone-exposed males spent significantly less time in the open than control 
males (p < 0.01). There was also a significant effect of sex on time spent in the center 
(p < 0.05; Fig 2.3A), driven by a sex difference in corticosterone exposure, with treated 
males spending less time in the open than treated females (p < 0.05). For distance ratio 
in the OF, there was a main effect of treatment, with corticosterone-exposed animals 
having smaller distance ratios than controls (p < 0.01; Fig 2.3A). As for the time in the 
center of the OF, this result was driven by corticosterone-exposed males having smaller 
distance ratios than control males (p < 0.01). There was also a significant sex difference 
in distance ratio, driven by a sex difference in corticosterone exposure, with treated 
males having smaller ratios than treated females (p < 0.01; Fig 2.3A). In the EPM, 
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corticosterone-exposed animals spent significantly less time in the open arms than 
controls (main effect of corticosterone exposure, p < 0.05; Fig 2.3A). Corticosterone-
treated animals also had a smaller open arm entry ratio than controls (overall, p < 0.01; 
males, p < 0.05; females, p < 0.05). In the NSF, there was a significant sex difference in 
latency (p < 0.01; Fig 2.3A), driven by the fact that corticosterone exposed males had 
longer latencies than treated females (p < 0.001). There was also a trend for an effect of 
treatment on latency (p = 0.09), with corticosterone exposed males having longer 
latencies than control males (p < 0.05). 
Using these results, z-score transformation was performed, first, within 
behavioral parameters, yielding, as expected, exactly the same statistical p-values as 
before normalization (Fig 2.3B). Z-scores were then averaged to obtain a single value 
per behavioral test, and group differences were assessed (Fig 2.3C). There was a 
significant main effect of treatment on OF z-score (p < 0.01), driven by the fact that 
corticosterone-treated males had higher z-scores than control males (p < 0.01). There 
was also a significant main effect of sex on OF z-score (p < 0.05), driven by 
corticosterone-treated males having higher OF z-scores than treated females (p < 
0.001). There was a significant main effect of treatment on EPM z-score, with 
corticosterone-treated animals displaying higher z-scores than controls (p < 0.01; 
males, p = 0.09; females, p < 0.05). There was a trend for a main effect of treatment on 
NSF z-score (p = 0.09), driven by corticosterone-exposed males having higher NSF z-
scores than untreated males (p < 0.05). There was also a significant main effect of sex 
on NSF z-score (p < 0.01), driven by a sex difference in corticosterone exposure, with 
treated males having higher NSF z-scores than treated females (p < 0.001). Finally, 
these values were averaged to obtain a single “emotionality score” per mouse, then per 
experimental group (Fig. 2.3D). Note that all three tests are weighted similarly, as 
within-test parameters were averaged at the prior step (Fig. 2.3C). Here, z-scoring 
confirmed that the smaller and variable effect sizes in female mice reflected an overall 
less robust, although still significant, impact (p<0.05) of corticosterone exposure in 
female mice.  
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Combining normalized measures in group emotionality z-scores augmented the 
overall statistical significance of the corticosterone main effect (Table 2.1, p < 0.0001 
versus 0.008 < p < 0.09, depending on the test), thus emphasizing the low but 
measurable convergence of behavior between tests, and confirming that individual mice 
displayed similar directionality of effects across tests, suggesting that integrated z-
scores provide a robust assessment (i.e. less sensitive to outlier values) of the effect of 
corticosterone on emotionality.  
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Figure 2.3. Integrated Emotionality z-score in corticosterone-treated male and 
female mice. (A) Raw data obtained from three independent behavioral tests (OF, EPM 
and NSF; n=14-22/group) performed in the same animals. (B) Normalization of data 
using the z-scoring method was performed for each parameter as described in the 
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methods. (C) Test z-values were obtained by averaging individual z-scores, and then 
combined to obtain emotionality z-scores. Data represent mean ± SEM (n=14-
22/group). * p<0.05, ** p<0.01, *** p<0.001 for effects of corticosterone exposure 
compared to the sex-matched non-stress group. § p<0.05, §§§ p<0.001 indicate sex 
differences within groups. 
 
 
Looking at the effect of sex, the emotionality z-score significance was lower in 
three out of five cases for the different parameters measured in the NSF, OF and EPM. 
The underlying cause of these more robust statistical parameters appears to rely on the 
fact that z-score normalization lowers the overall variance of the behavioral 
measurements (Table 2.1). This is consistent with the notion that the underlying 
changes in emotionality were similar in the three tests, but that test-specific variability in 
measures partly obscured its accurate measurement within individual tests. Hence, 
under these experimental conditions, emotionality z-scoring provided the best 
combination of low p-values, due to lower coefficient of variation of integrated values. 
Because the number of behavioral tests included in the analysis can also affect the 
overall statistical power and z-score values, we compared z-score values 
(Supplemental Figure B.1 or Supplemental Table B.1) and statistical results 
(Supplemental Table B.2) obtained by averaging data from either 2 or 3 behavioral 
tests. As expected the lowest variability in measures was observed when averaging z-
scores from 3 tests, as demonstrated by a combination of a lower coefficient of variation 
and a higher statistical significance.  
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Table 2.1. P-values for 2-way ANOVA main effects corresponding to data shown 
in Fig. 3. 
 
 
 
 
 
 
Combining emotionality z-scores across experiments and models provided 
additional analytical opportunities across independent studies: quantitative 
differences and sexual dimorphism in the UCMS and corticosterone models of 
altered mood states.  
Results from the UCMS and corticosterone exposure studies suggested 
differences in opposite directions between males and females across the two models 
(Figs 2.1, 2.3). To further investigate this potential sexual dimorphism, we took 
advantage of the fact that, similar to clinical meta-analysis approaches, normalized z-
scores can allow for comparison and pooling of results across experiments, hence 
increasing sample size and analytical power. Indeed, in meta-analysis, the same 
measure [e.g. a scaled measure of depressive state for example] is used in different 
studies, while here the same measure, emotionality Z-score, [e.g. an equivalent of a 
scaled diagnosis of animal behavioral state] was derived in different experiments and 
subjects and compared across studies. Here, combined experimental group sizes 
ranged from 22 to 51 animals per sex for each model. Integrated emotionality z-scores 
from two experiments using the UCMS paradigm confirmed that stress increases 
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emotionality in both sexes (male: p<0.01; female: p<0.001) and revealed a higher 
female response to UCMS (Fig. 2.4A, Female > Male, p<0.01) (Dalla et al. 2005; 
Joeyen-Waldorf et al. 2009). On the other hand, integrating results from two 
independent corticosterone experiments confirmed the robust effect in males (p<0.001), 
strengthened the conclusion of less robust female results (p<0.05), and revealed a 
significant sex difference in increased emotionality (Fig. 2.4A, Male > Female, p<0.001) 
while no group x sex interaction was observed (p=0.17, Fig. 2.4A). No baseline sex 
difference was observed (p=0.31), although more female mice displayed baseline 
emotionality scores greater than 0.5 (p<0.001; see next section).  
In Fig 2.4B we present an alternate use of z-scoring, where locomotion z-scores 
were derived from related locomotor parameters across two tests (total ambulatory 
distance in the OF and total entries in EPM). Integrated locomotion z-scores from these 
same experiments using the UCMS and corticosterone exposure paradigms showed 
that (i) females had overall higher baseline locomotion activity compared to males 
(p<0.001), (ii) corticosterone induced a decrease in locomotor activity in males 
(p<0.001), but not in females (p=0.50), and that (iii) chronic stress induced no effect on 
locomotion parameters in either sex (males: p=0.06; females p=0.33). Estrous state did 
not correlate with altered behavior in individual tests.  
Together, these results provide examples of the application of z-scoring across 
experiments initially performed separately. Here, for instance, integrated z-scores 
across behavioral tests and experiments revealed significant sex differences that were 
at best at trend level in individual experiments. 
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Figure 2.4. Emotionality and locomotion scores in two animal models of 
anxiety/depression. Use of z-score normalization allowed pooling of various 
experiments and multiple cohorts (n=22-51 mice/group), highlighting sex differences 
after chronic stress or corticosterone exposure. (A) Sex differences in emotionality 
responses to either stress or corticosterone exposure. Specifically, females (red) were 
significantly more sensitive to stress and less sensitive to corticosterone exposure 
compared to males (blue). (B) Applying similar normalization to locomotors parameters 
extracted from different behavioral tests (total crosses in OF and in EPM) revealed 
baseline sex differences, and in response to stress and corticosterone exposure. Data 
represent mean ± SEM (n=22-51/group). * p<0.05, ** p<0.01, *** p<0.001 for effects of 
corticosterone or stress exposure compared to the sex-matched control group. §§ 
p<0.01, §§§ p<0.001 indicate sex differences within groups. 
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Emotionality z-scores combined across cohorts revealed qualitative baseline sex 
differences  
Elevated baseline emotionality was observed in female mice in some behavioral 
tests, but did not reach significance for individual experiments. Notably, highlighting 
consistent sex differences in mouse behavior can be difficult, as it requires a large 
group of animals, control for estrous state in females, and the direction of change can 
vary across different tests (Palanza 2001; Voikar et al. 2001). Here, we speculated that 
integrating results across these tests may reveal baseline differences, either in mean 
group differences or in the distribution of z-scores within groups. We thus integrated 
emotionality z-scores over three experiments and focused on control animals (n=42 
males, 34 females; Fig. 2.5). Results revealed higher baseline emotionality in females 
(male, z = 0.00; female z = 0.574; p<0.001). We next assessed the distributions of 
emotionality scores (“low”, scores below -0.5; “normal”, scores between -0.5 and +0.5; 
“high”, scores greater than +0.5). This alternate use of z-scores revealed a highly 
significant shift to higher emotionality in females (χ2=16.8, df=2, p<0.001), indicative of 
high baseline emotionality in 71% of female mice, but only in 24% of males. Notably, 
this difference did not correspond with estrous state in individual female mice, and in 
fact, represent integrated measures over a period of several days, hence encompassing 
most estrous states within individual mice. 
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Figure 2.5. Dissecting sex differences in baseline emotionality. Combining 
emotionality z-scores in control animals across several experiments shows that the 
distribution of baseline emotionality scores is significantly skewed towards higher values 
in females, as more females (red) show higher emotionality states compared to males 
(blue). Emotionality scores were separated in “low” (scores below -0.5), “normal”, 
(scores between -0.5 and +0.5) and “high” (scores greater than +0.5) (n=34-42 mice/sex 
extracted from 3 different cohorts). Relative proportions of animals in each group are 
indicated within bars. χ2 analysis on group distributions revealed sex differences (§§§ 
p<0.001). 
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2.5 DISCUSSION 
Principles of z-scoring methods adapted for behavioral measurements 
To address inherent difficulties in behavioral phenotyping of mice over time and 
to obtain summarized results over tests and studies, we propose a method based on z-
normalization principles for the quantification of behaviors in an integrative manner 
along coherent dimensions, such as shown here for emotionality. Indeed, it is often 
difficult to reconcile positive or intermediate findings across tests, especially for 
behavioral measures that are subject to known variability. We show that applying a z-
normalization method across complementary behavioral measures related to aspects of 
emotionality can facilitate the “diagnosis” of an animal state. Emotionality in animal 
models is classically reflected by altered behavior monitored in different paradigms that 
can be restored after antidepressants (as performed here), by variations in physiological 
parameters (HPA axis, locomotor activity), and potentially through identification of brain 
region-specific genomic biomarkers of altered behavior (Krishnan et al. 2007; Sibille et 
al. 2009). Interestingly, since human mood is defined as an emotional state over time 
that is remote from proximal stimuli, we speculate that rodent emotionality z-scores may 
in fact represent the closest homolog of human mood. Indeed, they integrate behavioral 
states observed in various and multiple paradigms over several days of testing, 
including across various neuroendocrine states (i.e. sex hormones), hence capturing a 
more stable and enduring state of emotionality in mice. Similarly, the combined analysis 
of converging behavior can be assimilated to the clinical characterization of the human 
illness, which is diagnosed by a set of variable symptoms over time. So it is not based 
on a single consistent behavior, but rather by a set of converging behavioral 
observations that together define a depressive syndrome. A recent study aimed at the 
same goal by combining different behavioral tests into a single apparatus ("triple test"; 
composed of OF, EPM and Light/Dark test physically linked together) to phenotype 
animal's behavior using a similar comprehensive strategy based on multiple testing 
(Fraser et al. 2010). The future value of such a test will need to be assessed in multiple 
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studies. Notably, it is still based on a one-time assessment of animal's behavior, in 
contrast to our proposed analytical method for behavioral assessment over time. 
Furthermore, emotionality z-scores – by allowing pooling of cohorts – can 
strengthen the reliability of effects and increase analytical opportunities. Specifically, we 
showed that emotionality z-scores reduced test-to-test variability for measures of 
dependent variables that are sensitive to multiple known (and unknown) environmental 
factors (time of day, animal facility-related events, experimenter, estrous phase, etc).  
The rationale for using z-normalization, instead of, for instance, calculating 
percentage of control response for each parameter and averaging them across groups 
and cohorts, is that the standard deviations of z-normalization values are similar across 
parameters and tests, Thus, averaging z-values avoids weighted effects of one 
parameter or one test over another. Z-score methodology also differs from multivariate 
statistics, such as principal component analysis, which are performed to investigate 
whether behavioral measures assess a single and intangible entity. However, as 
discussed in the introduction, “emotionality” is by definition an underlying state that is 
vulnerable to timely fluctuations due to variable environmental and biological stimuli, 
and that may manifest as different behaviors, or “symptoms” over time. So we actually 
do not seek, and may not even expect, high correlation across tests, but rather we 
expect convergence of results obtained with integrated z-scores. Instead, we expect 
that a true underlying emotionality state will be revealed through similarities in effect 
size and directions over cohorts and tests over time. Similarly, other types of 
multivariate analysis, like MANOVA, assume linear relationships among dependent 
variables and covariates; therefore, when the relationship deviates from linearity – 
which might happen due to fluctuation in animal's behavior - the power of the analysis 
will be compromised. Similarly, multivariate analyses rely on similar assumptions of 
correlation rather than convergence, and therefore may not work as well. Finally, z-
normalization within and across different behavioral tests results in a single score per 
mouse which may be seen as a quantitative “diagnosis” of their emotionality, a 
translational – and of course limited - equivalent to the way human depression is  
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quantified by structured interviews, such as the Global Assessment of Functioning scale 
or the Hamilton Depression Rating Scale .  
Defining new tools for behavioral analysis in neuropsychopharmacology 
necessitates assessing their validity. As emotionality is an integrative behavioral entity 
that is composed of different parameters, such as anxiety, depression, and fear of novel 
environment, that are measured over time, our methodology has a strong face validity 
as it combines these multiple aspects. Predictive validity of the z-score method has 
been tested here by looking at antidepressant reversal of stress induced-emotionality. 
 
Proof of concept: Application of z-scoring methods to two different models of 
altered mood disorders and to behavioral sex differences 
Here we applied behavioral z-scoring methods to the quantification of 
emotionality in two rodent models that are frequently used to induce higher anxiety- and 
depressive-like behavior in mice. UCMS is based on chronic psychosocial stress, while 
chronic corticosterone exposure relies on neuroendocrine dysfunction. In our studies, 
main effects of either UCMS or corticosterone exposure were observed in most, but not 
all, of the single tests performed within individual cohorts (Fig 2.1A and 2.3A). Z-score 
normalization appeared to increase the robustness of the analyses by decreasing the 
variability of integrated measures (Fig 2.1D and 2.3D; Table 2.1).  Combining 
emotionality z-scores across experiments revealed significant sex differences in 
response to stress or corticosterone exposures (Fig. 2.4), hence demonstrating the 
value of the approach at detecting effects that were either not significant or at trend 
levels in experiments performed separately. Notably, the goal of these integrated 
analyses is not to “increase statistical significance”, but rather to extract underlying 
trends out of apparently variable results. For instance, we showed that, compared to 
males, females were more sensitive to chronic stress, but less sensitive to chronic 
corticosterone administration. Greater female behavioral and physiological stress 
sensitivity has previously been reported (Dalla et al. 2005; Joeyen-Waldorf et al. 2009), 
associated with higher corticosterone levels after various stressors (Handa et al. 1994). 
Although corticosterone administration can induce high emotionality in males (Gourley 
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et al. 2008; Murray et al. 2008; Zhao et al. 2008; David et al. 2009) and females 
(Ardayfio and Kim 2006), sex differences had not yet been directly studied. Using 
emotionality z-scores, we were able to combine individual experiments and showed that 
females were overall less sensitive than males to corticosterone exposure, thus 
consolidating a large literature on sex-related differences in response to glucocorticoids 
and in HPA-axis dysregulation in rodents (Galea et al. 1997; Liu et al. 2006) and 
humans (Young and Ribeiro 2006; Bremmer et al. 2007; Young et al. 2007; Binder et al. 
2009). Of course, since both the rodent and human literature are mostly male-biased, 
an alternative interpretation is that males are more sensitive to corticosterone exposure 
and less to the effects of chronic stress. In summary, these results support our 
hypothesis that z-scoring normalization of related behavior can reveal consistent and 
stable changes in underlying emotionality in mice, despite apparent and often 
unexplained variability. Using this approach augmented the translational validity of the 
models by suggesting similar directions for sex differences that are observed in human 
subjects. 
 
Application of behavioral z-scores 
By definition, z-scores normalize results across tests, experiments and cohorts, 
as they take into consideration differences from mean group values in terms of numbers 
of standard deviations from the control mean (See methods). The approach is not new 
by itself, as it is commonly applied in clinical and epidemiological studies. An important 
feature of its application to behavioral data is to ensure conformity with the direction of 
effects. For instance, increased emotionality in mice is revealed by decreased values of 
dependent variables in some tests (OF and EPM) and by increased values in other tests 
(NSF), and thus all measures indicative of increased emotionality should be reflected by 
positive numbers of standard deviations from the control group mean. While our z-score 
calculation here was based on data extracted from three behavioral tests commonly 
used in neuropsychopharmacology, it could be extended to other behavioral tasks that 
measure other parameters related to emotionality, such as number of fecal boluses in a 
new environment, elevated O maze, marble burying, light/dark transition, etc. Here we 
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use the term of emotionality to cover both anxiety-like and depressive-like behaviors, as 
they are difficult to fully dissociate in rodents, but the approach can be expanded to 
include more specific tests. However, while multiple testing in the same animal is 
necessary to robustly assess emotionality, experimenters should verify that response to 
one behavioral test was not altered by prior testing. Notably, the integrated approach 
does not detract from the analysis of distinct components of individual tests, which may 
reveal nuances in behavioral responses and changes. The potential application of 
behavioral z-scoring is quite extensive, from dissociating emotionality-related behavior 
in stressed/control animals, knockout or transgenics/wild-type (using combined group 
scores), to identify consistent outliers or segregate resilient from responder animals to 
environmental exposure or pharmacological treatment (e.g. through score histograms), 
or to measure antidepressant-predictive behaviors or antidepressant reversal of induced 
behavioral syndromes.  
Behavioral z-scores can also be applied to other behavioral dimensions (memory 
tests, addiction tests, etc.). Here we briefly showed a similar approach applied to 
locomotion. Indeed, while emotionality z-scores already include locomotor-controlled 
parameters extracted from each test, normalization of locomotion-specific parameters 
can further evaluate overall locomotor activity under baseline conditions, between males 
and females and after experimental manipulations for instance (i.e. UCMS or 
corticosterone exposure).  
Some of the critical aspects and potential limitations that need to be further 
characterized include, amongst others: (i) reliable behavioral protocols across 
experiments (Wahlsten et al. 2006), (ii) combining results across strains (Milner and 
Crabbe 2008; Yalcin et al. 2008), especially in the context of sex differences (Voikar et 
al. 2001), and (iii) careful consideration of behavioral dimensions to be integrated. 
 
Conclusion 
In summary, we suggest that using an easy-to-apply and "generalizable" z-score 
methodology can increase the reliability and comprehensiveness of behavioral testing 
from a variety of non-exclusive tasks, but along cohesive behavioral dimensions, for 
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complex behaviors such as emotionality of animals. Here, the application of this method 
to quantify emotionality in mice demonstrated that mice display subtle baseline 
emotionality sex differences that are similar to those observed in humans (Brebner 
2003), support the use of chronic mild stress as a comprehensive model to induce an 
anxiety-like/depressive-like syndrome, and points to corticosterone exposure as a 
model for male neuroendocrine vulnerability to mood disorders.  
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3.1 ABSTRACT 
Altered oligodendrocyte structure and function is implicated in major psychiatric 
illnesses, including low cell number and reduced oligodendrocyte-specific gene 
expression in major depressive disorder (MDD). These features are also observed in 
the unpredictable chronic mild stress (UCMS) rodent model of the illness, suggesting 
that they are consequential to environmental precipitants; however, whether 
oligodendrocyte changes contribute causally to low emotionality is unknown. Focusing 
on 2’-3’-cyclic nucleotide 3’-phosphodiesterase (CNP1), a crucial component of axoglial 
communication deregulated in the amygdala of MDD subjects and UCMS-exposed 
mice, we show that altered oligodendrocyte integrity can play an unexpected functional 
role in affect regulation. Mice lacking CNP1 (knockout, KO) displayed a decreased 
anxiety- and depressive-like phenotype (i.e. low emotionality) at baseline, which 
developed progressively between 3 and 9 months of age.  This phenotype was 
accompanied by increased motor activity, but was evident prior to neurodegenerative-
associated motor coordination deficits (≤9-12 months). Notably, CNP1KO mice were less 
vulnerable to developing a depressive-like syndrome after either UCMS or chronic 
corticosterone exposure. CNP1KO mice also displayed reduced fear expression during 
extinction despite normal amygdala c-Fos induction after acute stress, together 
implicating dysfunction of an amygdala-related neural network, and consistent with 
proposed mechanisms for stress resiliency. However, the CNP1KO behavioral 
phenotype was also accompanied by massive upregulation of oligodendrocyte- and 
immune-related genes in the basolateral amygdala, suggesting an attempt at functional 
compensation. Together, we demonstrate that the lack of oligodendrocyte-specific 
CNP1 leads to resilient emotionality. Yet, combined with substantial molecular changes 
and late-onset neurodegeneration, these results suggest the low CNP1 seen in MDD 
may cause unsustainable and maladaptive molecular compensations contributing to the 
disease pathophysiology. 
 
Keywords: oligodendrocyte, CNP, depression, UCMS, emotionality, myelin, stress  
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3.2 INTRODUCTION  
Disruptions in neuronal signaling have long been the focus of research on major 
depressive disorder (MDD). More recently, however, glial disruptions have been 
postulated to contribute to the pathophysiology of MDD (Fields 2008; Hercher et al. 
2009; Fields 2010), and the roles of specialized glial subtypes are now being 
investigated. While alterations in microglia (Muller and Schwarz 2007; Steiner et al. 
2008; Miller et al. 2009) and astrocyte-related components (Choudary et al. 2005; 
Rajkowska and Miguel-Hidalgo 2007; Valentine and Sanacora 2009; Banasr et al. 2010) 
are observed in MDD, oligodendrocyte alterations in MDD are becoming a primary 
focus of research (Fields 2008).  Oligodendrocytes, the main myelin-forming cells of the 
central nervous system (CNS), provide both structural and trophic support for neurons, 
and facilitate axonal conduction. In the amygdala and prefrontal cortex of MDD subjects, 
previously-reported decreases in glial cell number were attributed to reduced 
oligodendrocyte number (Hamidi et al. 2004; Uranova et al. 2004), consistent with 
patterns of downregulation of oligodendrocyte-related transcripts in amygdala (Sibille et 
al. 2009) and nearby temporal cortex (Aston et al. 2005). Changes in NG2 cells, a cell 
type sharing a common lineage with oligodendrocytes (Belachew et al. 2001; Mallon et 
al. 2002), have also been associated with depression-related characteristics in rodents. 
For instance, both chronic corticosterone exposure and chronic stress in rodents 
decreased cortical and limbic oligodendrocyte (Banasr et al. 2007) and NG2 cell 
proliferation (Alonso 2000; Wennstrom et al. 2006). Rats given electroconvulsive 
seizure therapy, an antidepressant treatment for otherwise non-responsive MDD 
subjects, showed increased proliferation of NG2 cells in the amygdala and 
hippocampus (Wennstrom et al. 2003; Wennstrom et al. 2004; Wennstrom et al. 2006). 
Thus, evidence suggests that oligodendrocytes, a crucial element for maintaining 
optimal neuronal function, may be vulnerable to stress-related insults and may 
contribute to the pathophysiology of MDD.   
We previously identified a set of dysregulated gene transcripts in the amygdala of 
male subjects with familial MDD, including robust downregulations of multiple 
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oligodendrocyte-related genes (Sibille et al. 2009). This pattern was also observed in 
mice following unpredictable chronic mild stress (UCMS) (Surget et al. 2008) and 
appeared restricted to the amygdala (not anterior cingulate cortex or dentate gyrus). 2’-
3’-cyclic nucleotide 3’-phosphodiesterase (CNP1) was one of several oligodendrocyte-
specific genes significantly downregulated across species. Additionally, CNP1 was 
previously implicated in MDD (Aston et al. 2005; Sequeira et al. 2009) and 
schizophrenia (Hakak et al. 2001; Peirce et al. 2006; Che et al. 2009), supporting the 
hypothesis that altered CNP1 function may participate in the pathophysiology of 
psychiatric disorders. While CNP1 is expressed at low levels in the periphery, it is 
expressed at higher levels in NG2 cells and it comprises ~4% of myelin-associated 
proteins in mature oligodendrocytes (Braun et al. 2004). CNP1 is localized to non-
compact myelin in the inner mesaxon and paranodal loops (Trapp et al. 1988), the 
principle sites of contact with the axon. CNP1 binds microtubules and regulates mRNA 
expression and transport at the paranode (Gravel et al. 2009), although its exact role in 
axoglial communication is not known. The lack of CNP1 protein in mice results in 
disorganization of nodal sodium channels and paranodal adhesion proteins (e.g. Caspr 
and Nav) (Lappe-Siefke et al. 2003; Edgar et al. 2009). Adult CNP1KO mice do not 
initially show an overt behavioral phenotype, but develop progressive axonal 
degeneration and motor deficits after 6 months of age, leading to premature death 
(Lappe-Siefke et al. 2003; Edgar et al. 2009).  
Healthy oligodendrocytes are necessary to maintain optimal axon function (Nave 
2010), however it remains to be determined whether oligodendrocyte-specific alterations 
are causal to MDD, or are simply compensatory or neutral side effects in psychiatric 
disorders. Here, we investigated the effect of a lack of CNP1 on emotionality (i.e. 
anxiety and depressive-like behaviors) in mice, under baseline conditions (trait) and 
after chronic stress or corticosterone exposure, two validated paradigms for inducing 
high emotionality states. As the amygdala is a central region in affect regulation and 
since our initial findings showed low CNP1 in the amygdala of MDD patients (Siegle et 
al. 2002), we also assessed amygdala function in CNP1KO mice using fear conditioning, 
c-Fos induction and gene expression profiling. The experiments show that lack of CNP1 
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results in low emotionality under baseline and induced states, along with reduced 
corticolimbic fear expression, a suggested mechanism for stress resilience. 
3.3 MATERIALS AND METHODS 
 
Animals. Adult male and female CNP1KO and wild-type (WT) littermate mice (C57BL/6 
background)(Lappe-Siefke et al. 2003) were obtained from heterozygous crossings and 
microchipped for identification. 5 cohorts were used: Baseline Cohort (N=11-17/group; 
6 and 9 months baseline), UCMS Cohort (N=8-12/group, 6 months of age), CORT 
Cohort (N=10-14/group; 3-month baseline and CORT exposure), Fear conditioning 
(FC) Cohort (N=16-19/group, 3 and 6 months of age, FC) and cFos Cohort 
(N=6/group, 6 months of age). Mice were maintained under standard conditions (group 
housed, 12/12-hour light/dark cycle, 22±1°C, food and water ad libitum). All testing was 
conducted in compliance with the NIH laboratory animal care guidelines and with 
protocols approved by the Institutional Animal Care and Use Committee. 
 
Behavioral measures. Major depression is defined as a syndrome (i.e. collection of 
symptoms) including low mood or anhedonia, accompanied by cognitive (e.g. attention, 
concentration) and physiological symptoms (e.g. weight, locomotor and sleep pattern 
changes), and frequently co-morbid with significant anxiety symptoms. Thus, its 
emotionality component is best characterized in mice by a comprehensive panel of 
behavioral tests for anxiety-like and depressive-like emotionality, and for 
antidepressant-like behavior. Hence, baseline, UCMS, and CORT cohorts were tested 
in the elevated plus maze (EPM), open field (OF), novelty suppressed feeding (NSF), 
forced swim test (FST), and rotarod (RR), as described (Joeyen-Waldorf et al. 2009) 
and in the following order: EPM, OF, NSF, FST, RR, separated by a minimum of 1-2 
days. Detailed methods are in the Supplemental Material. 
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Behavioral z-scoring. To address behavioral variability and obtain comprehensive and 
integrated measures in each group, emotionality- and locomotion-related data were 
normalized using a Z-score methodology previously described (Guilloux et al. 2011). 
Briefly, for each behavioral measure, Z-scores for individual animals were calculated 
using the formula below, which indicates how many standard deviations (σ) an 
observation (X) is above or below the mean of a control group (µ). 
 
 
 
Z-scores for behavioral measures were first averaged within test, and then 
across test to insure equal weighting of the four tests comprising the final Z-score 
(Figure 3.1B-C). Separate Z-scores were calculated for the Baseline, UCMS, and CORT 
cohorts using the means and standard deviations of the respective control groups (i.e. 
“WT” for Baseline or “WT control” for UCMS and CORT).  Locomotion Z-scores were 
similarly obtained from EPM (total crosses) and OF (total distance traveled) data.  
 
Estrous phase. Female mice in the UCMS and 3-month baseline cohorts were 
assessed for estrous phase on the day of behavioral testing after the EPM, OF or NSF 
test to control for potential effects of hormonal fluctuations on behavior. Estrus, 
metestrus, diestrus, and proestrus were determined via vaginal cytology (Goldman et al. 
2007) as previously described (Guilloux et al. 2011).  
 
Unpredictable chronic mild stress (UCMS). Single housed mice were subjected to 
four weeks of a randomized schedule of 1-2 mild stressors per day, seven days per 
week. Detailed methods are in the supplements and full table of stressors in 
Supplementary Table C.1. 
 
Chronic corticosterone treatment (CORT). As described previously (Guilloux et al. 
2011), mice were given corticosterone (35µg/ml; Sigma-C2505) dissolved in 20% 
σ
µ−
=
Xz
92 
 
cyclodextrin (Sigma H107) as their only water supply for four weeks. Due to reduced 
cohort size, behavior of all mice was tested both prior to (3-month baseline) and 
following CORT exposure. 
 
Fear conditioning. The protocol was performed over three days using a computer-
controlled system (Coulbourn Instruments, Allentown, PA) (Figure 3.3A). On day 1, 
mice were trained to associate a conditioned stimulus ([CS]; 80db, 2KHz, 15s tone) to 
an unconditioned stimulus ([US]; 0.5mA, 0.5s footshock) in context A (shock floor, 
silver/aluminum walls, 70% ethanol cleanser). On day 2, mice received 30 trials of the 
CS only in context B (non-shock grid floor, black walls, Windex cleanser). On day 3, 
mice were placed back in context B (extinction recall) followed by context A (fear 
renewal) 1hr later; and freezing was recorded during 5 CS exposures in each context. 
On each day, a 2-minute acclimation period preceded and followed testing. Trials were 
presented with a variable inter-trial interval (25-35s) and percent freezing was measured 
during the 15s CS. 
 
Immunohistochemistry. Stress-induced c-Fos immunoreactivity was performed as 
described (Sibille et al. 1997). Brains were collected by perfusion 120 minutes following 
a 15-minute restraint stress. 40um sections (6/mouse) were incubated with c-Fos 
antibody (polyclonal rabbit anti-c-Fos; 1:5000 dilution; Calbiochem, San Diego, CA), 
followed by secondary biotinylated goat-anti-rabbit IgG (1:500 dilution; Vector 
Laboratories, Burlingame, CA), and visualized with diaminobenzidine solution (DAB 
Peroxidase Substrate Kit; Vector Laboratories, Burlingame, CA). Total numbers of c-
Fos positive cells were counted in the basolateral amygdala (BLA).  
 
Gene array. Brains from the UCMS cohort (n=11-13 mice per group) were selected 
based on emotionality Z-scores that were closest to the means of their group. Following 
dissection, brains were immediately flash frozen on dry ice. As the other hemisphere 
was allotted for other experiments, the left BLA was dissected directly on the cryostat 
using a 0.5mm micropunch, tissue samples were frozen at -80°C until extraction, and 
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total RNA was extracted using an RNeasy Mini Kit (Qiagen, Germantown, MD). 
Concentration and purity were tested using a Bioanalyzer and Nanodrop 
Spectrophotometer (260/280>1.8). One half of each RNA sample (~150ng) was 
processed on Illumina Mouse WG-6v2 Expression BeadChips at the Keck Microarray 
facility (Yale University) and expression levels were determined using the Illumina 
BeadArray Reader. The other half was used for independent verification by qPCR. Two 
internal controls verified the validity of the arrays (see results): 1) CNP1 is 
downregulated/absent in CNP1KO and 2) Cnp1 is downregulated in WT mice following 
UCMS (Surget et al. 2008).  
 
Real time quantitative polymerase chain reaction (qPCR). Total RNA was converted 
into cDNA using the qScript cDNA synthesis kit (Quanta Biosciences, Gaithersburg, 
MD). As previously described, qPCR reactions were assessed by SYBR green 
fluorescence signal (Invitrogen, Carlsbad, CA) using the Opticon Monitor DNA Engine 
(Bio-Rad, Berkeley, CA) (Sibille et al. 2009). Briefly, samples were run in quadruplicate 
and ∆Ct values were determined by comparison to the geometric mean o f three 
reference genes (housekeeping genes: actin, GAPDH, cyclophilin). Signal intensities 
(SI=100*2-∆C(t)) were used for comparison to microarray expression values.  
 
Statistical Analysis.  There were no significant effects of sex or estrous phase in all 
examined cohorts, so male and female groups were combined, where appropriate. 
Genotype differences in Baseline and CORT cohorts were assessed using repeated 
measures ANOVA for age and treatment, respectively. Genotype comparisons with the 
3-month baseline group were made using one-way ANOVA. UCMS Z-scores were 
assessed using a two-way ANOVA for genotype and treatment. Weekly measures in 
UCMS (fur rating, body weight, and corticosterone levels) were assessed using two-way 
repeated measures ANOVA for week with genotype and treatment as co-factors. 
Genotype differences in the FC cohort were assessed using repeated measures 
ANCOVA with age as a covariate for days 1 (conditioning) and 2 (extinction) and one-
way ANCOVA for day 3 (recall and renewal). Genotype differences in the c-Fos cohort 
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were determined using two-way ANOVA for genotype and stress. Gene expression 
changes across genotype were assessed in four subgroups: WT-Control (WC), WT-
UCMS (WU), KO-Control (KC) and KO-UCMS (KU), using ANOVA followed by two-
group student t-tests for gene selection.  LSD and Tukey's tests were also used for 
post-hoc analysis (Supplementary Table 2). Selection criteria were set at p<0.01 and 
effect size greater than 30%. Genotype differences in qPCR were assessed with one-
way ANOVA. 
3.4 RESULTS 
CNP1KO mice display low baseline/trait emotionality and high locomotor activity 
 Consistent with prior reports, CNP1KO mice showed normal motor coordination in 
the rotarod test at 3 and 6 months of age and deficits at 9 months of age (Figure 3.1A). 
Mice were grossly impaired at 12 months of age and could not perform the rotarod test 
(data not shown). Therefore, we tested the impact of reduced CNP1 on emotionality in 
male and female mice at 3, 6 and 9 months of age (i.e. prior to and during mild 
neurodegenerative-related stages), using four behavioral paradigms (EPM, OF, NSF 
and FST). To extract stable patterns underlying behavioral variability, emotionality-
related measures were normalized to the 3-month WT group, and averaged per mouse 
across tests to obtain integrated “emotionality Z-scores” (Guilloux et al. 2011) (See 
methods, and example of 6-month time-point in Figure 3.1B). CNP1KO were comparable 
to WT mice at 3 months of age and displayed progressively decreasing emotionality z-
scores at 6 and 9 months of age (Figure 3.1C and Supplementary Figures 3.1-3.3). It is 
unlikely that changes were due to repeated testing (at 6 and 9 months) since a pattern 
of decreased emotionality in WT mice would be expected, although CNP1KO-specific 
memory-related events cannot be ruled out (See fear-conditioning tests). While EPM 
and OF emotionality measures were controlled for locomotor activity, FST results could 
reflect differences in activity. Removing the FST from the emotionality Z-score 
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decreased power, but the same progressive pattern of low emotionality was observed in 
CNP1KO mice (6mo p=0.07; 9mo p<0.0004; Supplementary Figure C.4).  
Integrated Z-score measures of locomotor activity revealed a concomitant 
progressive increase from 3 to 9 months of age in CNP1KO mice (Figure 3.1D and 
Supplementary Figures C.1-C.3). CNP1KO mice also displayed lower body weight at 6 
and 9 months compared to WT, but had normal levels of stress hormones 
(Supplementary Figures C.5A-B). Together, these results are supportive of a time-
dependent decrease in emotionality in CNP1KO mice, which is paralleled by a 
progressive elevated locomotor phenotype. 
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Figure 3.1. CNP1KO baseline behavior at 3, 6, and 9 months of age. A) Latency to 
fall on the rotarod. CNP1KO mice show significant motor coordination deficits at 9 
months. B) Example of individual behavioral measures combined in the emotionality Z-
scores (6-month time-point). CNP1KO mice showed significant changes in EPM and 
FST, and non-significant changes in NSF and OF. In NSF, no differences in weight loss 
or post-test food consumption were noted (data not shown).  EPM, OF, NSF, and FST 
measures were normalized using WT means and standard deviations, and averaged 
per group (see Methods and (Guilloux et al. 2011)). Breakdown of z-scores for other 
age groups are presented in supplementary figures C.1-C.3. C) High emotionality Z-
scores indicate elevated anxiety- related and depressive-like behaviors. D) Similarly-
derived locomotion Z-scores indicate elevated locomotor activity. Z-scores are 
normalized to the 3 month WT group for both emotionality and locomotion. Red 
asterisks represent within-genotype age comparisons. Black asterisks represent across 
genotype comparisons. Data represent mean ± SEM (n=9-18/group). *p<0.05, **p<0.01, 
***p<0.001, # represent statistical trends (p<0.1). 
 
 
 
CNP1KO mice are resistant to developing high emotionality states in two distinct 
rodent models of depression 
 To test whether low baseline emotionality also conferred reduced vulnerability to 
develop high emotionality states, we exposed two independent cohorts of CNP1KO mice 
to environmental (UCMS) or neuroendocrine (CORT) stressors for a period of four 
weeks. In both experiments, WT groups responded with robust and characteristic 
increases in emotionality (Figures 3.2A-B). CNP1KO mice responded with increased 
emotionality after UCMS compared to non-stressed CNP1KO mice (Figure 3.2A; 
Supplementary Figure C.6), but displayed a trend toward lower emotionality following 
CORT exposure (Figure 3.2B; Supplementary Figure C.7). Notably, following both 
paradigms, CNP1KO mice remained at emotionality levels that were lower than WT non-
stressed groups (Figure 3.2A-B). These differences remained when FST was excluded 
98 
 
from Z-score analyses (Supplementary Figure C.8A-B) and were confirmed in an 
independent cohort (Supplementary Figure C.9). Note that the UCMS cohort was 6-
months of age at testing, so the low emotionality and high locomotion of CNP1KO mice 
match prior results (Figure 3.1), hence independently confirming the baseline 
phenotype.  
UCMS increased locomotion in WT (trend level) but not in CNP1KO mice (Figure 
3.2C; Supplementary Figure C.6). CORT exposure reduced locomotion in WT and 
increased locomotion in CNP1KO mice (Figure 3.2D; Supplementary Figure C.7). No 
notable genotype differences were seen in weight gain, fur rating, or corticosterone 
levels in either paradigm (Supplementary Figures C.10A-C and C.11A-C). In summary, 
CNP1KO mice displayed reduced vulnerability to develop high emotionality behaviors 
after chronic environmental and neuroendocrine challenges, as emotionality z-scores 
never reached WT levels. Notably, dissociations between changes in emotionality and 
locomotor activity were observed between genotype groups (Figure 3.2E- 
F).  
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Figure 3.2. Effects of two rodent models of depression in CNP1KO mice.  
Emotionality Z-scores in the unpredictable chronic mild stress (UCMS) (A) and chronic 
corticosterone treatment (CORT) (B) cohorts. Locomotion Z-scores in the UCMS (C) 
and CORT (D) cohorts. Z-scores were normalized to WT control groups within each 
experimental cohort. Differences in CNP1KO control groups between cohorts reflect age 
differences (UCMS, 6 months; CORT, 3 months). Schematic diagrams of emotionality 
and locomotion interactions in WT and CNP1KO mice across age (E) and after UCMS or 
CORT exposure (F). WT mice showed a dissociation in emotionality/locomotion effects 
between the two depression models, while changes in CNP1KO remained along the 
same axis. Red asterisks represent within genotype age comparisons. Black asterisks 
represent across genotype comparisons. Data represent mean ± SEM (n=10-14/group). 
*p<0.05, **p<0.01, ***p<0.001, # represent statistical trends (p<0.1). 
 
 
 
Normal fear conditioning and cellular reactivity to stress, but reduced fear 
expression, suggest low encoding of emotional salience in CNP1KO mice  
 Our motivating study indicated reduced CNP1 levels in the amygdala of MDD 
subjects and UCMS-exposed mice. To test whether the observed behavioral phenotype 
included disrupted amygdala function, we assessed CNP1KO mice in the fear 
conditioning paradigm (Figure 3.3A), a test relying on amygdala processing. Similar to 
WT, CNP1KO mice learned to associate the conditioned stimulus (CS) with the 
unconditioned stimulus (US) on day 1 (Figure 3.3B-left panel). On day 2, both groups 
showed intact extinction learning, but CNP1KO mice displayed lower CS-induced 
freezing from the onset, resulting in significantly lower freezing throughout the extinction 
paradigm (Figure 3.3B-right panel), an indication of low fear expression (Sierra-Mercado 
et al. 2011). No significant differences in pain sensitivity were observed in the hot plate 
test (Supplementary Figure C.12). These results were confirmed in a separate cohort 
(n=8-12/genotype; p<0.01 for extinction; Supplementary Figure C.13). This robust 
genotype difference was consistently observed during the following extinction recall and 
101 
 
fear renewal, and was not due to lack of consolidation of fear memory (Supplementary 
Figure C.14).  
To assess whether the observed differences could reflect baseline changes in 
stress-induced activation of the amygdala, we measured the expression of the 
immediate early gene c-Fos in the BLA of a separate cohort of animals following a 15-
minute restraint stress. WT and CNP1KO mice displayed similar baseline (although at 
trend level for low reactivity in CNP1KO mice) and stress-induced number of c-Fos 
positive cells (Figure 3.3C-D), indicating intact BLA response to acute stress in CNP1KO 
mice.  
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Figure 3.3. Fear conditioning and c-Fos analysis. A) Fear conditioning protocol. 
Percent freezing during (B) fear conditioning and extinction. C-D) Analysis of stress-
induced cFos expression in BLA of WT and Cnp1KO mice. C) c-Fos expression in the 
amygdala under 10x magnification, Bar=0.1mm. D) Total c-Fos positive cell counts. 
While there was a trend (p<0.1) toward a genotype difference in the non-stressed 
groups, no significant differences were found between WT and CNP1KO. In all panels, 
red asterisks represent within-genotype comparisons. Black asterisks represent across-
genotype comparisons. Data represent mean±SEM (n=16-19/group), (n=9-18/group). 
*p<0.05, **p<0.01, ***p<0.001, # represent statistical trends (p<0.1).   
 
 
 
Upregulated oligodendrocyte- and immune-related gene transcripts in the BLA of 
CNP1KO mice 
 To investigate putative underlying amygdala-related mechanisms, large-scale 
gene expression was assessed by microarray in the BLA of WT and CNP1KO mice from 
the UCMS cohort (Figure 3.4A). Internal verification of the array data confirmed that 
CNP1 levels were undetectable in CNP1KO mice (Figure 3.4B) and downregulated in 
UCMS-exposed WT (WU) mice for two out of three probes (Figure 3.4C).(Surget et al. 
2008; Sibille et al. 2009) UCMS-exposed CNP1KO (KU) mice showed a similar pattern of 
transcript changes as UCMS-exposed WT (WU) mice (R=0.72; Supplementary Figure 
C.15), indicating that the broad biological response to stress is intact. However, due to 
the phenotypic differences, these UCMS-related genes are unlikely to be related to the 
behavioral phenotype in CNP1KO mice. Instead, based on consistent low emotionality in 
control and UCMS-exposed CNP1KO mice, we focused on genes displaying similar 
changes under control and UCMS conditions, as potential “mediators” of the behavioral 
phenotype. 114 “CNP1KO-associated probesets” were identified by the following criteria: 
1) significant difference in CNP1KO under control (KC vs WC) and UCMS-exposed (KU 
vs WU) conditions (p<0.01; effect size>30%), 2) consistent directionality of effect in both 
groups, and 3) no change in WT after UCMS (p>0.1). 
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Figure 3.4. BLA gene array analysis and qPCR validation. A) BLA tissue 
micropunch. B) Absence of expression of the three CNP1 probes in CNP1KO mice. 
Expression levels were at the threshold of detection (~100-120 units; gray shading). C) 
Downregulation of two out of three CNP1 probes in WT mice exposed to UCMS. D) RT-
qPCR confirms significant upregulation of 8 out of 9 genes. Data represent mean±SEM 
(Microarray n=11-13/group; qPCR n=6/group). *p<0.05, **p<0.01, ***p<0.001, # 
represent statistical trends (p<0.1).   
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Based on prior identification of relative glial/neuronal enrichment of transcript 
origin  (Sibille et al. 2008), 97% of the 114 identified transcripts were enriched in glial or 
mixed glial/neuronal origin. Specifically, a systematic upregulation of oligodendrocyte-
related transcripts was observed (24% of CNP1KO-associated genes), including genes 
involved in structure, function and production of the myelin sheath (Table 3.1). In 
parallel, we observed a significant upregulation of immune-related transcripts (32% of 
KO-associated genes) including genes associated with the immune complement system 
and major histocompatibility complex (Table 3.1; see also Supplementary Table C.2). 
Ingenuity pathway analysis of CNP1KO-associated genes identified a gene network that 
closely links oligodendrocyte with immune genes, suggesting that the upregulation of 
immune-related genes may be synchronized with the dysregulation of oligodendrocyte-
related genes in CNP1KO mice. Only two neuronal-enriched genes were identified 
(Cortistatin and Serpina3n) suggesting minimal structural and/or functional adjustment 
in neurons.  
 
 
 
 
 
 
Table 3.1. Selection of significantly affected neuronal, oligodendrocyte and 
immune-related genes between CNP1KO vs WT control mice. Number of redundant 
probes are shown following the gene symbol. Red=neuronal-enriched genes; 
Blue=oligodendrocyte-enriched genes; Underline=Immune-related genes. Alr=average 
log ratio (CNP1KO/WT). The listed p-values represent the main genotype effect from the 
ANOVA analysis (See Supplementary Table C.2). 
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3.5 DISCUSSION 
Focusing on an oligodendrocyte gene (CNP1) that is critical for neuronal support and 
that is dysregulated in MDD, we tested the potential mechanistic link between altered 
oligodendrocyte function and emotionality in mice. We show that removal of CNP1 in 
mice leads to unexpected reduced baseline emotionality, reduced fear expression 
(during extinction) and lower vulnerability to develop high emotionality states using two 
rodent paradigms to induce depressive-like states. This behavioral profile suggests the 
presence of a dysfucntional amygdala-related network that is consistent with proposed 
mechanisms for stress resiliency. Gene array analysis in the BLA of CNP1KO mice 
revealed a robust upregulation of oligodendrocyte- and immune-related transcripts, 
potentially representing functional compensations.  
CNP1KO mice exhibit a low baseline emotionality phenotype (trait) that appears 
progressively over time, but that is observed prior to the onset of motor coordination 
deficits (9-12 months), indicating that it is not due to the late-onset widespread axonal 
degeneration observed in CNP1KO mice (Lappe-Siefke et al. 2003). Rather, more 
discrete molecular changes in myelin structure have been observed at earlier ages, 
which may contribute to the observed phenotype. For instance, the direct functional 
consequence of CNP1 ablation is not known, but disorganization of critical proteins (e.g. 
Caspr, Nav) at the paranode region at 3 months and degeneration in some small 
diameter axons as early as post-natal day 15 were reported in CNP1KO mice (Rasband 
et al. 2005; Edgar et al. 2009). So deregulated paranode function may translate into 
suboptimal support for neuronal axons, hence priming the system for deregulated 
physiological responses to stress/fear.  
CNP1KO mice also display a concomitant increase in locomotor activity. Tests of 
emotionality control for activity, but locomotor and emotionality phenotypes are often 
difficult to dissociate in rodent models. In fact, quantitative trait loci mapping studies 
have identified regions on chromosomes 2, 7, and 8 that encode for both anxiety-related 
behavior and locomotion in rats (Conti et al. 2004), and the well-characterized high 
emotionality and low locomotion phenotypes of mice (Holmes et al. 2003) or rats 
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(Homberg et al. 2010) lacking the serotonin transporter associate with common genetic 
loci (Homberg et al. 2010). So, instead of a confounding factor, altered locomotor 
activity may represent an epistatic outcome of genetic disruptions of emotionality 
regulators, which are nevertheless dissociable under certain genetic and/or stress-
induced conditions (Figure 3.2E-F). 
CNP1KO mice have normal amygdala cellular reactivity (c-Fos measures) and 
fear acquisition, but display low fear expression during extinction learning (Figure 3.3), 
which was not likely due to poor consolidation of the fear memory (Supplementary 
Figure C.14). Instead, we speculate that reduced fear expression in CNP1KO mice may 
result from low encoding of emotionality salient stimuli (e.g. the original fear 
association). Accordingly, CNP1KO mice respond to chronic behavioral (UCMS) or 
physiological (CORT) stress (Figure 3.2A), but their induced emotionality states 
remained significantly  below the levels associated with depressive-like states in WT 
mice (Figure 3.2A-B). Together, this behavioral pattern is consistent with stress resilient 
phenotype. Indeed, in humans, resilience is associated with the ability to adapt to 
chronic stress (Feder et al. 2009) and to perceive stressful events in a less threatening 
way (Kobasa 1979; Tugade and Fredrickson 2004; Southwick et al. 2005), both 
characteristics observed here in CNP1KO mice. Fear expression is dependent on BLA 
function (Herry et al. 2006; Sotres-Bayon et al. 2007), but is also modulated by regions 
of the prefrontal cortex (Jovanovic and Ressler 2010; Sierra-Mercado et al. 2011). 
Similarly, in humans, the ventromedial prefrontal cortex (vmPFC) modulates amygdala 
function during fear extinction (Delgado et al. 2008), and potent vmPFC inhibition of the 
amygdala is postulated to occur in resilient individuals (Liberzon and Sripada 2008; 
Feder et al. 2009). Together, this suggests the presence of a dysfunctional amygdala-
related neural network in CNP1KO mice, consistent with proposed mechanisms for 
stress resilience. As disruption in related networks including prefromtal and/or 
hippocampal regions cannot be excluded, site-specific and time-dependent alterations 
could further refine the role of CNP1. 
Microarray evaluation of transcript levels within the BLA of CNP1KO mice 
indicated a robust pattern of upregulated oligodendrocyte-related transcripts. This 
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suggests an attempted compensation for the lack of structure/function due to missing 
CNP1, and potentially reflecting prior reports of enlargement of the myelin inner tongue 
in small diameter axons and of whirls of excess redundant myelin sheaths seen early in 
CNP1KO mice (Edgar et al. 2009). Microarray assessment also revealed a pattern of 
upregulated immune-related transcripts (MHC class II, complement system, 
inflammatory mediators: Table 3.1), consistent with reports of reactive gliosis and 
microglial activation in CNP1KO mice (Lappe-Siefke et al. 2003). Interestingly, 
components of the complement system can be either deleterious or beneficial (Shen 
and Meri 2003). Recent evidence of upregulated immune-related genes (e.g. c1qc, 
cd74, serpina3, tyrobp) was associated with protected cognition in old subjects (Katsel 
et al. 2009), suggesting neuroprotective potential. Here, upregulated immune-related 
genes in CNP1KO mice show ~40% overlap with the gene set implicated in that study, 
suggesting potential mixed deleterious/neuroprotective effects of immune-related gene 
changes in CNP1KO mice. Surprisingly, only two neuronal-associated transcripts were 
found changed (upregulated) in CNP1KO mice, and both are associated with immune 
function. Cortistatin, a neuropeptide, has anti-inflammatory and neuroprotective 
properties in mice (Gonzalez-Rey et al. 2006) and humans (Carrasco et al. 2008; van 
Hagen et al. 2008), while Serpina3, a serine peptidase inhibitor, is upregulated in 
response to inflammation in the rodent brain (Tsuda et al. 1996; Takamiya et al. 2002) 
suggesting a protective role for these genes in CNP1KO mice.  
Whether increased immune- and oligodendrocyte-related transcripts may be an 
attempt of the system to “repair” damage and/or protect against further damage due to 
the lack of CNP1-related function, is not known. However, Ingenuity-based functional 
analyses suggest that the two processes are inter-related, a finding consistent with 
reports in most mental illnesses (Ryan et al. 2006; Rao et al. 2010; Shelton et al. 2010) 
and highlighted by the comorbidity of emotion regulation disorders (i.e. anxiety, 
depression) in patients with multiple sclerosis, an inflammatory demyelinating CNS 
disease (Hogancamp et al. 1997; Chwastiak and Ehde 2007). Consequently, CNP1 
could be a critical component of the mechanistic link between oligodendrocytes and 
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immune function underlying psychiatric and other CNS disorders (Nave 2010; Konradi 
et al. 2011). 
While the molecular phenotype of the CNP1KO appears confined to non-neuronal 
compartments, one of the primary functions of myelinating oligodendrocytes is to 
support electrical signal conduction along the axon (Poliak and Peles 2003). The 
paranode region, where CNP1 is localized, is critical for maintaining axonal integrity 
(Garcia-Fresco et al. 2006; Rosenbluth 2009). CNP1 and other gene products in this 
region are thought to maintain optimal functioning of axonal mitochondria and it is 
suggested that perturbations at the paranode could disrupt this fragile metabolic 
coupling (Nave 2010). Electrophysiological changes in oligodendrocytes can modulate 
axonal conduction velocity (Yamazaki et al. 2007) and the firing of action potentials in 
NG2 cells is dependent on axonal synapses (Karadottir et al. 2008), highlighting the 
functional connectivity between neurons and oligodendrocytes (Fields 2008). In 
addition, structural changes in oligodendrocytes specifically at the paranode region, are 
suggested to be a potential mechanism for subtle alterations in axonal conduction and 
associated loss of signal integrity (Edgar and Nave 2009; Yamazaki et al. 2010). 
Accordingly, improper signal conduction in amygdala-related circuitry in CNP1KO mice 
(due to paranode disruption) could account for the low encoding of emotionally-salient 
information, and related phenotypic abnormalities.  
In summary, initial studies reported low CNP1 in MDD and in response to chronic 
stress (Surget et al. 2008; Sibille et al. 2009) (Figure 3.4). We now demonstrate that 
disruption of oligodendrocyte function (via CNP1 ablation) can impact circuits mediating 
emotionality in mice, leading to a resilient emotionality phenotype. Thus, although these 
studies indicate that CNP1 disruption is not likely a causal factor in MDD, however, the 
current results suggest that low CNP1 and/or disruption of a critical axoglial junction 
may contribute to clinical symptoms of mood disorders in an unexpected and potentially 
maladaptive way (due to massive molecular changes), and should therefore be further 
examined in relation to psychiatric illnesses and potential treatments. 
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4.0  GENERAL DISCUSSION 
MDD is a devastating disorder with severe personal and societal consequences, but the 
fundamental neurobiology underlying MDD is complex and not well understood. It is 
crucial to gain insight into these mechanisms in order to stimulate the development of 
new interventions and therapies.  Oligodendrocyte disturbances are consistently found 
in both MDD subjects and animals exposed to chronic stressors, however, it is unclear if 
these disturbances play a functional role in the precipitation of the disorder.  The studies 
in this dissertation investigated the consequences of oligodendrocyte disruption 
(ablation of CNP1) on behavioral and molecular aspects of emotionality in mice and 
emphasize new approaches for examining emotionality in mice. We demonstrate that 
CNP1KO mice display resilient emotionality, altered corticolimbic function, and molecular 
disruptions in the BLA. Below, I discuss the broad implications of these findings and 
propose a role for CNP1 in maintaining the integrity of axoglial interactions and ensuing 
downstream processes.  
4.1 METHODOLOGICAL CONSIDERATIONS IN INVESTIGATING 
EMOTIONALITY 
The complex symptomatology and neurobiology of MDD make it difficult to use animals 
to model the precise nuances of the disorder (Cryan and Holmes 2005).  Thus, there is 
a need for new approaches to investigate depressive-like symptoms in rodents.  In this 
portion of the discussion, I will describe how we have initiated use of Z-score 
normalization to both counteract variability and gain a more comprehensive view of 
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depressive-like symptoms in rodents.  In addition, I describe the application of the fear 
conditioning paradigm as a way to assess corticolimbic function related to emotionality 
in mice.  Finally, I discuss how application of these approaches revealed a pattern of 
resilient emotionality in CNP1KO mice.  
4.1.1 Z-score Normalization and Assessment of Emotionality 
While the use of animals is crucial for investigating neurobiological facets of MDD, a 
wide range of difficulties exist when attempting to model aspects of the disorder (see 
section 1.2.1).  In particular, the current strategy in the field is to use multiple behavioral 
tests to assess convergent “endophenotypes” of depressive-like behavior (Cryan and 
Mombereau 2004).  However, in rodents, behavioral tests often suffer from both internal 
and external variability sometimes making it difficult to assign conclusions.  In Chapter 
2, we extend the notion of a behavioral test battery to model a single aspect of MDD:  
emotionality in mice.  We show that Z-score normalization and multiple test integration 
allows for a more comprehensive assessment of a depressive-like phenotype in mice 
across several dimensions.  First, Z-scoring stabilized variability between tests due to 
external factors (e.g. time of day, experimenter, etc.).  Second, combining multiple 
common features of tests by application of the Z-score methodology revealed trends in 
the data that may not have otherwise been revealed (see below).  Third, Z-scoring can 
be used to pool multiple data sets, thereby increasing analytical power and potential for 
different analyses.  Finally, the diagnosis of human MDD has a temporal component, 
where the symptomatology must be present for a minimum of 2 weeks.  Z-score 
normalization can take this temporal component into account by combining test results 
from multiple days allowing an assessment of the emotionality “state” of the animal over 
time.      
Specific applications of Z-score normalization in Chapters 2 and 3 revealed 
trends in emotionality that may have otherwise gone undetected.  In Chapter 2, 
combining several experimental cohorts of WT mice using Z-score methodology 
revealed intriguing sex differences in baseline emotionality and vulnerability to develop 
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a depressive-like syndrome.  In Chapter 3, application of Z-score normalization revealed 
robust and unexpected patterns of altered emotionality in CNP1KO mice.  CNP1KO mice 
had decreased emotionality at baseline and decreased vulnerability to a depressive-like 
syndrome in two rodent models (UCMS and CORT) compared with WT mice.  While the 
amount and variety of data from these experiments could promote over-interpretation of 
single parameters, Z-score analysis instead allowed us to gain a broad assessment of 
the emotionality phenotype in CNP1KO mice.  The aforementioned applications of Z-
score methodology display the power of this technique to reveal both underlying trends 
and global patterns of emotionality in mice. 
Using the Z-score to combine emotionality parameters or “endophenotypes” into 
one comprehensive score may be the closest researchers can get to assessing an 
actual “syndrome” in mice.  Indeed, the future of behavioral phenotyping may be in 
determining behavioral patterns in animal models which could parallel subtypes of 
complex human disorders or even patterns of pharmacological responsiveness.  For 
instance, a pattern of high emotionality in EPM and OF, but not NSF, may be indicative 
of an anxiety-like phenotype, whereas high emotionality in NSF and FST might be 
indicative of a depressive-like phenotype.  Going one step further, Z-scoring could be 
used to assess other parameters, such as cognition, locomotion (also shown here), or 
even physiological measures.  Potentially, an algorithm could be developed where 
multiple Z-scores, each containing a different combination of test parameters, are 
assessed (and perhaps weighted) to determine the disorder most closely related with 
the observed “pattern”.  In conclusion, the Z-score method has the potential to enhance 
the translational validity of animal testing in MDD and potentially other complex 
disorders.  
4.1.2 Fear Conditioning and Assessment of Corticolimbic Function 
PTSD and MDD share a strong comorbidity (Blanchard et al. 1998) and there is 
considerable overlap between pathways implicated in both disorders, suggesting 
common mechanistic underpinnings.  Indeed, corticolimbic function has been shown to 
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be dysregulated in both disorders.  Yet, while the fear conditioning paradigm has been 
used to assess corticolimbic dysfunction in PTSD (Jovanovic and Ressler 2010), only a 
single study has investigated fear conditioning in MDD subjects.  This study found MDD 
patients display enhanced fear learning, however, fear extinction or extinction recall was 
not investigated in these subjects (Nissen et al. 2010).  In animals, mice exposed to the 
UCMS model of depression have been shown to have abnormal extinction learning 
(Baran et al. 2009) and one report found impaired extinction recall in SERT knockout 
mice (Wellman et al. 2007), which display classic depressive-like symptoms.  In 
addition, results in Chapter 3 show decreased depressive-like symptoms concurrent 
with low fear expression during extinction (i.e. less freezing during entire extinction 
period), together suggesting a connection between depressive-like symptoms and 
extinction mechanisms in rodents (see also 4.1.3).  Accordingly, the fear conditioning 
paradigm may be useful in assessing an “endophenotype” of MDD-related corticolimbic 
dysfunction, a parameter that could also be utilized in the Z-score method.   
What type of fear conditioning pattern might we expect to see in an MDD patient?  
Neurobiologically, MDD patients display heightened amygdala reactivity and decreased 
corticolimbic association (Surguladze et al. 2005; Matthews et al. 2008).  During the fear 
conditioning paradigm, the amygdala plays a central role in fear learning, extinction, and 
recall; and prefrontal regions conventionally are thought to inhibit amygdala output (i.e. 
fear) (Sierra-Mercado et al. 2011). Thus, in MDD subjects exposed to a fear 
conditioning paradigm we could expect to see one or more of the following: 1) increased 
fear learning [shown in (Nissen et al. 2010)], 2) heightened fear expression during 
extinction, 3) decreased/impaired fear extinction, 4) increased fear renewal, and/or 5) 
decreased extinction recall.  While these predicted characteristics may share some 
overlap with those seen in PTSD (Jovanovic and Ressler 2010), it would be worthwhile 
to tease apart disorder-specific patterns, as subtle differences between PTSD and MDD 
subjects have been observed in fear inhibition during a startle paradigm (Jovanovic et 
al. 2010). 
Another challenge in using animal research to investigate MDD is that many 
symptoms of depression (e.g. sadness, guilt, rumination, negative thinking) are difficult 
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to accurately recapitulate in animals (Nestler and Hyman 2010).  There is evidence that 
the fear conditioning paradigm has the potential to portray some of these “human-
associated” traits in mice (Table 4.1).  First, individuals with MDD tend to assess 
interactions and events at a more negative value and anticipate more negative future 
events (Lavender and Watkins 2004), an action akin to encoding a stimulus at a high 
emotional valence, potentially reflected by enhanced fear learning, increased fear 
expression, or impaired fear extinction.  Second, MDD subjects frequently exhibit stress 
vulnerability (or lack of resilience), a characteristic that appears to be reflected during 
extinction portions of the paradigm (see section 4.1.3).  Finally, rumination, an 
unintentional and recurrent thought process, either self-directed or directed at a 
perceived object of despair (Nolen-Hoeksema 1991), has been shown to involve 
regions of the prefrontal cortex (Hamilton et al. 2011).  A rodent equivalent of rumination 
could be reflected by an inability to extinguish fear, ineffective extinction recall, or 
enhanced fear renewal.  Consequently, these apparently abstract features of MDD may 
simply be manifestations of a more tangible corticolimbic dysregulation.  While it could 
be argued that the circuitry affected in MDD may involve uniquely human pathways 
(Crawley 2000), the corticolimbic pathway described in rodent fear conditioning is most 
certainly phylogenetically conserved (Quirk et al. 2010) making it an excellent paradigm 
for examining the conserved or “primitive” emotional pathway. 
 
 
 
Table 4.1. Comparison of human MDD symptoms to measurable mouse behaviors 
and corresponding tests.  The ten listed human MDD symptoms correspond to the 
diagnostic and statistal manual of mental disorders (DSM-IV TR) criteria for MDD, with 
more measurable characteristics listed below each symptoms category. Tests 
highlighted in red are components of a fear conditioning paradigm which can be used to 
test corticolimbic function.  OF=open field, EPM=elevated plus maze, NSF=novelty 
suppressed feeding. 
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HUMAN
Symptom Behavior Test
1
Low or depressed mood / comorbid 
anxiety (Kessler 1996)
Anxiety-/Depressive-like behavior                      
fearfulness
OF, EPM, NSF                         
Fear conditioning
•   Increased acute stress reactivity       
(i.e. Lack of stress resilience)
Increased stress reactivity FST, TST, Fear learning
•    Increased chronic stress vulnerability Increased fear / emotionality
UCMS, CORT, Fear extinction 
and recall
•   Abnormal risk/fear  assessment
Assignment of high emotional 
valence to fear or risk
Fear learning, extinction, 
expression
•   Sadness / hopelessness No correlate No test
2 Anhedonia
Reduced consumption of pallatable 
food
Sucrose Preference Test
3 Feelings of worthlessness/guilt
•   Rumination
Decreased fear extinction or 
extinction recall
Extinction learning and recall
•   Social withdrawl Social avoidance or attack Social interaction test
4 Sleep disturbances Abnormal sleep patterns Homecage activity
5 Appetite and weight changes
Weight loss change in food 
consumption
Body weight, food 
consumption
6 Fatigue / low energy Activity Homecage activity
7 Psychomotor agitation
Locomotor activity following acute 
or chronic stress
Open field, homecage 
activity
8 Difficulty concentrating Poor working memory Morris water maze, Y-maze
9 Poor hygiene Poor coat condition Coat Test, splash test
10 Suicidality
•  Suicidal attempts/completion Impulsivity
Lever press / delayed reward 
task
•  Suicide thoughts No correlate No test
MOUSE
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4.1.3 Convergent Methodological Approaches Reveal Resilient Emotionality in 
CNP1KO Mice 
Downregulation of CNP1 has been implicated in MDD (Aston et al. 2005; Sequeira et al. 
2009) and a recent study in our lab found that CNP1 was specifically downregulated in 
the amygdala of human MDD patients and mice exposed to the UCMS model of 
depression (Surget et al. 2008; Sibille et al. 2009).  Utilization of the Z-score 
normalization method and fear conditioning paradigm in CNP1KO mice revealed a 
surprising pattern.  The results presented in Chapter 3 show that CNP1KO mice have 
decreased vulnerability to develop a depressive-like syndrome following the UCMS and 
CORT rodent models of depression (Figure 4.1).  In addition, CNP1KO mice displayed 
low fear expression during the extinction learning phase of our fear conditioning 
paradigm, suggestive of low encoding of emotionality salient stimuli.  In humans, 
emotional resilience is defined as the ability to successfully adapt to chronic stress 
(Charney 2004; Feder et al. 2009) and the ability to perceive stressful events in a less 
threatening way (Southwick et al. 2005), both characteristics displayed by the CNP1KO 
mouse.  In addition, Feder (2009) suggests that resilient individuals have optimal 
functioning of fear extinction mechanisms (Feder et al. 2009) and Charney (2004) states 
that resilience is "an ability to quickly attenuate learned fear through a powerful 
extinction process” (Charney 2004).  Together, this evidence indicates that the pattern 
exhibited by CNP1KO mice is characteristic of stress resilience. 
Reports indicate that resilience is not only the absence of vulnerability to stress 
but, is itself, an active neurobiological process (Krishnan et al. 2007).  This is supported 
by investigations showing that stress vulnerable and stress resilient mice actually have 
quite different transcriptional profiles, rather than opposite patterns (Bergstrom et al. 
2007). There is evidence that resilience is mediated by the same corticolimibic regions 
involved in MDD and fear (Charney 2004).  Similar to our findings in Chapter 3, mice 
lacking the intracellular signaling molecule ERK (extracellular signal-regulated kinase) 
displayed both enhanced fear extinction and reduced depressive–like behaviors 
(Tronson et al. 2008). In accord with these findings, a polymorphism (G196A) in the 
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BDNF (brain-derived neurotrophic factor) gene has been associated with both stress 
resilience and altered fear extinction in mice (Krishnan et al. 2007; Soliman et al. 2010).  
These examples demonstrate that, similar to depressive symptoms (section 4.1.2), 
stress resilience is closely associated with fear extinction mechanisms, a notion that 
should be more thoroughly explored in the context of MDD. 
4.2 INFLUENCE OF EXAMINED RISK FACTORS ON BEHAVIORAL OUTPUTS 
Here, I describe the effects of putative MDD risk factors (age, sex, and stress) on 
behavioral outputs in both WT and CNP1KO mice.  Notably, a distinct dissociation was 
found between WT and CNP1KO mice, with WT mice responding with increased 
emotionality to all risk factors while CNP1KO mice responded variably to individual risk 
factors, suggesting the CNP1 gene interacts with various risk factors differentially 
(Figure 4.1).  In the following sections, I first discuss the effects of age and sex on 
emotionality in WT and CNP1KO mice followed by observed locomotor effects. 
4.2.1 Effects of Risk Factors on Emotionality Outputs 
4.2.1.1 Age 
 
While older individuals often have reduced rates of depression due to greater 
psychological resilience (i.e. wisdom), late-onset depression is a subclass of MDD that 
develops in older individuals.  Similar to this sub-class, previous studies in our lab 
showed increased emotionality in older C57BL/6 WT mice compared to younger 
animals (Joeyen-Waldorf et al. 2009). In Chapter 2, we also show that older WT mice 
exhibit a slight increase in emotionality suggesting: 1) age needs to be carefully 
controlled when designing studies for emotionality in mice and 2) certain strains of mice, 
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such as C57BL/6, could be used to examine subclasses of MDD, such as late-onset 
depression.    
In contrast to WT animals, CNP1KO mice show a pronounced and progressive 
decrease in emotionality with age (Chapter 3) (Figure 4.1).  Similar to previous studies 
(Lappe-Siefke et al. 2003), we that found motor coordination deficits occur in these mice 
around 9 months of age, and are likely due to large scale axonal degeneration (Lappe-
Siefke et al. 2003)  However, we saw decreased emotionality as early as 6 months of 
age.  Previous studies have shown that CNP1KO mice have disorganization of paranodal 
proteins (e.g. Caspr) at 3 months of age (Rasband et al. 2005) and degenerative 
changes in small diameter axons as early as 15 days (Edgar et al. 2009).   
Consequently, emotionality circuits may be sensitive to these more discrete alterations 
in myelin structure (e.g. at the paranode), rather than overt axonal degeneration. 
In healthy rhesus monkeys, age-related increases in dysfunctional CNP1 cause 
disruption of lipid raft signaling systems (Hinman et al. 2008), implying that  dysfunction 
of CNP1 (whether ablation or overexpression of the aberrant protein) may be related to 
age-associated or progressive disorders.  Similar to this situation, both the PLPKO and 
the PLP overexpressor mouse exhibit progressive axonal degeneration (Griffiths et al. 
1998; Griffiths et al. 1998), providing support that overexpression of CNP1 in vivo may 
result in a similar progressive neurodegeneration as seen in the knockout (see also 
4.3.2.3).   
Although CNP1KO mice display emotional resilience rather than susceptibility, 
concurrent dysregulation of both of these traits is reminiscent of some forms of 
dementia that are preceded by MDD (Alexopoulos et al. 1993; Cannon-Spoor et al. 
2005).  In fact three recent longitudinal studies indicate that depression and number of 
depressive episodes are risk factors for development of cognitive disorders, particularly 
Alzheimer’s disease (Dotson et al. 2010; Saczynski et al. 2010; Wilson et al. 2010).  
This evidence implies that MDD may share a common neuropathology with Alzheimer’s 
disease.  Accordingly, a recent review implicates the MDD-induced dysfunction of the 
stress pathway as a precipitating factor in the onset of Alzheimer’s disease (Aznar and 
Knudsen 2011). Our results show that the CNP1KO has pre-motor affective 
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dysregulation and significant changes in several Alzheimer’s-related genes (Serpina3n, 
Cort, c1qB; see Table 3.1), suggesting these genes, along with CNP1, may share roles 
in both affect and neurodegenerative pathways. Therefore, it may be relevant to 
examine cognitive function in CNP1KO mice.  
4.2.1.2  Sex 
 
Female subjects are twice as likely to develop MDD than male counterparts and 
fluctuations in hormones correlate with depressive episodes (Kornstein et al. 2000). 
While few studies have purposely examined sexual dimorphism in animal studies, there 
is evidence that female rodents are more susceptible to UCMS than males (Dalla et al. 
2005; Joeyen-Waldorf et al. 2009).  In Chapter 2, we combine data from WT animals 
across several experimental cohorts to reveal sexual dimorphism in two models of 
depression.  Similar to previous studies, we found female mice had higher emotionality 
at baseline and were more susceptible to UCMS.  However, males were more 
susceptible to chronic CORT treatment (Figure 4.1).  These results reveal interesting 
sex differences between stress and neuroendocrine responses, and add to an 
increasing literature of stress-related sex differences in both rodents (Galea et al. 1997; 
Liu et al. 2006) and human MDD patients (Young and Ribeiro 2006; Binder et al. 2009).  
These models could therefore provide future avenues for investigating MDD-related sex 
differences.   
In Chapter 3, we examined sex differences in several cohorts of CNP1KO mice, 
and consistently observed no main effect of sex in all examined tests.  On the surface, 
this would suggest CNP1 does not interact with sex hormones to alter vulnerability.   An 
alternative interpretation could be that CNP1 does interact with sex because the typical 
(WT) sex difference is not seen in the CNP1KO mouse, indicating that absence of CNP1 
somehow counteracts female vulnerability to UCMS.   
Some subtypes of MDD are associated with hormonal fluctuations (Becker et al. 
2007; Grigoriadis and Robinson 2007).  An ongoing study in our lab revealed that 
behavioral sexual dimorphism following UCMS is primarily due to organizational effects 
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of hormones (permanent effects of developmental hormones) rather than activational 
effects (transient effects of gonadal hormones) (M. Seney, personal communication). In 
Chapters 2 and 3, we found no differential effects of estrous phase on depressive-like 
behaviors in female WT or CNP1KO mice exposed to UCMS or CORT, further 
supporting that there are not robust activational effects of hormones on depressive-like 
susceptibility in mice.  Thus, the UCMS and CORT models appear to be associated with 
organizational rather than activational effects of hormones, suggesting they would not 
be robust models for subtypes of MDD associated with circulating sex hormones (e.g. 
postpartum depression).  However, these effects may be obscured by a dysregulation of 
the estrous cycle in females exposed to UCMS (Dalla et al. 2005), and a more directed 
analysis may reveal subtle influences of circulating hormones.   
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Figure 4.1. Summary diagram representing relative effects of individual risk 
factors on disease susceptibility in WT and CNP1KO mice.  In humans, both clinical 
and neurobiological factors determine the relative risk of an individual.  Here, we tested 
putative risk factors in WT and CNP1KO mice.  WT mice respond with increased 
emotionality to all risk factors.  CNP1KO mice respond with decreased emotionality to 
age and CORT, increased emotionality to UCMS, and neutrally to female sex.  
Hypothetically, a certain level of emotionality may push an individual across the 
“disease threshold”, defined here as the level of emotionality significantly different from 
the WT no risk group (red dashed line).  Critically, CNP1KO mice never reached the 
“disease threshold” and remained well below all WT groups, highlighting their resilience 
to a depressive-like syndrome. 
4.2.2 Effects of Risk Factors on Locomotor Outputs 
Psychomotor changes often occur in MDD and changes in locomotion can be a 
confounding factor when examining emotionality in mice (Conti et al. 2004; Strekalova 
et al. 2005; Leventhal et al. 2008).  While we weren’t specifically examining locomotor 
changes in our studies, we wanted to both carefully control for locomotion, and explore 
whether locomotor changes parallel emotionality changes in these studies.  In Chapter 
2, we found WT females tend to have increased locomotor activity at baseline.  
Following CORT exposure, females again had increased locomotor activity while males 
had decreased locomotor activity, indicating sexually dimorphic factors may play a role 
in locomotor activity.  In Chapter 3, we show CNP1KO mice have increased locomotor 
activity with age.  UCMS exposure unexpectedly decreased locomotion and CORT 
exposure increased locomotion in CNP1KO mice, the opposite of the pattern seen in WT 
mice.  Overall, it appears that female sex positively regulates locomotion, while absence 
of CNP1 completely deregulates locomotor behaviors, highlighting the need to consider 
locomotion parameters in study design. 
Quantitative trait locus (QTL) mapping studies have pinpointed certain 
chromosomal regions that encode both anxiety and locomotor behavior, suggesting an 
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epistatic interaction between these traits (Conti et al. 2004).  In addition, genes 
associated with hyperactivity in mice (e.g. in KO mice) are expressed at much higher 
levels in “mood-associated” regions such as the amygdala, cerebral cortex and 
hippocampus, when compared with non-locomotion-associated genes (Mignogna and 
Viggiano 2010), providing further support for a connection between emotionality and 
locomotion.  Classic examples of this association in mutant mice include the serotonin 
transporterKO mouse (Holmes et al. 2003) and the 5HT1ARKO (Heisler et al. 1998; Parks 
et al. 1998; Ramboz et al. 1998), which both show increased anxiety and decreased 
locomotion.  In addition, stress paradigms commonly elicit hyperactivity in WT animals, 
along with heightened emotionality (Strekalova et al. 2005). In Chapter 3, we show that 
WT animals (males and females grouped together) exposed to UCMS display increased 
emotionality and increased locomotion as expected, but CORT elicits increased 
emotionality and an unexpected decrease in locomotion. Thus, the CORT and UCMS 
paradigms elicit different locomotor changes, again suggesting these models may work 
through different mechanisms. In summary, our data provide further supporting 
evidence that there are connections between locomotion and emotionality, although, it 
appears that these phenotypes are dissociable under stress conditions (i.e. CORT).   
4.3 INFLUENCE OF CNP1 ON THE NEUROBIOLOGY OF MOOD REGULATION 
In this portion of the discussion, I discuss how the ablation of CNP1 has influenced the 
neurobiology of mood regulation, on a molecular, cellular, and circuit level, expanding 
on topics touched on briefly in the discussion of Chapter 3.  I also discuss predictions 
regarding how this ablation might impact neurobiological components not directly tested 
here.  Lastly, I present a potential model incorporating potential neurobiological 
consequences of CNP1 alteration or ablation. 
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4.3.1 Molecular Effects of CNP1 Ablation 
While the exact function of CNP1 remains unknown, it appears to play a role in diverse 
processes including axoglial communication, outgrowth of the myelin sheath, RNA 
binding, and microtubule and actin binding (section 1.4).  In Chapter 3, CNP1 ablation 
led to a robust upregulation of other oligodendrocyte-related transcripts in the BLA, 
indicating an attempted compensation for the absence of structural and functional roles 
of CNP1.   Alternatively, this upregulation could be a non-specific attempt for the cell to 
regain functional and structural homeostasis. While a seemingly minor difference, we 
could examine the molecular profile of CNP1 overexpressor (CNP1OE) mice to 
determine if we see an opposite transcriptional profile (CNP1-specific changes) or a 
similar pattern of upregulation (non-specific homeostasis-related changes).   
Patients with MDD have been shown to have increases in immune-mediators, 
and injections of lipopolysaccharide (LPS; a cytokine inducer) can induce depressive-
like symptoms in humans and mice (Reichenberg et al. 2001; Dantzer et al. 2008). In 
contrast to these reports, we saw an unexpected upregulation of immune-related 
transcripts in parallel with decreased emotionality and resilience in CNP1KO mice 
(Chapter 3).  Interestingly, rats that were resilient to a chronic mild stress (CMS) 
paradigm displayed an upregulation of immune response genes in the hippocampus 
relative to control animals, and this response reflected neuroprotective immune 
regulator genes (Bergstrom et al. 2007). In addition, a report revealed that many of the 
same immune-associated genes found in our study were involved in protected cognition 
(Katsel et al. 2009), together suggesting this subset of immune regulator genes may be 
involved in resilience and/or neuroprotective mechanisms.   
Adding to the notion that CNP1 ablation may induce neuroprotective 
inflammatory responses, the only two neuronal-associated transcripts found to be 
significantly upregulated in the CNP1KO were cortistatin, a neuroprotective anti-
inflammatory neuropeptide, and SPI-3n, a serine peptidase inhibitor.  SPI-3 has been 
shown to be upregulated in the brain after LPS treatment (Tsuda et al. 1996; Takamiya 
et al. 2002), and is transcriptionally regulated by interleukin-6 and glucocorticoids 
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(Kordula et al. 1996).  Similarly, cortistatin has been shown to downregulate 
inflammatory mediators in mice (Gonzalez-Rey et al. 2006).  It also plays a role in 
mediating immune function in humans (van Hagen et al. 2008) and low cortistatin 
expression is associated with increases in GFAP and apoptosis (Carrasco et al. 2008).  
Additionally, recent findings in our lab have revealed downregulation of cortistatin in the 
amygdala and anterior cingulate cortex of MDD subjects (E. Sibille, personal 
communication), supporting the notion of cortistatin as a positive mediator of resilience. 
Overall, these results indicate that the observed increases in certain immune- and 
oligodendrocyte-related genes may be an attempt of the system to “repair” damage 
and/or protect against future damage due to the removal of CNP1.    
Our results in Chapter 3 also suggest a connection between altered 
oligodendrocyte components and immune-related components in CNP1KO mice.  Prior 
reports indicate oligodendrocytes interact with microglial cells, the main immune 
response cells in the CNS.  For instance, microglial processes have been shown to 
interact directly with NG2 cells (Nishiyama et al. 1997).  In vitro, oligodendrocyte stress 
signals recruit nonreactive microglia (Nicholas et al. 2003), which play a role in survival 
and maturation of OPCs (Nicholas et al. 2001).  However, active microglia can also 
induce contact-dependent death of oligodendrocytes (Nicholas et al. 2003).  Genetic 
perturbation of oligodendrocytes is thought to trigger an influx of certain immune-
mediators, leading to a detrimental cycle of inflammation and degeneration (Nave 
2010).  Supporting this notion, mice overexpressing oligodendrocyte-specific, PLP, 
exhibit secondary inflammation including microgliosis and T-cell infiltration (Anderson et 
al. 1998).  Blockade of T-cell function in this mouse ameliorates the phenotype, pointing 
toward an active role for immune-related factors during oligodendrocyte distress (Ip et 
al. 2006; Kroner et al. 2010).  The relationship between oligodendrocytes and immune 
function is highlighted in multiple sclerosis (MS), an inflammatory demyelinating CNS 
disease.  Patients with MS also share a strong comorbidity with MDD (Chwastiak and 
Ehde 2007).  Interestingly, a recent report found approximately 44% of multiple 
sclerosis patients had autoantibodies against CNP1 (Lovato et al. 2008).  Combined 
with our data from chapter 3, we can infer that CNP1 could serve as a molecular link 
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between altered oligodendrocyte function and immune/microglial activation, a notion 
that could be further explored in CNP1KO mice or mice exposed to LPS.   
4.3.2 Cellular Effects of CNP1 Ablation 
4.3.2.1  Neuronal Alterations 
 
Similar to stress-induced oligodendrocyte alterations, stress and glucocorticoid 
treatment have been shown to affect neuronal plasticity in emotionality-related brain 
regions in rodents [reviewed in (Roozendaal et al. 2009)], suggesting a potential link 
between neuronal and oligodendrocyte cellular changes.  Specifically, acute 
glucocorticoid treatment and chronic stress result in hypertrophy of BLA neurons (Vyas 
et al. 2002; Vyas et al. 2004; Mitra and Sapolsky 2008), and chronic stress produces 
atrophy in IL [(Izquierdo et al. 2006); see also Figure 1.2]. Moreover, dendritic 
hypotrophy in the BLA was found to be a marker for resilience to anxiety-like behaviors 
(Mitra et al. 2009) and stress-induced atrophy in IL neurons was correlated with 
resistance to fear extinction (Izquierdo et al. 2006).  Based on these studies and the 
fear extinction phenotype of CNP1KO mice, we might expect to see neuronal changes 
such as amygdala hypotrophy and increased IL branching in CNP1KO mice.  In fact, a 
recent study found that CNP interacts with the neurite outgrowth inhibitor, NOGO-A, 
indicating that alterations (or ablation) of the oligodendrocyte-specific gene CNP may 
influence neuronal outgrowth (Sumiyoshi et al. 2010) and pointing toward CNP1 as a 
potential link between stress-induced neuronal and oligodendrocyte alterations.  These 
plausible neuronal characteristics could be measured in the CNP1KO using Golgi 
staining and subsequent analysis with Sholl or a similar morphological procedure. 
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4.3.2.2  Oligodendrocyte Alterations 
 
Decreased oligodendrocyte density and downregulation of oligodendrocyte-related 
transcripts have been reported in MDD and rodents exposed to chronic stress or 
glucocorticoids (Hamidi et al. 2004; Aston et al. 2005; Banasr et al. 2007; Sibille et al. 
2009).  However, whether these alterations are causal or simply side effects of the 
disorder is unknown.  In Chapter 3, we compromised oligodendrocyte function via CNP1 
ablation and found resilient emotionality in mice, along with a robust upregulation of 
oligodendrocyte-related genes in the BLA of CNP1KO mice.  The latter finding is 
consistent with a reported excess and swelling of myelin in the CNP1KO (Edgar and 
Nave 2009), and may reflect compensatory changes attributed to lack of 
oligodendrocyte structure and function.  It is also plausible that this upregulation reflects 
increased oligodendrocyte number in the CNP1KO, a hypothesis that could be tested via 
cell counts or density analysis, and would be particularly interesting in light of the 
reported decreased oligodendrocyte density in MDD (Hamidi et al. 2004).  While it is 
clear that stress leads to decreased oligodendrocyte number, we have shown that 
disruption of oligodendrocyte function (but not number/density) results in resilient 
emotionality.  Thus, it is still unclear whether decreased oligodendrocyte number/density 
leads to depressive-like symptoms.  To address this, it would be beneficial to examine 
effects of global or region-specific decreases in oligodendrocyte number/density to see 
if a depressive-like phenotype emerges.  This could be accomplished globally by 
systemic administration of the copper chelator, cuprizone, which induces apoptosis in 
oligodendrocytes [method reviewed in  (Matsushima and Morell 2001)]; or in a region-
specific manner with other demyelinating toxins such as lysolecithin (Woodruff and 
Franklin 1999). 
Our results in Chapter 3 indicate that CNP1KO mice overall have resilient 
emotionality compared with WT mice.  Considering the vulnerability of oligodendrocytes 
to stress and glucocorticoid toxicity, this could suggest that absence of CNP1 alters the 
stress-responsiveness of oligodendrocytes.  Interestingly, it has been proposed that 
mechanisms of allostasis (adaptation to challenge) in corticolimbic regions may be 
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crucial to understanding stress resilience (Charney 2004; McEwen 2007; Krishnan and 
Nestler 2008).  The evidence provided here implicates CNP1 as a potential genetic 
factor involved in oligodendrocyte-mediated resilience.  Considering that CNP1 is 
localized to the paranode region of oligodendrocytes, our data support that the 
paranode region could be a critical site for regulating stress responsiveness, potentially 
through allostatic mechanisms (see below).   
4.3.2.3  Paranodal Alterations 
 
One of the primary functions of oligodendrocytes is to promote axonal conduction and 
actively regulate neuronal properties (Poliak and Peles 2003) and depolarization of 
oligodendrocytes has been shown to disrupt axonal conduction (Yamazaki et al. 2007; 
Yamazaki et al. 2010).  CNP1 is localized to the paranodal junction of oligodendrocytes, 
the critical site of interaction between the myelin sheath and axon (Trapp et al. 1988; 
Salzer 2003; Rosenbluth 2009) (see section 1.3.1.3).  In mice lacking the paranodal 
protein, Caspr, the paranode region fails to form and these mice exhibit decreased 
nerve conduction velocity (Bhat et al. 2001), suggesting the paranode region is critical 
for proper axonal signal transmission.  While a single report found no difference in 
compound action potential between CNP1KO and WT mice (Edgar et al. 2009), reports 
suggest it may be the more subtle leak currents that are impacted by paranode 
disruptions resulting in more (or less) rapid depolarizations (Yamazaki et al. 2010).  
Evidence suggests that disruption of CNP1 may lead to aberrant signal conduction and 
downstream dysregulation of circuitry and behavior (Figure 4.3).  Therefore, it would be 
highly relevant to thoroughly examine cellular and electrophysiological properties in 
CNP1KO mice.   
While alterations in oligodendrocytes impact neuronal firing (see above), 
repetitive action potential propagation, in turn, leads to paranodal swelling (Wurtz and 
Ellisman 1986), indicating a fine-tuned bidirectional balance between axonal activity and 
the paranode.  The concept of a homeostatic relationship between oligodendrocytes 
and neurons is also supported by Nave, who hypothesized that oligodendrocyte 
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mutations cause reduced metabolic coupling between the myelin and the axon (Nave 
2010).  Ablation of proteins, such as CNP1 and Caspr, cause disorganization at the 
paranode (Rasband et al. 2005; Sun et al. 2009), potentially generating a disruption in 
axoglial homeostasis.  It is difficult to determine from these studies if the observed 
phenotype of CNP1KO mice in Chapter 3 is due to disrupted paranodal integrity (i.e. 
homeostasis) or a dose-dependent effect of CNP1.  Examination of CNP1 heterozygous 
or overexpressor mice would reveal if there is a dose-dependent effect of CNP1 on the 
emotionality phenotype.  While expectations may be that CNP1 is a positive regulator of 
axoglial function, and a CNP1 overexpressor mouse would have an opposite phenotype 
(i.e. depressive-like symptoms), this may not be the case.  An excess of CNP1 at the 
axoglial junction, may instead, disrupt paranodal homeostasis resulting in a similar 
phenotype as CNP1KO mice (i.e. resilience).  In support of this notion, and as previously 
mentioned, PLPKO and PLP overexpressor mice both show axonal degeneration 
implying that an imbalance (rather than linear dose) of PLP elicits disruptions of axoglial 
communication (Griffiths et al. 1998; Griffiths et al. 1998).  Examination of emotionality 
in other oligodendrocyte mutant mice (e.g. Caspr) may also shed light on the role of 
specific myelin compartments. 
4.3.3 Circuit-Level Effects of CNP1 Ablation 
A large body of research implicates dysregulation of corticolimbic networks in MDD and 
points toward the amygdala as the central region involved in mood regulation (Mayberg 
1997; Seminowicz et al. 2004). The fear conditioning paradigm is well-established in 
both humans and mice and has been shown to be dependent upon corticolimbic 
circuitry, specifically the BLA (Sah and Westbrook 2008; Jovanovic and Ressler 2010).  
In Chapter 3, we used a fear conditioning paradigm to examine amygdala-based 
corticolimbic function in CNP1KO mice and found that they have normal fear 
conditioning, but decreased fear expression during extinction.  Our results in this 
paradigm are similar to studies that pharmacologically inactivate either BLA or PL, a 
manipulation which produces low freezing (i.e. fear expression) throughout the 
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extinction phase (Sierra-Mercado et al. 2011).  Therefore, on a circuit level, it appears 
that CNP1KO mice have abnormal corticolimbic function which may be a result of 
hypofunction of the amygdala or decreased “top-down” control from the PL (Figure 4.2).  
Supporting this notion, Charney (2004) states that resilience “may be due to inhibition of 
amygdala activity mediated by the medial prefrontal cortex".  This hypothesis could be 
tested in CNP1KO mice by: 1) electrophysiological recordings (e.g. compound action 
potential) in BLA and PL to examine firing rate during the extinction phase, 2) examining 
BLA and PL C-Fos expression following extinction learning, or 3) pharmacologically 
inactivating (GABAA agonist muscimol) or activating (GABAA antagonist bicuculline) 
BLA or PL and examining resulting fear expression behavior.  Alternatively, a PL or BLA 
specific CNP1 knockdown or overexpressor (using means outlined in Appendix A) 
could be used to test the region-specific effects of CNP1 alteration on behavioral or 
electrophysiological outputs. 
The fear conditioning paradigm can be used to examine both fear memory 
(amygdala based) and contextual memory (hippocampus based) (LeDoux 2000); 
processes we attempt to dissociate in Chapter 3.  Extinction recall and fear renewal 
results, indicated contextual memory, and therefore hippocampal function, was intact in 
CNP1KO mice (Figure 3.3).  However, large differences in baseline freezing between WT 
and CNP1KO mice on days 2 and 3 make this difficult to accurately confirm.  Thus, it 
might be beneficial to perform memory based cognitive tasks on CNP1KO mice such as 
the Morris water maze or Y maze.  Performance during extinction (day 2) indicates 
CNP1KO mice display low freezing during the initial extinction trials, a behavior that 
could be the result of either a fear memory deficit or a low threat assessment of the CS.  
In support of a low threat assessment, we saw a significant change in freezing behavior 
during early extinction trials compared to late extinction trials (i.e. rate of extinction), 
implying that fear memory (memory of the CS-US pairing) is intact.  In addition, results 
from a pilot study where mice are re-exposed to five trials of the CS-US pairing indicate 
CNP1KO mice initially display a fear response similar to WT mice, but quickly display a 
diminished fear response (Appendix D).  This suggests: 1) they remember the CS and 
2) they temper their response after re-exposure to the pairing.  These results support 
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that both contextual and fear memory are intact in CNP1KO mice, and instead, provide 
evidence that CNP1KO mice encode the CS at a low threat level.   
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Figure 4.2. Model of potential circuitry changes in CNP1KO mice.  WT mice receive 
input from PFC to the BLA which together determine input to CeA and subsequent fear 
output.  Results from the fear conditioning paradigm suggest that CNP1KO animals likely 
have either reduced PFC input to BLA (green) or normal PFC function and hypofunction 
of BLA (red).  Either scenario would result in decreased input to CeA and low fear 
output. The proposed changes are testable hypotheses (see text) and would result in 
the pattern of low expression observed during the extinction phase of the paradigm.   
Modified from (Vidal-Gonzalez et al. 2006). 
 
 
4.3.4 Conclusions on the Neurobiological Consequences of CNP1 Ablation 
In previous studies from our lab, CNP1 was found to be downregulated in the amygdala 
of MDD subjects and WT mice exposed to UCMS.  Here, our results indicate that 
CNP1KO mice have: 1) low emotionality, 2) decreased vulnerability to develop a 
depressive-like syndrome, 3) deregulation of amygdala-mediated corticolimbic circuitry, 
and 4) robust upregulation of oligodendrocyte and immune-related transcripts.  As 
CNP1 is localized to the paranode region, we suspect paranode function may be a 
critical factor involved in homeostasis and/or allostasis of MDD-associated brain 
regions.  Disruption of oligodendrocyte function at the paranode can impact circuits 
mediating emotionality in mice, resulting in resilient emotionality (Figure 4.3).  In 
support of this notion, the white matter abnormalities found in human MDD subjects 
using diffusion tensor imaging have been suggested to disrupt neural circuits involved in 
MDD (Ma et al. 2007).  In conclusion, dysfunction of this region could translate into 
suboptimal support for neuronal axons, priming the system for deregulated physiological 
responses to stress and inducing compensatory/neuroprotective changes.   
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Figure 4.3. Proposed model of downstream consequences of altered paranode 
integrity.  There is evidence that disruption of paranode integrity (e.g. CNP1 ablation) 
[1] causes altered structure and function of oligodendrocytes [2].  This, in turn, could 
lead to aberrant signal transmission along the axon [3] resulting in altered integration of 
emotionality salient stimuli within the amygdala (e.g.) [4].  Abnormal amygdala function 
may cause downstream deregulation of corticolimbic circuitry involved in mood 
regulation [5], ultimately resulting in abnormal emotionality behaviors [6].  Molecular 
changes such as increased oligodendrocyte and immune-related components could be 
side effects of specific points of disruption.  See text for supporting information. 
4.4 DOES CNP1 PLAY A CAUSAL ROLE IN MDD? 
The goal of the studies outlined in this dissertation was to determine whether 
downregulation of CNP1 could be a causative factor in the onset of MDD.  We 
examined the emotionality phenotype, amygdala-specific behavior, and the molecular 
profile of CNP1KO mice to determine whether CNP1 might play a causal role in MDD 
onset. Criteria for a causal MDD-associated gene may be 1) altered levels (i.e. 
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upregulated or downregulated) in MDD subjects, 2) comparable alteration of the gene in 
an animal model of MDD, 3) an induced change of the gene in an animal elicits 
depressive-like symptoms, and 4) an induced change of the gene in an animal elicits 
molecular and cellular changes similar to those seen in MDD.  CNP1 met criteria 1 and 
2.  However, outcomes for criteria 3 and 4 were opposite of what was anticipated, 
indicating CNP1 is not a causal MDD-associated gene. Instead, they indicate 
downregulation of CNP1 in MDD may elicit a phenotypic compensation in MDD.  
However, it is difficult to conclusively make this determination in a global CNP1KO  
mouse since diseases rarely include full loss of gene function and the phenotype we 
see could be due to compensatory effects (e.g. absence of CNP1 during development) 
unrelated to CNP1.  In addition, CNP1 is found throughout the brain making it difficult to 
pinpoint regional effects and warranting further exploration using heterozygous and site- 
and temporal-specific CNP1 mutants.  While there are many unknowns about the 
function of CNP1 in MDD, we provide clear evidence that disruption of CNP1 does play 
a role in mood regulation.  Thus, while not a causative gene in MDD, it is a potentially 
relevant gene in secondary aspects of mood regulation, axoglial interactions, or in 
therapeutic aspects of MDD (see below) and other psychiatric disorders. 
Our results indicate that CNP1KO mice display resilience, raising the possibility 
that CNP1 could be a potential therapeutic target.  However, our results combined with 
prior evidence would suggest that CNP1 is not likely a good target because a reduction 
in CNP1 has maladaptive effects that eventually lead to widespread axonal 
degeneration and death.  Since CNP1 is highly expressed throughout the brain, it might 
be difficult to achieve site-specific effects with pharmacological agents, increasing the 
likelihood of numerous side effects.  Several organophosphorus compounds have been 
reported to decrease levels of CNP1 (Olajos 1987).  Notably, aniline, an organic 
compound used to make dyes, plastics, and even drugs, first increases then drastically 
decreases levels of CNP1 when given to rats orally.  The eventual decrease in CNP1 
correlates with increased swelling of oligodendrocyte cytoplasm and ultrastructural 
myelin splitting (Kanno et al. 2010), which both raises concern about the harmful 
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neurological properties of organophosphorus compounds and implies pharmaceutical 
targeting of CNP1 may have detrimental side effects.  
While our studies indicate CNP1 is not causative to MDD and may not be a 
suitable target for pharmacological intervention, investigations of CNP1 function can 
help to clarify the roles of oligodendrocytes and paranodal junctions in MDD.  Since 
CNP1 is widely used as a marker for oligodendrocytes, some tools have been 
developed that may be utilized for this purpose.  For instance, mice with markers 
attached to the CNP1 promoter have been developed (e.g. CNP-β-galactosidase and 
CNP-GFP), which could be useful in isolating cells that selectively express CNP1 
(Chandross et al. 1999; Roy et al. 1999; Belachew et al. 2001).  In addition, most of the 
traditional viral vectors used in viral-mediated gene delivery (e.g. adeno-associated 
virus or lentivirus) infect mainly neurons and not oligodendrocytes, which might make it 
difficult to perform site-specific manipulations of CNP1.  An alternative approach may be 
to use an organophosphorus compound such as aniline which directly targets CNP1.     
4.5 OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
Investigations into the role of oligodendrocytes in MDD and other psychiatric disorders 
are gaining momentum as more evidence points toward oligodendrocytes as active and 
integral components of neural functioning.  Here, we explored CNP1 as a potential 
MDD-associated gene and component of proper oligodendrocyte functioning. We 
applied a novel Z-score normalization procedure and traditional fear conditioning 
paradigm to assess emotionality and associated corticolimbic function in a more 
comprehensive and translational manner.  Z-score analysis in WT animals revealed that 
age, sex, and locomotion are factors that can influence emotionality and should be 
taken into consideration when designing, analyzing and interpreting behavioral 
measures in mice.  Z-score analysis also allowed for a broad assessment of the 
behavioral state of CNP1KO mice, revealing an unexpected behavioral pattern indicative 
of resilience.  CNP1 was implicated as a component involved in mediating the function 
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of corticolimbic regions responsible for mood regulation.  Our data suggest that 
downregulation of CNP1 may lead to a phenotypic compensation in MDD, but long-term 
downregulation of CNP1 has an unsustainable and maladaptive trajectory.  Together, 
our results suggest a model where disrupted axoglial interaction (via the paranode) has 
a direct impact on the function of the amygdala and associated corticolimbic circuits 
resulting in subsequent altered emotionality (Figure 4.3).  Furthermore, it suggests the 
paranode region of oligodendrocytes may be involved in maintaining homeostasis of the 
axoglial interface. This region may also be a critical site for regulating stress 
responsiveness (allostasis).  
Future studies should be aimed at deciphering the role of CNP1 using temporal 
and site-specific mutants, characterizing the role of the paranode region in MDD, 
exploring more causal roles of oligodendrocyte alterations in MDD, and examining 
polymorphisms in the CNP1 gene and their relation to MDD.  Future research into 
oligodendrocyte function may change the current notion that neurons and neuron-
networks are the solitary substrate for higher level functions such as complex behavior, 
emotion, and cognition. 
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APPENDIX A 
PAPER 3 – GENETICALLY MODIFIED ANIMALS  
 
Nicole Edgar and Etienne Sibille 
 
Center for Neuroscience, Department of Psychiatry 
University of Pittsburgh, Pittsburgh, PA 15213 
 
Definition of a genetically modified animal 
An animal whose genetic material has been altered by the use of genetic engineering or 
recombinant DNA technology. In biomedical sciences, genetically modified animals are 
typically generated for the purpose of studying the function of a particular gene.  
 
Principles and Role in Psychopharmacology 
One of the main goals of the field of genetics is to classify and functionally 
characterize individual genes. The investigative approach to studying genes in living 
organisms has principally been divided into three strategies: 1) analysis of natural 
variation, 2) random mutagenesis and, 3) targeted mutagenesis and transgenesis 
(Rudolph and Mohler 1999).  Analysis of natural variation (e.g. spontaneous mutations) 
and random mutagenesis (e.g. chemical or irradiation) are the primary approaches of 
‘forward genetics’ where the genetic cause (genotype) of an altered or abnormal 
phenotype is investigated. However, with random mutagenesis, many chromosomal loci 
are often targeted and it is difficult to trace any phenotype back to a specific genetic 
origin. The development of ‘reverse genetic’ approaches, where a particular gene is 
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altered and the phenotype is investigated, provided tools to investigate specific gene 
function in a more targeted manner (Brusa 1999). Since the development of these tools 
in the 1980s and 1990s, their use in the field of biomedical research and pharmacology 
has been substantial due to the ability to develop suitable animal models of specific 
diseases, the ability to genetically dissect the underlying mechanisms of disease, and 
the ability to identify and verify molecular targets of pharmacological agents.  
In the past two decades, a variety of techniques have been developed to 
introduce genetic modifications in various species for specific research purposes. 
Among the most targeted species are Drosophila melanogaster, Caenorhabditis 
elegans and mice, which have each played integral roles in identifying genes involved in 
development, aging, cell differentiation, and other major biological functions. Other 
genetically modified animals that have been developed include xenopus, zebrafish, 
rabbits, pigs, and cows. More recently, transgenic and knockout rats have been 
developed which will allow more extensive research in the neurosciences due to their 
extensive use in behavioral paradigms (Abbott 2004). In addition, the first transgenic 
primate disease model (for Huntington’s disease) was recently created (Yang et al. 
2008). While a wide variety of genetically modified organisms have been created to date 
for numerous research purposes, techniques for genetically modifying mice are the 
most advanced and the most applicable to the field of psychopharmacology, which 
represent the main focus of the remainder of this article.  
 
Transgenic Technology 
While the term “transgenic” has grown to include any type of genetically modified 
animal, the traditional definition of a transgenic organism is one containing foreign DNA, 
whether from the same species or a different one. The expression of foreign DNA in a 
mouse is a valuable technique since it allows for the investigation of the functional role 
of this gene in a living organism. For instance, transgenic mice overexpressing a 
particular gene are often generated to analyze exaggerated phenotypes. The 
expression of a human gene or a mutated gene in mice is also often used to explore 
gene function, particularly in the context of a specific disease.  
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There are several ways to create a transgenic mouse, however, all methods 
consist of first designing a DNA fragment, or “genetic construct”, which contains the 
gene of interest (GOI) and other features necessary for the expression of this gene in a 
mammalian system (e.g. gene promoter, enhancer, polyA signal, etc). The traditional 
transgenic method consists of physically injecting the transgenic construct into the 
nucleus of a fertilized egg (pronuclear microinjection), allowing it to develop in vitro to 
the blastocyst stage, and then implanting the egg into a pseudopregnant female (Fig 
A.1a). The embryos must then be screened for the presence of the transgene and 
unlike the production of knockouts, the transgene typically occurs in an all or none 
fashion, with the embryo either containing the transgene in every cell or in no cells at all.  
Alternatively, transgenic animals can be produced by viral infection of the fertilized 
embryo (see below) or transfection of embryonic stem cells (ES) with the gene of 
interest (Dale 2002).  While the transgenic approach is fast and efficient, limitations of 
the technology include: 1) The GOI may randomly integrate into the genome which can 
result in expression in ecotopic sites, interference with the endogenous gene, or severe 
disruption of the homeostasis of the cells and organism; 2) The level of gene expression 
is unable to be controlled and is dependent upon where the gene inserts into the host 
genome and on the number of copies inserted. Overexpression of the gene could have 
unexpected detrimental effects, including lethality; 3) Mosaic or chimeric animals are 
sometimes produced, particularly when the transgenic animal is generated with the viral 
method, due to infection of only a subset of cells within the blastocyst; 4) The genetic 
background of mice can considerably influence the ability of the manipulated egg to 
survive microinjection, implant in the uterus, and develop to term (Brusa 1999; Dale 
2002)  
     
Gene Knockout Technology 
The creation of a traditional knockout (i.e. removal of a gene) mouse consists of 
disrupting all or part of the coding sequence of the GOI, with the purpose of exploring 
the phenotype in the absence of the gene. The exact locus of the GOI can be targeted 
by creating a genetic construct that is homologous to the region of the GOI on a 
141 
 
particular chromosome. The genetic construct is injected into embryonic stem cells 
where rare homologous recombination events can occur with the endogeneous GOI at 
the intended chromosomal locus. In the knockout approach, the GOI is often replaced 
with neomycin (Neo) or another selectable marker which allows for in vitro selection and 
identification of the stem cell colonies that have undergone appropriate recombination 
(Fig. A.1b). Selection against random integration into the genome is often attained by 
using a second selectable marker outside the inserted region.  Once the mutated stem 
cells are identified and verified, they are microinjected into a blastocyst and implanted 
into a pseudopregnant female as in a transgenic mouse. Most of the offspring produced 
using this technique are chimeras (or mosaics) due to the presence of both mutated and 
non-mutated stem cells within the blastocyst. Embryonic stem cells from a different 
color strain of mice than the fertilized egg are often used because the chimeric mice are 
then easily identifiable due to bi-colored fur. The next step consists of breeding chimeric 
mice to identify individuals with germ cells that have undergone homologous 
recombination. These founder mice will then be bred to produce homozygous mutant 
animals (Dale 2002).  Similar to knockout mice, knockin technology, where one or more 
exons of a certain gene are replaced with an altered version (Fig. A.1b), is often used 
to study specific polymorphisms, or the human equivalent of the GOI.  
While knockout organisms have been paramount in the goal to elucidate the 
function of specific genes, problems associated with knockout technology include that 
removal of a gene is often lethal or that the absence of the gene product during 
development leads to compensatory events that can obscure the analysis of the 
function of the missing gene. Specifically, these compensatory developments likely 
differ from the disease mechanisms that the knockout animal is intended to model, as 
disease processes rarely include full loss of gene function. 
  
Conditional Knockout Technology  
The desire for greater specificity and the need to bypass potential developmental 
compensations and occasional lethality has lead to the development of conditional or 
inducible knockouts, where the experimenter has either temporal or regional control 
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over expression of the GOI. Several systems have been developed for this purpose 
including the Cre-LoxP system, Flp-FRT system, and the Tetracycline-inducible system. 
The Cre-LoxP system of bacterial origin, employs Cre recombinase, which mediates 
site-specific recombination by targeting a DNA sequence called LoxP (Houdebine 
2007). To implement this system, one strain of mice is engineered to express Cre under 
a tissue- or developmental stage-specific promoter and these mice are bred to a second 
strain of mice in which the GOI has been flanked with LoxP sites. The resulting offspring 
then have the GOI removed only in the tissues (or at the developmental timepoint) 
where/when Cre is expressed (Fig. A.1c). The Flp-FRT system originates in yeast and 
is used in the same manner as the Cre-LoxP system with Flp recombinase excising the 
GOI flanked by FRT DNA sequences (Houdebine 2007).  Importantly, these two 
systems can be used together to allow for a range of additional approaches.  
The tetracycline-inducible system is based on the tetracycline resistant gene 
from bacteria and has been modified for use in mammals to essentially act as a switch 
to initiate or terminate gene expression. In bacteria, the tetracycline resistance gene is 
typically kept in the off position by a repressor bound to a specialized DNA sequence in 
the promoter of the gene, the tetracycline operator (tetO) sequence. For use in 
mammalian transgenics, the repressor protein was modified into a transactivator (tTA) 
which allows constitutive expression of genes bound to tetO. Thus, in the presence of 
tetracycline, gene expression is terminated when the drug binds to tTA, removing it or 
preventing its binding to tetO. A modified version of tTA (rtTA) requires the presence of 
tetracycline to bind to tetO thereby allowing activation of a gene in the presence of 
tetracycline. For these systems to work, two transgenes in a single animal are needed; 
one expressing tTA under the control of a site- or temporal-specific promoter and the 
GOI under control of the tetO (Fig. A.1d) (Brusa 1999). 
  
RNAi and Gene Transfer in vivo 
The recent discovery and exploitation of the endogenous RNA interference 
(RNAi) mechanism has aided in the development of loss of function models. The 
endogenous mechanism consists of short sequences of double stranded RNA which 
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bind and cleave complementary mRNA sequences thereby silencing or inducing 
downregulation of the specific gene (Dunn et al. 2005). Short sequences of double 
stranded RNA (~22 nucleotides), termed small interfering RNA (siRNA), are easily 
synthesized and can be delivered in vivo using a variety of gene transfer techniques 
(see below and Fig. A.1e). Similar to RNAi, antisense technology is the expression of 
the reverse complement of mRNA which interferes with normal translation thereby 
reducing protein synthesis (Dale 2002). 
While conditional and inducible knockouts provide certain level of site and 
temporal specificity, they are dependent upon the availability of promoters that provide 
the desired specificity. The development of viral-mediated gene transfer has allowed 
more flexibility in producing the desired manipulations. In addition to an alternative 
method of producing transgenic animals (discussed above), viral vectors can be used to 
transfer genetic material in a temporal and site specific manner in both neonatal and 
adult mice. Modified virons such as herpes, lenti-, adeno-, and adeno-associated 
viruses can be engineered to carry a transgene, siRNA, or other genetic material. These 
viral vectors are then able to infect cells and transmit the desired genetic material. Viral-
mediated gene transfer has the additional advantage over conditional mutants that the 
genetic manipulation occurs only at the site of infection and cell-type specific promoters 
can be used for additional specificity. Depending upon the type of virus used, the 
genetic material may be integrated into the genome or may remain epichromosomal. 
The type of virus also influences the infection rate, type of cells infected, and the size of 
DNA insert (Dunn et al. 2005).  While viral-mediatd gene transfer technology is 
widespread, non-viral gene transfer to the central nervous system has also been 
achieved using in vivo electroporation and both intracerebroventricular and intrathecal 
infusion (Gilmore et al. 2006). 
 
 
 
144 
 
 
 
 
Figure A.1. Diagrams of methods for producing genetically modified animals. 
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Roles of Genetically Modified Animals in Psychopharmacology  
The creation of the first knockout mouse in 1989 let to a noble prize for Sir Martin 
Evans (Cardiff University in Wales), Oliver Smithies (University of North Carolina at 
Chapel Hill), and Mario Capecchi (University of Utah in Salt Lake City) in 2007. Since 
the development of the technology, using knockout mice along with other types of 
mutants to investigate critical questions in psychopharmacology has become standard 
practice.  In particular, genetically modified mice have been essential in 
psychopharmacology for 1) Elucidating both the function of a gene and the molecular 
elements associated with a gene;  2) Creating animal models of human disease; 3) 
Identifying and validating drug targets and drug specificity and; 4) Examining temporal 
aspects of gene function.  
One of the first major breakthroughs in the field of neuroscience using targeted 
mutagenesis came from Eric Kandel’s group at Columbia University. In a series of 
experiments using the tetracycline inducible system, they were able to express a 
calcium-independent form of the forebrain specific calcium dependent kinase, calcium-
calmodulin kinase II (CaMKII) and found deficits in spatial memory and hippocampal 
long-term potentiation (LTP) (Mayford et al. 1996). These groundbreaking experiments 
provide a classic example of the power of how spatial and temporal control over 
molecular elements can aid in elucidating the function of specific genes and their role in 
higher brain function. The CaMKII promoter still remains one of the most popular 
promoters to express numerous genetic constructs in the mouse forebrain.  
Another critical role for transgenic animals is the development of animal models 
for human disease, by either the introduction of a mutated gene or the elimination of a 
gene putatively involved in the illness. In the field of neuroscience this has been 
particularly useful in modeling a wide variety of disorders, including Alzheimers disease, 
Huntington’s disease, neuropsychiatric disorders, and cerebral ischemia.  In particular, 
Alzheimers disease (AD) is characterized by the formation of neurofibrillary tangles of 
hyper-phosphorylated tau protein and by amyloid β-peptide (Aβ) plaques.  Mutations in 
the amyloid precursor protein (APP), presenilin 1 and 2 (PS1, PS2) and apolipoprotein 
E (APOE) are all implicated in the disease. Studies now show that mice overexpressing 
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APP and PS1 form Aβ plaques and display memory deficits, both characteristic 
symptoms of Alzheimers disease (Brusa 1999), consequently highlighting the important 
role of genetically modified animals in testing potentially causal mechanisms involved in 
human disease.  In some cases it is necessary to replace the murine gene with the 
human gene due to distinct structural differences between the human gene and mouse 
homologue at the molecular level (Rudolph and Mohler 1999).  
The development of genetic animal models for human diseases has provided a 
solid foundation for drug discovery and for the identification of drug targets. The 
specificity of the genetic manipulation (i.e. removing a gene coding for a particular 
receptor subtype) ensures virtually absolute selectivity thereby offering a great 
advantage over classical pharmacological approaches. For instance, the function of 
receptor subtypes can be examined using both knock-in and knockout approaches. A 
particularly relevant example is that of the utilization of transgenic mice in determining 
the role of specific GABA receptor subunits in distinct actions of the benzodiazepine, 
diazepam. Diazepam is known to act on GABAA receptors containing the α1-, α2-, α3-, 
or α5- subunits. By examining mice carrying point mutations in the benzodiazepine 
binding sites of each subunit, investigators were able to genetically dissect the different 
functions of diazepam (e.g. sedative vs. anxiolytic) acting at otherwise similar GABAA 
receptors  (Rudolph and Mohler 1999). 
Other critical uses of genetically modified animals are the dissection of second 
messenger signaling pathways and the determination of critical developmental time-
windows for gene function. The latter was elegantly demonstrated by the use of a 
tetracycline inducible knockout of the serotonin 1A receptor.  Gross et al. 2002, showed 
that when the 1A receptor was knocked out during development, it resulted in behavior 
similar to the knockout mouse (increased anxiety).  However, when the receptor was 
knocked out in adults, the phenotype was absent (anxiety levels were normal) thereby 
implicating the 1A receptor as a critical developmental factor for normal emotional 
behavior (Gross et al. 2002).  
In summary, the primary goal of reverse genetics is to create a targeted mutation 
and then investigate the resulting phenotype.  We briefly discussed several methods of 
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targeted mutagenesis including the development of transgenic animals and the 
techniques for developing global, conditional and inducible knockouts.  The values of 
this technology have been far-reaching and have played a considerable role in 
psychopharmacology.  We have highlighted some of the most common uses for 
genetically modified animals in this field including the dissection of molecular 
mechanisms, modeling human disease, drug discovery and validation, and the 
investigation of critical time windows in gene function.  While several other approaches 
for creating genetically modified animals exist (e.g. the use of modified male gametes) 
along with other applications for these animals (e.g. pharming), we focused on the role 
of genetically modified mice in psychopharmacology, as their impact on this field has 
been substantial.  New approaches to developing and using genetically modified 
organisms are quickly evolving, including modifications and combinations of the 
discussed systems, which will likely further impact psychopharmacology. 
 
Short Definitions from Paper 3: Genetically Modified Animals 
 
Transgenic Organism 
Synonyms 
Mutant 
Definition 
Traditionally, an organism with the addition of foreign DNA, whether from the same 
species or a different one.  More recently the term transgenic has been used to refer to 
any genetically modified organism.   
 
Knockout / Knockin 
Synonyms 
Global knockout; Constitutive knockout 
Definition 
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Knockout - The removal or complete disruption of a specific gene in an animal from the 
blastocyst stage through adulthood.  Knockin – The introduction of a mutated version of 
a specific gene in place of the wild type version.   
 
Conditional knockout  
Synonyms 
Site-specific knockout, region-specific knockout, cell type-specific knockout 
Definition 
The removal or complete disruption of a specific gene in a manner that controls the cell 
types and brain region or site where the disruption occurs. The Cre/loxP system is 
frequently used to produce conditional knockouts and in this system, the promoter 
expressing Cre recombinase will give rise to the specificity of the excised gene. 
 
Inducible knockout 
Synonyms 
Time-specific knockout, temporal knockout 
Definition 
The use of a system where the experimenter controls the timing of gene removal.  The 
tetracycline inducible system is frequently used to produce animals where a simple 
injection of tetracycline will either terminate or initiate gene transcription. 
 
RNAi 
Synonyms 
siRNA 
Definition 
An endogenous system where short sequences of double stranded RNA molecules 
induce the cleavage of matching mRNA resulting in downregulation of a particular gene.  
This system can be manipulated for experimental by using exogenous siRNA to 
downregulate a GOI.  
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Chimera 
Synonyms 
Mosaic 
Definition 
An animal in which individual cells contain genetic material from only one of two 
potential lineages.  These animals are often produced in the creation of knockout mice 
where a mutated ES cell is introduced into the blastocyst containing wild type ES cells.  
 
Forward Genetics / Reverse Genetics 
Synonyms 
Forward genetics – Random mutagenesis; Reverse genetics – Targeted mutagenesis 
Definition 
Forward genetics is the examination of the genetic cause of an altered or abnormal 
phenotype introduced by a chemical mutagenesis or mutation by irradiation (e.g. 
phenotype → genotype).  In reverse genetics,  a particular gene is altered and the 
phenotype is investigated (e.g. genotype → phenotype). 
 
Phenotype/Genotype 
Synonyms 
      ----- 
Definition 
Genotype is the specific genetic constittution of an organism including the gene allelic 
make-up.  Phenotype is the physical trait or characteristic arising from the genotype. 
 
Pseudopregnant  
Synonyms 
     ----- 
Definition 
A hormonal state similar to pregnancy that is induced in mice by mating a female with a 
vasectomized male.  In this state, the uterus is receptive to an implanted embryo. 
150 
 
APPENDIX B 
SUPPLEMENTAL INFORMATION PAPER 1 
 
 
Table B.1. Z-score values (Mean ± SEM) obtained by different combinations of 2 
or 3 behavioral tests. 
 
 
 
 
 
 
 
 
Tests 
Male 
Vehicle 
Male 
Corticosterone 
Female 
Vehicle 
Female 
Corticosterone 
EPM/OF -0.02±0.20 0.70±0.12 -0.12±0.18 0.33±0.21 
EPM/NSF -0.05±0.15 0.57±0.13 -0.24±0.17 0.34±0.19 
OF/NSF -0.03±0.16 0.73±0.10 -0.46±0.20 -0.07±0.19 
EPM/OF/NSF -0.04±0.14 0.67±0.10 -0.27±0.15 0.25±0.17 
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Figure B.1. Z-scores values (Mean ± SEM) obtained by different combinations of 2 
or 3 behavioral tests  
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Table B.2. P-values for 2-way ANOVA main effects calculated in different 
combinations of 2 or 3 behavioral tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tests 
Main effect 
of sex 
Main effect of 
cort 
Sex x cort 
interaction 
Coefficient of 
variation 
EPM/OF 0.197 0.002 0.445 2.74 
EPM/NSF 0.184 < 0.001 0.896 3.42 
OF/NSF 0.001 < 0.001 0.486 5.08 
EPM/OF/NSF 0.018 < 0.001 0.511 3.04 
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C.1 SUPPLEMENTARY METHODS 
C.1.1 Behavioral Measures 
Elevated plus maze (EPM)
 
: The EPM test consisted of four elevated runways (81cm 
height): two open arms (without walls) and two closed arms (with walls) (36x6cm arms). 
Mice were placed in the EPM for 10 minutes and anxiety-like behaviors were assessed 
by measuring the amount of time spent on the open arms (relative to the 10 minute total 
time in the maze) and the ratio of crosses into the open arms. Total number of crosses 
into either open or closed arms was used as a measure for overall locomotor activity.  
Open field (OF):
 
 Behavior in the OF was measured using ActiVMeter Open Field Cages 
(dimensions: 45 x 45cm; BioSeb Inc., Vitrolles Cedex, France). This system measures 
the movement of the animal using a weight and vibration-sensitive platform, accurately 
recording the spatial position of the animal. Mice were placed in the OF for 10 minutes 
and anxiety-like behavior was measured by time spent in the center (relative to the 10 
minute total time in the maze) and the ratio of distance traveled in the center. Locomotor 
activity was measured by total distance traveled. 
Novelty suppressed feeding (NSF):
 
 The NSF test consisted of food-depriving mice 
overnight (~16 hours), then providing them with a single food pellet placed in the middle 
of a novel, aversive environment (a brightly lit 51 x 51cm enclosure). The latency to start 
feeding (during 12 min. assay) was used as a measure for depressive-like behavior. 
Food consumption (8 minutes post-test) and weight loss were measured as controls for 
potential feeding differences.  
Forced Swim Test (FST): Mice were tested for acute stress response using the forced 
swim test. Mice were placed in a one liter beaker filled with room temperature water 
(~22°C) for 6 minutes. The time spent swimming during the last four minutes of testing 
was used as a measure of stress-responsiveness.  
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Rotarod (RR):
C.1.2 Physiological Measures  
 Motor deficits have been previously reported in Cnp1KO mice after 6 
months of age (Lappe-Siefke et al. 2003). Here, mice were placed on a rotating, 
accelerating rod (0-40 rpm over 60 seconds) (Rotamex-5; Columbus Instruments, 
Columbus, OH) and the latency to fall was recorded over 10 consecutive trials. The 
average latency of trials 8-10 was used as a measure for motor coordination.  
Stress hormone levels were assessed in Baseline, UCMS and CORT groups prior to the 
start of the emotionality phenotyping test battery. To monitor glucocorticoid levels we 
used a non-invasive technique assessing corticosterone metabolites in fecal samples of 
mice, which has been extensively validated for this species (Touma et al. 2003; Touma 
et al. 2004). Since sampling of feces can be performed completely non-invasively and 
allows even frequent sampling of the same individual or group, the monitoring of fecal 
hormone metabolites avoids all stress effects related to common blood sampling 
procedures in mice. Additionally, in the feces circulating hormone levels are integrated 
over a certain period of time and probably the production rate is reflected rather than 
actual steroid concentrations (i.e. hormone metabolite concentrations in feces reflect the 
cumulative secretion and elimination of hormones over a number of hours (Touma and 
Palme 2005). Fecal samples, therefore, do not only represent a single sample point like 
blood samples but also are less affected by episodic fluctuations of hormone secretion. 
Consequently, steroid metabolite concentrations measured in the feces might represent 
the animal’s hormonal status more accurately. For sample collection, the bedding of the 
mouse cages was changed the night prior to feces collection, insuring that older feces 
were not accidentally collected, and feces were grouped according to genotype and sex 
(n=3-5 samples/group consisting of 3-4 animals per sample). Following collection, fecal 
samples were stored at -20°C until 0.05g of the dried sample were extracted using 80% 
methanol and corticosterone metabolite levels were determined in a 5alpha-pregnane-
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3beta,11beta,21-triol-20-one enzyme immunoassay (for details see (Touma et al. 2003; 
Touma et al. 2004)).  
 
Body weight:
 
 Body weight (g) was recorded at each age in animals in the baseline 
cohort and weekly in UCMS and CORT cohorts to monitor weight gain in all 
experimental groups. 
Fur rating
C.1.3  Unpredictable chronic mild stress (UCMS) 
 has previously been shown to be an accurate marker of the progression of 
the depressive-like state (Mineur et al. 2003). Here, individual animals in the UCMS and 
CORT cohorts were assessed weekly using a rating scale of 1-4, with 1 indicating a 
well-groomed coat and 4 indicating a tousled coat with bald patches. 
UCMS-exposed mice were maintained under standard laboratory conditions, however, 
UCMS-exposed animals were single housed throughout the paradigm, as an additional 
stressor. Control mice were grouped housed to avoid the stress of single housing. The 
UCMS group was subjected to 4 weeks of 1-2 mild stressors per day.  Stressors include 
forced bath (~2cm of water in a rat cage for 15 min), wet bedding, aversive smell (1hr 
exposure to fox urine), light cycle reversal or disruption (variable times), social stress 
(rotate mice into previously occupied “dirty” cages), tilted cage (45º tilt), restraint (50ml 
tube with airhole for 15 min), no bedding, and bedding change (replace soiled bedding 
with clean bedding).  Two or three stressors were sometimes used simultaneously to 
contribute to the random nature of the paradigm.  Full schedule of stressors can be 
viewed in Supplementary Table C.1. 
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C.1.4  Hotplate test for pain sensitivity  
In rodents, pain sensitivity is modeled by acute pain tests that measure the threshold to 
high-intensity stimuli. To determine whether Cnp1 KO mice have the same pain 
sensitivity as WT mice, the same cohort of mice used in the fear conditioning (FC) 
experiment was tested in the hotplate test. Mice were placed on a hotplate (Columbus 
Instruments, Columbus, OH) set to 55°C and surrounded by clear plexiglass walls and a 
lid. The latency for the mouse to withdraw and lick a hindpaw is measured. Differences 
in the latencies between genotypes were assessed using one way ANOVA. 
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C.2 SUPPLEMENTARY FIGURES 
 
 
 
 
Figure C.1. Individual tests comprising 3 month emotionality and locomotion Z-
scores. In NSF, there was no difference in weight loss but reduced food consumption in 
Cnp1KO, which may have confounded the negative results in that test (data not shown). 
Z-scores are normalized to the WT group. Data represent mean ± SEM. *p<0.05, 
**p<0.01, ***p<0.001, # represent statistical trends (p<0.1). 
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Figure C.2. Individual tests comprising 6 month locomotion Z-score. See text (and 
Figure 1b) for breakdown of 6 month emotionality Z-score. Z-score is normalized to WT 
group. Data represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, # represent 
statistical trends (p<0.1). 
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Figure C.3. Individual tests comprising 9 month emotionality and locomotion Z-
scores. In NSF, similar to the 3-month time-point (but not 6-month), there was no 
difference in weight loss but reduced food consumption in the Cnp1KO, which may have 
confounded the negative results in that test (data not shown). Z-scores are normalized 
to the WT group. Data represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, # 
represent statistical trends (p<0.1). 
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Figure C.4. Baseline emotionality Z-scores excluding FST. While emotionality 
measures in the EPM and OF are controlled for locomotion, hyperactivity could affect 
results in the FST. Here, with FST removed from the emotionality Z-score calculation, 
we still see a pronounced and progressive low emotionality phenotype in the Cnp1KO. 
Data represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, # represent statistical 
trends (p<0.1). 
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Figure C.5. Physiological measures in the baseline cohort. A) Fecal corticosterone 
metabolite levels. At each age, there were no genotype differences. Differences 
between ages were not examined as they likely reflect unknown factors in the animal 
colony on the day of sample collection. B) Body weight. Cnp1KO had lower body weight 
at 6 and 9 months. Data represent mean ± SEM (n=9-18/group). *p<0.05, **p<0.01, 
***p<0.001, # represent statistical trends (p<0.1). 
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Figure C.6. Individual tests comprising UCMS emotionality and locomotion Z-
scores. Cnp1KO mice exposed to UCMS lost more weight during the NSF food 
deprivation (P<0.001), but consumed less food following the test (p<0.05), suggesting 
the decreased latency in the NSF is not due to increased appetite (data not shown).  Z-
scores are normalized to the WT control group. Red asterisks represent within genotype 
age comparisons, while black asterisks represent across genotype comparisons. Data 
represent mean±SEM (n=9-18/group). *p<0.05, **p<0.01, ***p<0.001, # represent 
statistical trends (p<0.1). 
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Figure C.7. Individual tests comprising CORT emotionality and locomotion Z-
scores. In the NSF, Cnp1KO mice consumed less food post-test, but showed no 
difference in %weight loss at baseline. Following CORT exposure, Cnp1KO mice lost 
more weight during NSF food deprivation (p<0.05), but had no difference in post-test 
food consumption (data not shown).  Z-scores are normalized to the WT baseline group. 
(n=21-26/group). Red asterisks represent within genotype age comparisons, while black 
asterisks represent across genotype comparisons. Data represent mean±SEM. *p<0.05, 
**p<0.01, ***p<0.001, # represent statistical trends (p<0.1).  
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Figure C.8. Emotionality Z-scores excluding the forced swim test. A) UCMS cohort. 
B) CORT cohort. Red asterisks represent within genotype age comparisons, while black 
asterisks represent across genotype comparisons. Data represent mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure C.9. Behavioral measures in a separate cohort exposed to an abbreviated 
(2 week) UCMS paradigm. Data represent mean±SEM (n=20WT, 12KO; age 6 mo.). 
*p<0.05, **p<0.01, ***p<0.001, # represent statistical trends (p<0.1). 
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Figure C.10. Physiological measures in the UCMS cohort. Since there were 
physiological sex differences in these measures, reports were split by sex. Week 0 
measures were taken prior to the start of the UCMS treatment, followed by weekly 
measures during treatment. A) Body Weight. Male and female Cnp1KO mice had 
significantly lower body weights during week 0. B) Fur Rating. In females, mice exposed 
to UCMS had higher fur rating ratings at week 4 (WT; black asterisks; Cnp1KO blue 
asterisk). Male Cnp1KO had higher fur ratings at week 4 (trend level). C) Fecal 
corticosterone metabolite levels showed no significant differences between the groups. 
Data represent mean± SEM (n=9-18/group). *)p<0.05, **p<0.01, ***p<0.001, # 
represent statistical trends (p<0.1).  
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Figure C.11. Physiological measures in the CORT cohort. Since there were 
physiological sex differences in these measures, reports were split by sex. Week 0 
measures were taken prior to the start of the CORT treatment, followed by weekly 
measures during treatment. A) Body Weight across week. B) Fur Rating across week 
C.) Fecal corticosterone metabolite levels before and during CORT treatment. Red 
asterisks represent within genotype comparisons. Data represent mean±SEM (n=9-
18/group). *p<0.05, **p<0.01, ***p<0.001, # represent statistical trends (p<0.1). 
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Figure C.12. Hot plate test. Test for pain sensitivity in the fear conditioning cohort. 
Data represent mean ± SEM (n=16-18/group). No significant differences were found 
(p>0.1). 
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Figure C.13. Fear conditioning in a separate cohort of mice. Fear acquisition (left 
panel) was normal in both WT and Cnp1KO mice, while fear extinction revealed low fear 
expression in Cnp1KO mice (right panel). Red asterisks represent within genotype 
comparisons, while black asterisks represent across genotype comparisons. Data 
represent mean±SEM (n=8-12/group). *p<0.05, **p<0.01. 
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Figure C.14. Extinction recall and fear renewal in the FC cohort. Lower fear 
expression during extinction on day 2 (i.e. decreased freezing time) could suggest an 
improper consolidation of fear memory (see Figure 3b, right panel). So on day 3, we 
assessed extinction recall and fear renewal. Both groups displayed recall freezing times 
similar to their pre-extinction levels, suggesting sub-optimal extinction recall. However, 
in both conditions, CNP1KO mice display significantly lower freezing compared with WT 
animals, a pattern similar to results during the extinction phase. Data are displayed as 
the mean percent freezing in context B or A during exposure to the conditioned tone (5 
total exposures). Asterisks represent between genotype comparisons.  Data represent 
mean±SEM (n=8-12/group). **p<0.01, ***p<0.001. 
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Figure C.15. Correlation between WT-UCMS and KO-UCMS genes. Genes 
significantly changed in WT mice exposed to UCMS correlate with genes changed in 
Cnp1KO mice exposed to UCMS (p<0.01 and 30% effect size), indicating an overall 
conservation of stress-associated gene changes. R=0.72, p=4.67x10-18. 
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C.3  SUPPLEMENTARY TABLES 
Table C.1. Schedule of UCMS stressors and behavioral tests. For descriptions of 
stressors, see supplementary methods (above).  EPM=elevated plus maze; OF=open 
field; NSF=novelty suppressed feeding; FST=forced swim test. Individual stressors are 
color coded.  Multiple simultaneous stressors are coded green. 
 
 
Time Monday Tuesday Wednesday Thursday Friday Saturday Sunday
8 feces collection
9
10
11
12 restraint (0.5hrs)
1
2
3 social stress
4
8
9
10
11
12
1
2
3
4 social stress 
8
9
10
11
12 forced bath 
1
2
3
4 social stress 
8
9
10
11
12
1
2 social stress 
3
4 social stress 
8
9
10
11
12
1
2
3
4 social stress
8
9
10
11
12
1
2
3
4
OF 2nd half                               
 Stress 1st  half  
(wet bedding)    
 Stress 2nd half  
(N=40) (cage tilt) food deprive for 
NSF
no bedding 
overnight
Evaluation
EPM 1st half 
(N=40)                            
EPM 2nd half 
(N=40)                                 
   Stress 1st half 
(N=40) (cage tilt)    
OF 1st half                           
 Stress 2nd half 
(wet bedding)    
Week 6 FST RRNSF
tilted cage + 
predator odor
forced bath
Sacrifice 1st 
Half
Sacrifice 2nd 
Half
Week 5
feces collection 
Evaluation
restraint (0.5 hrs) 
altered light cycle 
Week 2
cage tilt + wet 
bedding (BR)
altered light cycle 
+ predator odor
feces collection
DAY OFF
predator odor + 
dark 
wet bedding + 
dark 
cage tilt + dark 
no bedding 
overnight
forced bath 
DAY OFF
social stress + wet 
bedding overnight
cage tilt + predator 
odor + dark 
Week 1
altered light cycle 
+ predator odor 
altered light cycle 
+ wet bedding cage tilt + no 
beddingpred. odor + dark
forced bath
no bedding 
overnight
wet bedding
no bedding 
overnight
no bedding + dark 
Week 4
Week 3
feces collection Evaluation
wet bedding + 
predator odor restraint (0.5hrs)
forced bath
altered light cycle 
DAY OFF
altered light cyle + 
predator odor
no bedding 
overnight
social stress + no 
bedding 
cage tilt + wet 
bedding
DAY OFF
no bedding 
overnight
feces collection Evaluation
altered light cycle 
+ predator odor restraint (0.5 hrs) 
social stress + no 
bedding 
Evalution
cage tilt
cage tilt + altered 
light cycle
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Table C.2. List of 114 probesets found to be significantly changed in Cnp1KO vs. WT mice. Genes are ordered by p-
value. Alr=average log ratio.   
  
Genotype Effect            
(KO vs. WT) 
Post-Hoc Comparison                              
(KO-control vs. WT-control) 
Post-Hoc Comparison                          
(KO-UCMS vs. WT-UCMS) 
   P-value  P-values  P-values 
Gene 
Symbol GeneTitle ALR ANOVA ALR T-test LSD Tukey ALR T-test LSD Tukey 
Adamts
4 
a disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 4 
0.729 2.66E-15 0.716 2.01E-07 0.00E+00 1.86E-09 0.738 1.47E-07 0.00E+00 4.94E-10 
Adssl1 adenylosuccinate synthetase like 1  0.477 7.37E-08 0.443 5.99E-05 2.25E-04 1.25E-03 0.503 4.55E-04 3.10E-05 1.76E-04 
Aebp1 AE binding protein 1  0.648 6.63E-10 0.496 1.71E-05 7.20E-05 4.04E-04 0.796 5.48E-04 0.00E+00 4.03E-08 
Aldh3b1 aldehyde dehydrogenase 3 family member B1  0.457 3.20E-10 0.394 1.63E-04 1.80E-05 1.04E-04 0.514 8.03E-07 0.00E+00 5.51E-07 
Aph1a anterior pharynx defective 1a homolog  0.594 1.02E-12 0.551 7.21E-06 0.00E+00 4.59E-07 0.633 3.54E-07 0.00E+00 1.16E-08 
Apoc1 apolipoprotein C-I  0.396 1.19E-05 0.401 2.55E-03 1.10E-03 5.83E-03 0.393 4.71E-03 1.10E-03 5.86E-03 
Arpc1b actin related protein 2/3 complex subunit 1B  0.568 1.22E-09 0.504 6.95E-05 2.50E-05 1.42E-04 0.625 1.03E-05 0.00E+00 2.41E-06 
Arpc1b actin related protein 2/3 complex subunit 1B  0.476 9.10E-10 0.383 2.39E-04 5.50E-05 3.13E-04 0.565 1.46E-06 0.00E+00 1.83E-07 
Arpc1b actin related protein 2/3 complex subunit 1B  0.654 1.10E-10 0.654 1.14E-04 1.00E-06 2.95E-06 0.651 4.54E-07 0.00E+00 2.25E-06 
B2m beta-2 microglobulin  0.588 3.69E-12 0.576 1.74E-05 0.00E+00 7.94E-07 0.595 1.04E-08 0.00E+00 2.66E-07 
B2m beta-2 microglobulin 0.535 1.16E-11 0.551 3.40E-05 0.00E+00 1.81E-06 0.512 1.94E-07 1.00E-06 5.25E-06 
Bcas1 breast carcinoma amplified sequence 1  1.362 5.79E-20 1.374 1.75E-11 0.00E+00 1.24E-12 1.346 1.03E-09 0.00E+00 1.24E-12 
Bcl2a1b B-cell leukemia/lymphoma 2 related protein A1b  0.646 1.24E-12 0.625 1.34E-05 0.00E+00 3.26E-07 0.663 1.86E-06 0.00E+00 5.50E-08 
Bcl2a1d B-cell leukemia/lymphoma 2 related protein A1d 0.741 1.17E-16 0.765 3.91E-08 0.00E+00 2.76E-11 0.716 1.78E-07 0.00E+00 1.06E-10 
C1qa complement component 1 q subcomponent alpha polypeptide  0.702 2.67E-15 0.700 1.08E-07 0.00E+00 2.09E-09 0.700 1.90E-06 0.00E+00 1.26E-09 
C1qb complement component 1 q subcomponent beta polypeptide  0.759 2.89E-15 0.774 1.54E-07 0.00E+00 3.99E-09 0.739 3.43E-07 0.00E+00 7.95E-09 
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C1qc complement component 1 q subcomponent C chain  0.690 3.47E-14 0.727 4.15E-07 0.00E+00 4.68E-09 0.649 1.20E-07 0.00E+00 4.86E-08 
C43000
4E15Rik RIKEN cDNA C430004E15 gene  0.483 1.29E-08 0.434 4.58E-05 8.10E-05 4.54E-04 0.527 1.30E-04 3.00E-06 1.62E-05 
C4a complement component 4A  1.552 7.82E-17 1.507 2.30E-06 0.00E+00 1.07E-10 1.591 3.92E-09 0.00E+00 1.38E-11 
C4a complement component 4A  1.452 8.37E-16 1.383 9.22E-07 0.00E+00 1.11E-09 1.516 2.16E-08 0.00E+00 5.21E-11 
C4b complement component 4B  1.242 9.36E-15 1.205 6.90E-07 0.00E+00 5.10E-09 1.276 1.66E-06 0.00E+00 6.84E-10 
Car14 carbonic anhydrase 14 0.578 2.34E-10 0.458 7.83E-04 3.30E-05 1.85E-04 0.690 5.20E-09 0.00E+00 4.96E-08 
Carhsp1 calcium regulated heat stable protein 1  0.597 3.16E-08 0.400 1.00E-02 1.80E-03 9.38E-03 0.785 3.62E-08 0.00E+00 2.45E-07 
Ccl9 chemokine (C-C motif) ligand 9  0.539 4.45E-10 0.564 2.35E-04 1.00E-06 3.34E-06 0.514 4.90E-06 2.00E-06 1.31E-05 
Cd52 CD52 antigen  1.394 4.74E-20 1.454 9.92E-11 0.00E+00 1.23E-12 1.328 1.08E-06 0.00E+00 2.20E-12 
Cd63 CD63 antigen 0.586 7.72E-16 0.576 1.83E-07 0.00E+00 7.25E-10 0.594 5.48E-09 0.00E+00 1.85E-10 
Cd68 CD68 antigen 0.562 1.98E-09 0.526 1.11E-03 1.70E-05 9.69E-05 0.592 8.69E-09 2.00E-06 9.63E-06 
Cd74 
CD74 antigen (major 
histocompatibility complex class II 
antigen-associated) transcript 
variant 2  
0.623 2.34E-06 0.593 1.30E-04 9.47E-04 5.05E-03 0.645 8.96E-03 2.95E-04 1.62E-03 
Cd74 
CD74 antigen (major 
histocompatibility complex class II 
antigen-associated) transcript 
variant 1  
0.693 3.24E-07 0.675 1.65E-05 2.70E-04 1.49E-03 0.701 7.51E-03 1.33E-04 7.45E-04 
Cd82 CD82 antigen 0.551 4.69E-09 0.516 2.20E-04 3.10E-05 1.76E-04 0.581 1.20E-05 3.00E-06 1.88E-05 
Cd9 CD9 antigen 0.750 9.35E-11 0.770 3.03E-07 0.00E+00 1.57E-06 0.729 1.45E-04 1.00E-06 3.20E-06 
Cldn11 claudin 11  0.975 2.59E-15 0.964 1.09E-09 0.00E+00 1.07E-09 0.985 2.05E-07 0.00E+00 3.63E-10 
Clic4 
chloride intracellular channel 4 
(mitochondrial) nuclear gene 
encoding mitochondrial protein  
0.451 9.36E-10 0.423 2.45E-04 7.00E-06 3.86E-05 0.479 1.36E-06 0.00E+00 2.88E-06 
Cort cortistatin  0.693 5.71E-06 0.690 2.17E-03 1.28E-03 6.74E-03 0.684 4.81E-03 1.15E-03 6.11E-03 
Cort cortistatin  0.773 4.58E-06 0.835 1.39E-03 4.73E-04 2.57E-03 0.700 3.29E-03 2.37E-03 1.22E-02 
Cryab crystallin alpha B  0.574 6.45E-10 0.453 4.49E-04 1.46E-04 8.14E-04 0.683 4.47E-06 0.00E+00 5.63E-07 
Ctsc cathepsin C   0.539 7.47E-13 0.543 1.63E-06 0.00E+00 1.09E-07 0.532 3.57E-06 0.00E+00 1.17E-07 
Ctsh cathepsin H  0.519 1.37E-11 0.497 3.20E-06 1.00E-06 3.68E-06 0.536 2.99E-05 0.00E+00 5.30E-07 
Ctsh cathepsin H 0.642 2.67E-14 0.589 8.26E-07 0.00E+00 1.99E-06 0.682 1.26E-05 0.00E+00 5.34E-08 
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Ctsz cathepsin Z  0.588 2.24E-08 0.539 9.95E-04 9.40E-05 5.28E-04 0.631 5.21E-06 6.00E-06 3.69E-05 
Ctsz cathepsin Z 0.571 2.05E-10 0.488 3.14E-04 2.00E-05 1.17E-04 0.645 6.18E-07 0.00E+00 4.87E-07 
Cyba cytochrome b-245 alpha polypeptide  0.652 1.49E-15 0.683 1.92E-08 0.00E+00 1.37E-09 0.615 2.22E-07 0.00E+00 1.22E-08 
Ddr1 discoidin domain receptor family member 1 transcript variant 1  0.503 1.09E-07 0.449 2.00E-04 2.51E-04 1.38E-03 0.553 1.26E-04 1.00E-05 5.51E-05 
Efhd1 EF hand domain containing 1 0.756 2.28E-17 0.691 4.98E-07 0.00E+00 2.77E-09 0.811 5.92E-09 0.00E+00 2.00E-11 
Elovl1 
elongation of very long chain fatty 
acids (FEN1/Elo2 SUR4/Elo3 
yeast)-like 1 transcript variant 2  
0.461 5.27E-10 0.400 1.97E-05 1.90E-05 1.10E-04 0.518 2.02E-05 0.00E+00 6.95E-07 
Evi2a ecotropic viral integration site 2a  transcript variant 2  0.508 1.37E-09 0.578 7.33E-07 0.00E+00 1.27E-06 0.438 2.55E-04 2.20E-05 1.27E-04 
Fa2h fatty acid 2-hydroxylase 0.441 5.64E-07 0.490 1.22E-04 4.00E-05 2.27E-04 0.391 1.51E-03 5.71E-04 3.09E-03 
Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 0.742 5.96E-18 0.741 5.03E-09 0.00E+00 2.29E-11 0.738 7.03E-10 0.00E+00 1.52E-11 
Fcgr3 Fc receptor IgG low affinity III   0.496 3.35E-13 0.519 1.05E-06 0.00E+00 6.89E-08 0.468 8.77E-07 0.00E+00 4.66E-07 
Fgfr2 fibroblast growth factor receptor 2 transcript variant 2  0.479 5.44E-11 0.461 1.91E-05 1.00E-06 5.99E-06 0.493 5.28E-06 0.00E+00 1.13E-06 
Gab1 growth factor receptor bound protein 2-associated protein 1  0.574 4.23E-13 0.483 1.04E-05 0.00E+00 1.98E-06 0.658 3.48E-08 0.00E+00 8.57E-10 
Gfap glial fibrillary acidic protein  0.967 1.50E-07 1.136 2.15E-04 5.00E-06 2.88E-05 0.801 8.66E-03 5.25E-04 2.85E-03 
Gjc2 gap junction protein gamma 2 transcript variant 2  0.686 4.09E-11 0.564 5.12E-04 1.20E-05 6.87E-05 0.797 3.70E-07 0.00E+00 4.95E-08 
Gltp glycolipid transfer protein  0.562 1.80E-11 0.552 3.69E-06 0.00E+00 1.12E-06 0.572 3.35E-06 0.00E+00 3.55E-07 
Grb14 growth factor receptor bound protein 14  0.455 1.73E-09 0.497 3.74E-05 1.00E-06 4.37E-06 0.416 1.28E-04 1.30E-05 7.21E-05 
H2-D1 histocompatibility 2 D region locus 1  0.505 7.08E-09 0.483 1.60E-03 5.60E-05 3.17E-04 0.518 7.51E-06 1.50E-05 8.67E-05 
Hvcn1 hydrogen voltage-gated channel 1 transcript variant 1  0.412 2.77E-12 0.396 2.64E-06 0.00E+00 2.61E-06 0.423 5.56E-06 0.00E+00 4.48E-07 
Igfbp5 insulin-like growth factor binding protein 5  0.468 1.26E-06 0.502 1.17E-03 1.78E-04 9.88E-04 0.441 4.08E-03 6.57E-04 3.54E-03 
Klhl6 kelch-like 6 (Drosophila)  0.398 3.93E-10 0.384 4.73E-05 5.00E-06 2.90E-05 0.408 2.54E-05 1.00E-06 6.92E-06 
Lag3 lymphocyte-activation gene 3 0.678 2.27E-09 0.679 5.98E-04 8.00E-06 4.64E-05 0.670 4.04E-05 7.00E-06 4.25E-05 
Lass2 LAG1 homolog ceramide synthase 2 0.508 8.65E-11 0.487 1.90E-04 1.00E-06 5.55E-06 0.527 1.98E-08 0.00E+00 7.68E-07 
Lass2 LAG1 homolog ceramide synthase 2 0.464 1.58E-09 0.464 5.06E-05 8.00E-06 4.89E-05 0.457 1.42E-04 8.00E-06 4.62E-05 
Lgals3 lectin galactose binding soluble 3 0.743 5.33E-13 0.825 9.27E-09 0.00E+00 4.78E-09 0.660 5.09E-07 0.00E+00 5.90E-07 
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Litaf LPS-induced TN factor 0.541 6.06E-10 0.488 1.23E-05 2.20E-05 1.26E-04 0.586 3.68E-05 1.00E-06 3.81E-06 
LOC100
047749 
PREDICTED: similar to cAMP-
specific cyclic nucleotide 
phosphodiesterase PDE8; MMPDE8  
0.498 1.59E-08 0.453 2.39E-05 6.20E-05 3.52E-04 0.540 2.69E-04 3.00E-06 1.64E-05 
Ly86 lymphocyte antigen 86  0.766 3.06E-20 0.760 1.12E-09 0.00E+00 1.21E-12 0.769 3.41E-10 0.00E+00 1.15E-12 
Lyz lysozyme  1.776 8.29E-21 1.812 3.16E-11 0.00E+00 1.26E-12 1.730 2.02E-07 0.00E+00 1.46E-12 
Lyz2 lysozyme 2 0.728 1.39E-09 0.685 5.83E-04 1.10E-05 6.06E-05 0.764 6.14E-07 1.00E-06 6.49E-06 
Lyzs lysozyme  0.777 2.10E-12 0.784 2.01E-07 0.00E+00 3.81E-07 0.764 4.03E-05 0.00E+00 4.44E-07 
Mag myelin-associated glycoprotein  1.160 6.64E-18 1.064 1.77E-07 0.00E+00 9.57E-11 1.248 3.79E-10 0.00E+00 1.57E-12 
Mal myelin and lymphocyte protein T-cell differentiation protein  0.834 1.48E-13 0.861 7.16E-08 0.00E+00 1.07E-08 0.806 4.10E-06 0.00E+00 3.39E-08 
Mbp myelin basic protein transcript variant 7  0.826 3.68E-15 0.812 2.14E-07 0.00E+00 3.08E-09 0.834 7.60E-09 0.00E+00 9.25E-10 
Mcam melanoma cell adhesion molecule 0.644 2.66E-11 0.553 1.79E-06 2.00E-06 1.39E-05 0.731 4.21E-06 0.00E+00 2.67E-08 
Mobp myelin-associated oligodendrocytic basic protein transcript variant 1  1.195 1.05E-16 1.151 2.15E-08 0.00E+00 1.60E-10 1.236 1.41E-07 0.00E+00 1.28E-11 
Mobp myelin-associated oligodendrocytic basic protein 0.928 4.16E-15 1.018 2.06E-08 0.00E+00 5.85E-11 0.841 1.80E-06 0.00E+00 6.20E-09 
Mobp myelin-associated oligodendrocytic basic protein transcript variant 3  0.814 4.32E-12 0.702 2.96E-06 1.00E-06 5.37E-06 0.917 1.58E-06 0.00E+00 9.88E-09 
Mobp myelin-associated oligodendrocytic basic protein transcript variant 3  0.853 3.43E-08 0.825 2.84E-03 4.70E-05 2.66E-04 0.877 7.16E-05 1.40E-05 7.98E-05 
Mog myelin oligodendrocyte glycoprotein  0.816 2.46E-07 0.830 5.43E-03 8.20E-05 4.61E-04 0.801 6.58E-05 1.03E-04 5.77E-04 
Mog myelin oligodendrocyte glycoprotein  0.715 1.59E-06 0.728 7.66E-03 2.71E-04 1.50E-03 0.701 1.82E-05 3.42E-04 1.88E-03 
Mpeg1 macrophage expressed gene 1  0.675 2.69E-13 0.716 2.99E-07 0.00E+00 7.60E-09 0.634 1.67E-06 0.00E+00 9.02E-08 
Ndrg1 N-myc downstream regulated gene 1  0.557 8.96E-10 0.416 1.17E-03 2.17E-04 1.20E-03 0.686 8.11E-07 0.00E+00 1.57E-07 
Ndrl N-myc downstream regulated-like 0.598 3.62E-11 0.462 1.04E-03 2.10E-05 1.19E-04 0.723 9.55E-09 0.00E+00 9.67E-09 
Nkx6-2 NK6 transcription factor related locus 2  0.454 1.14E-05 0.419 5.54E-04 2.52E-03 1.29E-02 0.487 9.55E-03 4.44E-04 2.42E-03 
Osmr oncostatin M receptor 0.451 2.12E-12 0.484 2.21E-06 0.00E+00 2.46E-08 0.419 3.77E-07 0.00E+00 4.51E-07 
P2ry6 pyrimidinergic receptor P2Y G-protein coupled 6  0.433 2.65E-09 0.435 1.09E-05 7.00E-06 4.13E-05 0.426 2.16E-04 8.00E-06 4.35E-05 
Pdlim2 PDZ and LIM domain 2 0.973 1.75E-13 0.999 4.44E-06 0.00E+00 2.11E-08 0.942 2.18E-07 0.00E+00 5.51E-08 
178 
 
Pdlim2 PDZ and LIM domain 2 1.375 1.31E-18 1.476 2.80E-09 0.00E+00 1.23E-12 1.275 7.80E-08 0.00E+00 6.99E-12 
Pdlim2 PDZ and LIM domain 2  1.492 8.58E-23 1.483 2.17E-11 0.00E+00 1.11E-12 1.499 9.15E-11 0.00E+00 1.11E-12 
Phldb1 pleckstrin homology-like domain family B member 1  0.623 1.76E-11 0.547 4.05E-05 3.00E-06 1.88E-05 0.691 1.65E-06 0.00E+00 1.12E-07 
Phldb1 pleckstrin homology-like domain family B member 1  0.559 3.49E-10 0.589 5.53E-05 1.00E-06 3.20E-06 0.527 2.32E-05 3.00E-06 1.83E-05 
Pigh phosphatidylinositol glycan anchor biosynthesis class H 0.806 4.81E-14 0.746 2.84E-07 0.00E+00 1.74E-07 0.857 3.41E-06 0.00E+00 3.86E-09 
Pld4 phospholipase D family member 4 0.432 5.53E-08 0.405 1.79E-03 2.49E-04 1.38E-03 0.452 1.01E-04 4.50E-05 2.56E-04 
Plekhb1 
pleckstrin homology domain 
containing family B (evectins) 
member 1 
0.452 1.19E-09 0.403 9.45E-05 1.70E-05 9.66E-05 0.497 1.23E-05 0.00E+00 1.62E-06 
Plekhg3 
pleckstrin homology domain 
containing family G (with RhoGef 
domain) member 3  
0.493 4.63E-08 0.423 5.58E-05 2.97E-04 1.64E-03 0.557 1.60E-04 4.00E-06 2.37E-05 
Pllp plasma membrane proteolipid 0.666 1.34E-12 0.647 2.44E-08 0.00E+00 2.63E-07 0.681 1.25E-05 0.00E+00 5.30E-08 
Plp1 proteolipid protein (myelin) 1  0.482 2.99E-12 0.536 1.09E-06 0.00E+00 1.18E-08 0.430 3.19E-06 0.00E+00 1.19E-06 
Pmp22 peripheral myelin protein 0.416 8.64E-07 0.379 2.34E-03 1.14E-03 6.03E-03 0.446 1.87E-04 1.39E-04 7.75E-04 
Ppap2c phosphatidic acid phosphatase type 2c 0.490 2.09E-11 0.430 5.14E-06 2.00E-06 1.12E-05 0.545 1.88E-06 0.00E+00 5.37E-08 
Prr18 proline rich region 18 0.663 7.32E-13 0.668 2.55E-07 0.00E+00 1.26E-07 0.655 3.11E-06 0.00E+00 1.30E-07 
Qdpr quinoid dihydropteridine reductase 0.667 2.55E-15 0.661 7.90E-08 0.00E+00 1.44E-09 0.670 1.09E-07 0.00E+00 6.02E-10 
Rapgefl
1 
Rap guanine nucleotide exchange 
factor (GEF)-like 1  
-
1.160 5.31E-17 
-
1.249 1.02E-11 0.00E+00 5.48E-12 
-
1.070 9.46E-08 0.00E+00 2.31E-10 
Rhog ras homolog gene family member G 0.629 1.62E-10 0.482 5.62E-04 3.00E-05 1.69E-04 0.770 1.03E-08 0.00E+00 1.05E-08 
Serpina
3n 
serine (or cysteine) peptidase 
inhibitor clade A member 3N 0.812 2.13E-10 0.801 4.65E-06 2.00E-06 9.95E-06 0.817 4.45E-05 1.00E-06 4.94E-06 
Slamf9 SLAM family member 9 0.575 2.73E-13 0.653 5.07E-07 0.00E+00 6.95E-10 0.498 1.52E-07 0.00E+00 3.34E-07 
Slc11a1 
solute carrier family 11 (proton-
coupled divalent metal ion 
transporters) member 1  
0.595 3.47E-12 0.590 1.95E-06 0.00E+00 4.16E-07 0.596 5.49E-06 0.00E+00 2.19E-07 
Slc12a2 solute carrier family 12 member 2 0.591 3.63E-11 0.607 6.08E-07 0.00E+00 7.18E-07 0.574 1.34E-05 0.00E+00 1.57E-06 
Slc12a2 solute carrier family 12 member 2  0.735 5.19E-14 0.681 9.75E-07 0.00E+00 4.47E-08 0.786 3.76E-09 0.00E+00 7.27E-10 
Slc15a3 solute carrier family 15 member 3  0.415 1.06E-09 0.407 3.32E-05 3.00E-06 1.93E-05 0.422 5.27E-05 1.00E-06 7.31E-06 
Slc44a1 solute carrier family 44 member 1 0.727 3.90E-13 0.652 1.52E-06 0.00E+00 4.84E-07 0.796 5.57E-07 0.00E+00 2.65E-09 
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Tmem1
0 transmembrane protein 10  1.103 6.76E-16 1.016 1.24E-07 0.00E+00 2.26E-09 1.185 6.22E-07 0.00E+00 1.92E-11 
Tmem1
25 transmembrane protein 125 0.805 9.05E-14 0.783 4.13E-08 0.00E+00 3.96E-08 0.822 1.41E-06 0.00E+00 7.34E-09 
Trem2 triggering receptor expressed on myeloid cells 2 0.698 8.75E-15 0.616 1.31E-06 0.00E+00 6.88E-08 0.773 6.81E-09 0.00E+00 1.19E-10 
Tspan2 tetraspanin 2 0.953 1.51E-16 0.943 2.45E-09 0.00E+00 1.80E-10 0.959 5.53E-09 0.00E+00 6.66E-11 
Tyrobp TYRO protein tyrosine kinase binding protein 0.732 5.52E-16 0.686 7.76E-08 0.00E+00 3.12E-09 0.772 1.11E-07 0.00E+00 7.57E-11 
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